Category,Category Name,Data Code,Data Name,Date,Patient Count,Normalized Patient Count
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2023-04-01,116.0,0.07327858496525584
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2023-04-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2023-04-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2023-04-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2023-04-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2023-04-01,18.0,0.011370814908401769
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2023-04-01,18.0,0.011370814908401769
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2023-04-01,48.0,0.030322173089071383
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2023-04-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2023-04-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2023-04-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2023-04-01,208.0,0.131396083385976
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2023-04-01,26.0,0.016424510423247
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2023-04-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2023-04-01,208.0,0.131396083385976
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2023-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2023-04-01,0.0,0.0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2023-04-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2023-04-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2023-04-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2023-04-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2023-04-01,100.0,0.5235602094240838
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2023-04-01,51.0,0.2670157068062827
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2023-04-01,2.0,0.010471204188481676
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2023-04-01,100.0,0.5235602094240838
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2023-04-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2023-04-01,0.0,0.0
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2023-04-01,100.0,0.5235602094240838
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2023-04-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2023-04-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2023-04-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2023-04-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2023-04-01,49.0,0.4536082474226804
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2023-04-01,8.0,0.030927835051546393
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2023-04-01,49.0,0.4536082474226804
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2023-04-01,46.0,0.24083769633507854
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2023-04-01,53.0,0.2774869109947644
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2023-04-01,7.0,0.03664921465968586
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2023-04-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2023-04-01,99.0,0.518324607329843
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2023-04-01,12.0,0.06282722513089005
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2023-04-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2023-04-01,99.0,0.518324607329843
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2023-04-01,99.0,0.518324607329843
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2023-04-01,99.0,0.518324607329843
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2023-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2023-04-01,50.0,1.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2023-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2023-04-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2023-04-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2023-04-01,99.0,0.47596153846153844
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2023-04-01,99.0,0.47596153846153844
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2023-04-01,99.0,0.47596153846153844
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2023-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2023-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2023-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2023-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2023-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2023-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2023-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2023-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2023-04-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2023-04-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2023-04-01,12.0,0.031088082901554404
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2023-04-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2023-04-01,10.0,0.025906735751295335
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2023-04-01,4.0,0.010362694300518135
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2023-04-01,10.0,0.025906735751295335
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2023-04-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2023-04-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2023-04-01,4.0,0.010362694300518135
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2023-04-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2023-04-01,11.0,0.02849740932642487
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2023-04-01,12.0,0.031088082901554404
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2023-04-01,6.0,0.015544041450777202
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2023-04-01,2.0,0.0051813471502590676
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2023-04-01,30.0,0.07772020725388601
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2023-04-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2023-04-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2023-04-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2023-04-01,0.0,0.0
M8,Family Planning,8.17.1,Complications following male sterilization,2023-04-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2023-04-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2023-04-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2023-04-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2023-04-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2023-04-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2023-04-01,0.0,0.0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2023-04-01,99.0,0.5238095238095238
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2023-04-01,99.0,0.5238095238095238
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2023-04-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2023-04-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2023-04-01,99.0,0.5238095238095238
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2023-04-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2023-04-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2023-04-01,99.0,0.5238095238095238
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2023-04-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2023-04-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2023-04-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2023-04-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2023-04-01,12.0,0.06349206349206349
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2023-04-01,14.0,0.07407407407407407
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2023-04-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2023-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2023-04-01,6.0,0.05084745762711865
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2023-04-01,6.0,0.05084745762711865
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2023-04-01,38.0,0.3220338983050847
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2023-04-01,18.0,0.15254237288135594
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2023-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2023-04-01,4.0,0.03389830508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2023-04-01,0.0,0.0
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2023-04-01,47.0,0.17669172932330826
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2023-04-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2023-04-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2023-04-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2023-04-01,43.0,0.16165413533834586
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2023-04-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2023-04-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2023-04-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2023-04-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2023-04-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-04-01,0.0,0.0
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-04-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-04-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-04-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2023-04-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2023-04-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2023-04-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2023-04-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2023-04-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2023-04-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2023-04-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2023-04-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2023-04-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2023-04-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2023-04-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2023-04-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2023-04-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2023-04-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2023-04-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2023-04-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2023-04-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2023-04-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2023-04-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2023-04-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2023-04-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2023-04-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2023-04-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2023-04-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2023-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2023-04-01,700.0,0.01847111908594348
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2023-04-01,575.0,0.01517270496345357
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2023-04-01,142.0,0.003746998443148534
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2023-04-01,1149.0,0.030319022613927223
M14 ,Patient Services,14.1.8,Outpatient - Dental,2023-04-01,864.0,0.022798638414650237
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2023-04-01,721.0,0.01902525265852178
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2023-04-01,16.0,0.00042219700767870806
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2023-04-01,950.0,0.025067947330923292
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2023-04-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2023-04-01,645.0,0.01701981687204792
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2023-04-01,15866.0,0.4186611077393989
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2023-04-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2023-04-01,71.0,0.001873499221574267
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2023-04-01,561.0,0.014803282581734701
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2023-04-01,67.0,0.0017679499696545901
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2023-04-01,611.0,0.016122648230730664
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2023-04-01,0.0,0.0
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2023-04-01,102.0,0.002691505923951764
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2023-04-01,481.0,0.012692297543341162
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2023-04-01,95.0,0.002506794733092329
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2023-04-01,564.0,0.01488244452067446
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2023-04-01,0.0,0.0
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2023-04-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2023-04-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2023-04-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2023-04-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2023-04-01,0.0,0.0
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2023-04-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2023-04-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2023-04-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2023-04-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2023-04-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2023-04-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2023-04-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2023-04-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2023-04-01,34.0,0.0008971686413172547
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2023-04-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2023-04-01,288.0,0.007599546138216746
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2023-04-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2023-04-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2023-04-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2023-04-01,0.0,0.0
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2023-04-01,33.0,0.0008707813283373355
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2023-04-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2023-04-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2023-04-01,7.0,0.00018471119085943478
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2023-04-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2023-04-01,75.0,0.0019790484734939443
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2023-04-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2023-04-01,1541.0,0.04066284930205557
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2023-04-01,580.0,0.015304641528353168
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2023-04-01,81.0,0.0021373723513734596
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2023-04-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2023-04-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2023-04-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2023-04-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2023-04-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2023-04-01,21.0,0.0005541335725783044
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2023-04-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2023-04-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2023-04-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2023-04-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2023-04-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2023-04-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2023-04-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2023-04-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2023-04-01,450.0,0.011874290840963664
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2023-04-01,24.0,0.0006332955115180621
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2023-04-01,274.0,0.007230123756497876
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2023-04-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2023-04-01,25.0,0.0006596828244979814
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2023-04-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2023-04-01,0.0,0.0
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2023-04-01,0.0,0.0
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2023-04-01,7099.0,0.18732353484444678
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2023-04-01,0.0,0.0
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2023-04-01,0.0,0.0
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2023-04-01,0.0,0.0
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2023-04-01,0.0,0.0
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2023-04-01,0.0,0.0
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2023-04-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2023-04-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2023-04-01,95.0,0.002506794733092329
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2023-04-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2023-04-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2023-04-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2023-04-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2023-04-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2023-04-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2023-04-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2023-04-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2023-04-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2023-04-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2023-04-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2023-04-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2023-04-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2023-04-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2023-04-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2023-04-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2023-04-01,0.0,0.0
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2023-04-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2023-04-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2023-04-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2023-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2023-04-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2023-04-01,34769.0,0.4889742075211656
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2023-04-01,2316.0,0.032571091047169015
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2023-04-01,16.0,0.00022501617303743706
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-04-01,430.0,0.006047309650381121
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-04-01,455.0,0.006398897420752117
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-04-01,62.0,0.0008719376705200687
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-04-01,204.0,0.0028689562062273227
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2023-04-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2023-04-01,44.0,0.000618794475852952
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2023-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2023-04-01,2639.0,0.03711360504036228
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2023-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2023-04-01,1130.0,0.015891767220768994
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2023-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2023-04-01,333.0,0.004683149101341659
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2023-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2023-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2023-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2023-04-01,320.0,0.004500323460748741
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2023-04-01,6.0,0.1935483870967742
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2023-04-01,4.0,0.12903225806451613
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2023-04-01,15.0,0.4838709677419355
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2023-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2023-04-01,15.0,0.4838709677419355
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2023-04-01,0.0,0.0
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2023-04-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2023-04-01,0.0,0.0
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2023-04-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2023-04-01,0.0,0.0
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2023-04-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2023-04-01,159.0,0.1150506512301013
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2023-04-01,159.0,0.1150506512301013
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2023-04-01,15.0,0.01085383502170767
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2023-04-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2023-04-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2023-04-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2023-04-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2023-04-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2023-04-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2023-04-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2023-04-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2023-04-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2023-04-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2023-04-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2023-04-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2023-04-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2023-05-01,146.0,0.09222994314592546
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2023-05-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2023-05-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2023-05-01,42.0,0.026531901452937462
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2023-05-01,42.0,0.026531901452937462
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2023-05-01,42.0,0.026531901452937462
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2023-05-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2023-05-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2023-05-01,15.0,0.009475679090334808
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2023-05-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2023-05-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2023-05-01,443.0,0.2798483891345546
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2023-05-01,23.0,0.014529374605180037
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2023-05-01,443.0,0.2798483891345546
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2023-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2023-05-01,0.0,0.0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2023-05-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2023-05-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2023-05-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2023-05-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2023-05-01,110.0,0.5759162303664922
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2023-05-01,54.0,0.28272251308900526
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2023-05-01,34.0,0.17801047120418848
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2023-05-01,110.0,0.5759162303664922
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2023-05-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2023-05-01,10.0,0.05235602094240838
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2023-05-01,100.0,0.5235602094240838
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2023-05-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2023-05-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2023-05-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2023-05-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2023-05-01,56.0,0.5257731958762887
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2023-05-01,7.0,0.020618556701030927
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2023-05-01,56.0,0.5257731958762887
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2023-05-01,60.0,0.31413612565445026
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2023-05-01,49.0,0.25654450261780104
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2023-05-01,9.0,0.04712041884816754
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2023-05-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2023-05-01,109.0,0.5706806282722513
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2023-05-01,10.0,0.05235602094240838
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2023-05-01,3.0,0.015706806282722512
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2023-05-01,109.0,0.5706806282722513
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2023-05-01,109.0,0.5706806282722513
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2023-05-01,109.0,0.5706806282722513
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2023-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2023-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2023-05-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2023-05-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2023-05-01,109.0,0.5240384615384616
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2023-05-01,109.0,0.5240384615384616
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2023-05-01,109.0,0.5240384615384616
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2023-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2023-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2023-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2023-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2023-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2023-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2023-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2023-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2023-05-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2023-05-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2023-05-01,19.0,0.04922279792746114
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2023-05-01,4.0,0.010362694300518135
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2023-05-01,10.0,0.025906735751295335
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2023-05-01,4.0,0.010362694300518135
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2023-05-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2023-05-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2023-05-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2023-05-01,7.0,0.018134715025906734
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2023-05-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2023-05-01,9.0,0.023316062176165803
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2023-05-01,12.0,0.031088082901554404
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2023-05-01,6.0,0.015544041450777202
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2023-05-01,2.0,0.0051813471502590676
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2023-05-01,22.0,0.05699481865284974
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2023-05-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2023-05-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2023-05-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2023-05-01,0.0,0.0
M8,Family Planning,8.17.1,Complications following male sterilization,2023-05-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2023-05-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2023-05-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2023-05-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2023-05-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2023-05-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2023-05-01,9.0,0.023316062176165803
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2023-05-01,109.0,0.5767195767195767
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2023-05-01,109.0,0.5767195767195767
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2023-05-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2023-05-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2023-05-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2023-05-01,109.0,0.5767195767195767
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2023-05-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2023-05-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2023-05-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2023-05-01,109.0,0.5767195767195767
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2023-05-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2023-05-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2023-05-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2023-05-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2023-05-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2023-05-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2023-05-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2023-05-01,16.0,0.08465608465608465
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2023-05-01,16.0,0.08465608465608465
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2023-05-01,16.0,0.08465608465608465
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2023-05-01,8.0,0.042328042328042326
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2023-05-01,8.0,0.042328042328042326
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2023-05-01,9.0,0.047619047619047616
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2023-05-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2023-05-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2023-05-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2023-05-01,16.0,0.08465608465608465
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2023-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2023-05-01,10.0,0.0847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2023-05-01,4.0,0.03389830508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2023-05-01,8.0,0.06779661016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2023-05-01,8.0,0.06779661016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2023-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2023-05-01,2.0,0.01694915254237288
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2023-05-01,6.0,0.05084745762711865
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2023-05-01,24.0,0.09022556390977443
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2023-05-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2023-05-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2023-05-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2023-05-01,33.0,0.12406015037593984
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2023-05-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2023-05-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2023-05-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2023-05-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2023-05-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-05-01,0.0,0.0
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-05-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-05-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-05-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2023-05-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2023-05-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2023-05-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2023-05-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2023-05-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2023-05-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2023-05-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2023-05-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2023-05-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2023-05-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2023-05-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2023-05-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2023-05-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2023-05-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2023-05-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2023-05-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2023-05-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2023-05-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2023-05-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2023-05-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2023-05-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2023-05-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2023-05-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2023-05-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2023-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2023-05-01,712.0,0.01878776684170251
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2023-05-01,670.0,0.017679499696545902
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2023-05-01,178.0,0.004696941710425628
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2023-05-01,1389.0,0.036651977729107846
M14 ,Patient Services,14.1.8,Outpatient - Dental,2023-05-01,919.0,0.024249940628545796
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2023-05-01,1035.0,0.02731086893421643
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2023-05-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2023-05-01,1055.0,0.027838615193814815
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2023-05-01,634.0,0.016729556429268808
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2023-05-01,0.0,0.0
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2023-05-01,18315.0,0.4832836372272212
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2023-05-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2023-05-01,130.0,0.003430350687389503
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2023-05-01,530.0,0.013985275879357205
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2023-05-01,100.0,0.0026387312979919255
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2023-05-01,651.0,0.017178140749927434
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2023-05-01,0.0,0.0
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2023-05-01,125.0,0.003298414122489907
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2023-05-01,525.0,0.013853339314457608
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2023-05-01,88.0,0.0023220835422328944
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2023-05-01,640.0,0.01688788030714832
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2023-05-01,0.0,0.0
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2023-05-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2023-05-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2023-05-01,0.0,0.0
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2023-05-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2023-05-01,0.0,0.0
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2023-05-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2023-05-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2023-05-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2023-05-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2023-05-01,11.0,0.0002902604427791118
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2023-05-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2023-05-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2023-05-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2023-05-01,41.0,0.0010818798321766895
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2023-05-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2023-05-01,361.0,0.00952581998575085
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2023-05-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2023-05-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2023-05-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2023-05-01,0.0,0.0
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2023-05-01,41.0,0.0010818798321766895
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2023-05-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2023-05-01,16.0,0.00042219700767870806
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2023-05-01,11.0,0.0002902604427791118
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2023-05-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2023-05-01,111.0,0.002928991740771037
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2023-05-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2023-05-01,1512.0,0.039897617225637914
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2023-05-01,470.0,0.01240203710056205
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2023-05-01,104.0,0.0027442805499116023
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2023-05-01,7.0,0.00018471119085943478
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2023-05-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2023-05-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2023-05-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2023-05-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2023-05-01,26.0,0.0006860701374779006
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2023-05-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2023-05-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2023-05-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2023-05-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2023-05-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2023-05-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2023-05-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2023-05-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2023-05-01,537.0,0.01416998707021664
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2023-05-01,26.0,0.0006860701374779006
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2023-05-01,309.0,0.00815367971079505
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2023-05-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2023-05-01,20.0,0.000527746259598385
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2023-05-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2023-05-01,0.0,0.0
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2023-05-01,0.0,0.0
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2023-05-01,7351.0,0.19397313771538643
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2023-05-01,0.0,0.0
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2023-05-01,0.0,0.0
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2023-05-01,0.0,0.0
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2023-05-01,0.0,0.0
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2023-05-01,0.0,0.0
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2023-05-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2023-05-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2023-05-01,109.0,0.0028762171148111987
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2023-05-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2023-05-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2023-05-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2023-05-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2023-05-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2023-05-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2023-05-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2023-05-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2023-05-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2023-05-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2023-05-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2023-05-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2023-05-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2023-05-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2023-05-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2023-05-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2023-05-01,0.0,0.0
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2023-05-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2023-05-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2023-05-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2023-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2023-05-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2023-05-01,41196.0,0.5793603915281411
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2023-05-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2023-05-01,3256.0,0.045790791213118444
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2023-05-01,21.0,0.00029533372711163615
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-05-01,385.0,0.00541445166371333
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-05-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2023-05-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-05-01,506.0,0.0071161364723089475
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-05-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2023-05-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-05-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-05-01,70.0,0.0009844457570387872
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-05-01,158.0,0.002222034708744691
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-05-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2023-05-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2023-05-01,49.0,0.000689112029927151
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2023-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2023-05-01,2728.0,0.03836525750288302
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2023-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2023-05-01,1291.0,0.018155992461958204
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2023-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2023-05-01,390.0,0.005484769217787528
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2023-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2023-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2023-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2023-05-01,400.0,0.005625404325935926
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2023-05-01,6.0,0.1935483870967742
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2023-05-01,3.0,0.0967741935483871
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2023-05-01,22.0,0.7096774193548387
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2023-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2023-05-01,22.0,0.7096774193548387
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2023-05-01,0.0,0.0
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2023-05-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2023-05-01,0.0,0.0
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2023-05-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2023-05-01,0.0,0.0
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2023-05-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2023-05-01,140.0,0.10130246020260492
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2023-05-01,140.0,0.10130246020260492
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2023-05-01,14.0,0.010130246020260492
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2023-05-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2023-05-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2023-05-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2023-05-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2023-05-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2023-05-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2023-05-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2023-05-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2023-05-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2023-05-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2023-05-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2023-05-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2023-05-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2023-06-01,235.0,0.14845230574857865
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2023-06-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2023-06-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2023-06-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2023-06-01,42.0,0.026531901452937462
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2023-06-01,28.0,0.017687934301958308
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2023-06-01,28.0,0.017687934301958308
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2023-06-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2023-06-01,82.0,0.05180037902716361
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2023-06-01,62.0,0.03916614024005054
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2023-06-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2023-06-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2023-06-01,262.0,0.1655085281111813
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2023-06-01,36.0,0.022741629816803537
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2023-06-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2023-06-01,262.0,0.1655085281111813
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2023-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2023-06-01,0.0,0.0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2023-06-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2023-06-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2023-06-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2023-06-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2023-06-01,117.0,0.612565445026178
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2023-06-01,61.0,0.3193717277486911
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2023-06-01,32.0,0.16753926701570682
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2023-06-01,117.0,0.612565445026178
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2023-06-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2023-06-01,14.0,0.07329842931937172
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2023-06-01,103.0,0.5392670157068062
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2023-06-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2023-06-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2023-06-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2023-06-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2023-06-01,56.0,0.5257731958762887
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2023-06-01,6.0,0.010309278350515464
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2023-06-01,56.0,0.5257731958762887
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2023-06-01,58.0,0.3036649214659686
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2023-06-01,54.0,0.28272251308900526
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2023-06-01,12.0,0.06282722513089005
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2023-06-01,5.0,0.02617801047120419
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2023-06-01,112.0,0.5863874345549738
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2023-06-01,8.0,0.041884816753926704
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2023-06-01,112.0,0.5863874345549738
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2023-06-01,112.0,0.5863874345549738
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2023-06-01,112.0,0.5863874345549738
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2023-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2023-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2023-06-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2023-06-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2023-06-01,110.0,0.5288461538461539
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2023-06-01,112.0,0.5384615384615384
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2023-06-01,112.0,0.5384615384615384
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2023-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2023-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2023-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2023-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2023-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2023-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2023-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2023-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2023-06-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2023-06-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2023-06-01,5.0,0.012953367875647668
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2023-06-01,2.0,0.0051813471502590676
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2023-06-01,11.0,0.02849740932642487
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2023-06-01,1.0,0.0025906735751295338
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2023-06-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2023-06-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2023-06-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2023-06-01,6.0,0.015544041450777202
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2023-06-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2023-06-01,10.0,0.025906735751295335
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2023-06-01,12.0,0.031088082901554404
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2023-06-01,8.0,0.02072538860103627
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2023-06-01,2.0,0.0051813471502590676
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2023-06-01,32.0,0.08290155440414508
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2023-06-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2023-06-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2023-06-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2023-06-01,0.0,0.0
M8,Family Planning,8.17.1,Complications following male sterilization,2023-06-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2023-06-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2023-06-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2023-06-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2023-06-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2023-06-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2023-06-01,20.0,0.05181347150259067
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2023-06-01,112.0,0.5925925925925926
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2023-06-01,112.0,0.5925925925925926
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2023-06-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2023-06-01,44.0,0.2328042328042328
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2023-06-01,36.0,0.19047619047619047
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2023-06-01,112.0,0.5925925925925926
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2023-06-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2023-06-01,44.0,0.2328042328042328
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2023-06-01,36.0,0.19047619047619047
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2023-06-01,112.0,0.5925925925925926
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2023-06-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2023-06-01,36.0,0.19047619047619047
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2023-06-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2023-06-01,44.0,0.2328042328042328
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2023-06-01,36.0,0.19047619047619047
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2023-06-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2023-06-01,36.0,0.19047619047619047
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2023-06-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2023-06-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2023-06-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2023-06-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2023-06-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2023-06-01,16.0,0.08465608465608465
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2023-06-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2023-06-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2023-06-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2023-06-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2023-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2023-06-01,4.0,0.03389830508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2023-06-01,2.0,0.01694915254237288
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2023-06-01,5.0,0.0423728813559322
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2023-06-01,5.0,0.0423728813559322
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2023-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2023-06-01,1.0,0.00847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2023-06-01,6.0,0.05084745762711865
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2023-06-01,28.0,0.10526315789473684
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2023-06-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2023-06-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2023-06-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2023-06-01,47.0,0.17669172932330826
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2023-06-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2023-06-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2023-06-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2023-06-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2023-06-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-06-01,0.0,0.0
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-06-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-06-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-06-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2023-06-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2023-06-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2023-06-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2023-06-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2023-06-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2023-06-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2023-06-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2023-06-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2023-06-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2023-06-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2023-06-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2023-06-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2023-06-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2023-06-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2023-06-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2023-06-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2023-06-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2023-06-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2023-06-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2023-06-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2023-06-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2023-06-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2023-06-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2023-06-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2023-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2023-06-01,770.0,0.020318230994537827
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2023-06-01,680.0,0.017943372826345092
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2023-06-01,223.0,0.005884370794521994
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2023-06-01,1365.0,0.03601868221758978
M14 ,Patient Services,14.1.8,Outpatient - Dental,2023-06-01,287.0,0.007573158825236826
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2023-06-01,950.0,0.025067947330923292
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2023-06-01,15.0,0.00039580969469878884
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2023-06-01,1040.0,0.027442805499116023
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2023-06-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2023-06-01,734.0,0.019368287727260732
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2023-06-01,19063.0,0.5030213473362007
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2023-06-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2023-06-01,79.0,0.002084597725413621
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2023-06-01,645.0,0.01701981687204792
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2023-06-01,95.0,0.002506794733092329
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2023-06-01,636.0,0.016782331055228646
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2023-06-01,0.0,0.0
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2023-06-01,122.0,0.003219252183550149
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2023-06-01,588.0,0.015515740032192521
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2023-06-01,99.0,0.002612343985012006
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2023-06-01,654.0,0.01725730268886719
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2023-06-01,0.0,0.0
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2023-06-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2023-06-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2023-06-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2023-06-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2023-06-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2023-06-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2023-06-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2023-06-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2023-06-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2023-06-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2023-06-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2023-06-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2023-06-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2023-06-01,45.0,0.0011874290840963664
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2023-06-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2023-06-01,346.0,0.009130010291052062
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2023-06-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2023-06-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2023-06-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2023-06-01,0.0,0.0
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2023-06-01,38.0,0.0010027178932369317
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2023-06-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2023-06-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2023-06-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2023-06-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2023-06-01,130.0,0.003430350687389503
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2023-06-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2023-06-01,1276.0,0.03367021136237697
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2023-06-01,355.0,0.009367496107871336
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2023-06-01,71.0,0.001873499221574267
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2023-06-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2023-06-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2023-06-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2023-06-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2023-06-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2023-06-01,30.0,0.0007916193893975777
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2023-06-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2023-06-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2023-06-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2023-06-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2023-06-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2023-06-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2023-06-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2023-06-01,0.0,0.0
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2023-06-01,538.0,0.014196374383196559
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2023-06-01,24.0,0.0006332955115180621
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2023-06-01,320.0,0.00844394015357416
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2023-06-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2023-06-01,18.0,0.0004749716336385466
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2023-06-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2023-06-01,0.0,0.0
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2023-06-01,0.0,0.0
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2023-06-01,7950.0,0.20977913819035807
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2023-06-01,0.0,0.0
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2023-06-01,0.0,0.0
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2023-06-01,0.0,0.0
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2023-06-01,0.0,0.0
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2023-06-01,0.0,0.0
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2023-06-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2023-06-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2023-06-01,112.0,0.0029553790537509565
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2023-06-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2023-06-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2023-06-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2023-06-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2023-06-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2023-06-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2023-06-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2023-06-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2023-06-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2023-06-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2023-06-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2023-06-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2023-06-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2023-06-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2023-06-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2023-06-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2023-06-01,0.0,0.0
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2023-06-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2023-06-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2023-06-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2023-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2023-06-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2023-06-01,40798.0,0.5737631142238349
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2023-06-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2023-06-01,3146.0,0.044243805023486064
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2023-06-01,21.0,0.00029533372711163615
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-06-01,441.0,0.0062020082693443595
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-06-01,4.0,5.6254043259359264e-05
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2023-06-01,4.0,5.6254043259359264e-05
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-06-01,534.0,0.007509914775124462
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-06-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2023-06-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-06-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-06-01,66.0,0.0009281917137794279
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-06-01,209.0,0.002939273760301522
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-06-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2023-06-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2023-06-01,82.0,0.001153207886816865
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2023-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2023-06-01,3017.0,0.04242961212837173
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2023-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2023-06-01,1377.0,0.019365454392034426
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2023-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2023-06-01,390.0,0.005484769217787528
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2023-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2023-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2023-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2023-06-01,415.0,0.005836356988158524
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2023-06-01,4.0,0.12903225806451613
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2023-06-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2023-06-01,21.0,0.6774193548387096
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2023-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2023-06-01,21.0,0.6774193548387096
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2023-06-01,0.0,0.0
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2023-06-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2023-06-01,0.0,0.0
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2023-06-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2023-06-01,0.0,0.0
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2023-06-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2023-06-01,173.0,0.1251808972503618
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2023-06-01,173.0,0.1251808972503618
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2023-06-01,12.0,0.008683068017366137
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2023-06-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2023-06-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2023-06-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2023-06-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2023-06-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2023-06-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2023-06-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2023-06-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2023-06-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2023-06-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2023-06-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2023-06-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2023-06-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2023-07-01,978.0,0.6178142766898295
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2023-07-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2023-07-01,14.0,0.008843967150979154
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2023-07-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2023-07-01,33.0,0.020846493998736577
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2023-07-01,24.0,0.015161086544535692
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2023-07-01,24.0,0.015161086544535692
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2023-07-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2023-07-01,56.0,0.035375868603916616
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2023-07-01,342.0,0.2160454832596336
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2023-07-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2023-07-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2023-07-01,343.0,0.21667719519898926
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2023-07-01,23.0,0.014529374605180037
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2023-07-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2023-07-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2023-07-01,356.0,0.22488945041061276
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2023-07-01,78.0,0.049273531269740996
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2023-07-01,62.0,0.03916614024005054
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2023-07-01,15.0,0.009475679090334808
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2023-07-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2023-07-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2023-07-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2023-07-01,112.0,0.07075173720783323
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2023-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2023-07-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2023-07-01,21.0,0.013265950726468731
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2023-07-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2023-07-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2023-07-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2023-07-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2023-07-01,107.0,0.5602094240837696
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2023-07-01,50.0,0.2617801047120419
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2023-07-01,25.0,0.13089005235602094
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2023-07-01,107.0,0.5602094240837696
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2023-07-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2023-07-01,10.0,0.05235602094240838
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2023-07-01,97.0,0.5078534031413613
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2023-07-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2023-07-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2023-07-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2023-07-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2023-07-01,57.0,0.5360824742268041
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2023-07-01,5.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2023-07-01,57.0,0.5360824742268041
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2023-07-01,54.0,0.28272251308900526
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2023-07-01,52.0,0.27225130890052357
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2023-07-01,10.0,0.05235602094240838
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2023-07-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2023-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2023-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2023-07-01,106.0,0.5549738219895288
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2023-07-01,26.0,0.13612565445026178
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2023-07-01,2.0,0.010471204188481676
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2023-07-01,106.0,0.5549738219895288
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2023-07-01,106.0,0.5549738219895288
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2023-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2023-07-01,106.0,0.5549738219895288
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2023-07-01,4.0,0.020942408376963352
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2023-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2023-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2023-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2023-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2023-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2023-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2023-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2023-07-01,4.0,0.020942408376963352
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2023-07-01,4.0,0.020942408376963352
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2023-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2023-07-01,6.0,0.12
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2023-07-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2023-07-01,106.0,0.5096153846153846
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2023-07-01,106.0,0.5096153846153846
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2023-07-01,106.0,0.5096153846153846
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2023-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2023-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2023-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2023-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2023-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2023-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2023-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2023-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2023-07-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2023-07-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2023-07-01,5.0,0.012953367875647668
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2023-07-01,2.0,0.0051813471502590676
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2023-07-01,4.0,0.010362694300518135
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2023-07-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2023-07-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2023-07-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2023-07-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2023-07-01,6.0,0.015544041450777202
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2023-07-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2023-07-01,12.0,0.031088082901554404
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2023-07-01,10.0,0.025906735751295335
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2023-07-01,12.0,0.031088082901554404
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2023-07-01,8.0,0.02072538860103627
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2023-07-01,30.0,0.07772020725388601
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2023-07-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2023-07-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2023-07-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2023-07-01,252.0,0.6528497409326425
M8,Family Planning,8.17.1,Complications following male sterilization,2023-07-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2023-07-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2023-07-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2023-07-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2023-07-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2023-07-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2023-07-01,12.0,0.031088082901554404
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2023-07-01,106.0,0.5608465608465608
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2023-07-01,106.0,0.5608465608465608
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2023-07-01,43.0,0.2275132275132275
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2023-07-01,46.0,0.24338624338624337
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2023-07-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2023-07-01,106.0,0.5608465608465608
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2023-07-01,43.0,0.2275132275132275
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2023-07-01,46.0,0.24338624338624337
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2023-07-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2023-07-01,106.0,0.5608465608465608
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2023-07-01,43.0,0.2275132275132275
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2023-07-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2023-07-01,43.0,0.2275132275132275
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2023-07-01,46.0,0.24338624338624337
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2023-07-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2023-07-01,43.0,0.2275132275132275
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2023-07-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2023-07-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2023-07-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2023-07-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2023-07-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2023-07-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2023-07-01,10.0,0.05291005291005291
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2023-07-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2023-07-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2023-07-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2023-07-01,4.0,0.021164021164021163
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2023-07-01,16.0,0.08465608465608465
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2023-07-01,6.0,0.031746031746031744
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2023-07-01,10.0,0.05291005291005291
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2023-07-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2023-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2023-07-01,3.0,0.025423728813559324
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2023-07-01,11.0,0.09322033898305085
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2023-07-01,1.0,0.00847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2023-07-01,60.0,0.5084745762711864
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2023-07-01,60.0,0.5084745762711864
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2023-07-01,60.0,0.5084745762711864
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2023-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2023-07-01,8.0,0.06779661016949153
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2023-07-01,40.0,0.15037593984962405
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2023-07-01,1.0,0.0037593984962406013
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2023-07-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2023-07-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2023-07-01,55.0,0.20676691729323307
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2023-07-01,1.0,0.0037593984962406013
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2023-07-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2023-07-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2023-07-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2023-07-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-07-01,2.0,0.007518796992481203
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-07-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-07-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-07-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2023-07-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2023-07-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2023-07-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2023-07-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2023-07-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2023-07-01,19.0,0.15079365079365079
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2023-07-01,8.0,0.06349206349206349
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2023-07-01,12.0,0.09523809523809523
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2023-07-01,6.0,0.047619047619047616
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2023-07-01,19.0,0.15079365079365079
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2023-07-01,8.0,0.06349206349206349
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2023-07-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2023-07-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2023-07-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2023-07-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2023-07-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2023-07-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2023-07-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2023-07-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2023-07-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2023-07-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2023-07-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2023-07-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2023-07-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2023-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2023-07-01,1.0,0.1
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2023-07-01,8.0,0.8
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2023-07-01,8.0,0.8
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2023-07-01,8.0,0.8
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2023-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2023-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2023-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2023-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2023-07-01,1.0,0.1
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2023-07-01,1.0,0.1
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2023-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2023-07-01,820.0,0.021637596643533787
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2023-07-01,730.0,0.019262738475341056
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2023-07-01,1524.0,0.04021426498139694
M14 ,Patient Services,14.1.8,Outpatient - Dental,2023-07-01,1000.0,0.026387312979919256
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2023-07-01,1003.0,0.026466474918859013
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2023-07-01,17.0,0.00044858432065862734
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2023-07-01,1375.0,0.03628255534738897
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2023-07-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2023-07-01,761.0,0.020080745177718552
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2023-07-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2023-07-01,20585.0,0.5431828376916379
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2023-07-01,138.0,0.003641449191228857
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2023-07-01,587.0,0.015489352719212602
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2023-07-01,99.0,0.002612343985012006
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2023-07-01,695.0,0.01833918252104388
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2023-07-01,140.0,0.0036942238171886956
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2023-07-01,593.0,0.015647676597092118
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2023-07-01,101.0,0.002665118610971845
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2023-07-01,663.0,0.017494788505686466
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2023-07-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2023-07-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2023-07-01,7.0,0.00018471119085943478
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2023-07-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2023-07-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2023-07-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2023-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2023-07-01,20.0,0.000527746259598385
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2023-07-01,0.0,0.0
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2023-07-01,42.0,0.0011082671451566088
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2023-07-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2023-07-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2023-07-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2023-07-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2023-07-01,150.0,0.003958096946987889
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2023-07-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2023-07-01,1902.0,0.05018866928780642
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2023-07-01,455.0,0.012006227405863261
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2023-07-01,55.0,0.001451302213895559
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2023-07-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2023-07-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2023-07-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2023-07-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2023-07-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2023-07-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2023-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2023-07-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2023-07-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2023-07-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2023-07-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2023-07-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2023-07-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2023-07-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2023-07-01,587.0,0.015489352719212602
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2023-07-01,21.0,0.0005541335725783044
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2023-07-01,320.0,0.00844394015357416
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2023-07-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2023-07-01,62.0,0.0016360134047549938
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2023-07-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2023-07-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2023-07-01,0.0,0.0
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2023-07-01,8268.0,0.21817030371797239
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2023-07-01,41.0,0.0010818798321766895
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2023-07-01,18.0,0.0004749716336385466
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2023-07-01,21.0,0.0005541335725783044
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2023-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2023-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2023-07-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2023-07-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2023-07-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2023-07-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2023-07-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2023-07-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2023-07-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2023-07-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2023-07-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2023-07-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2023-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2023-07-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2023-07-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2023-07-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2023-07-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2023-07-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2023-07-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2023-07-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2023-07-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2023-07-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2023-07-01,197.0,0.005198300657044093
M14 ,Patient Services,14.21,Total number of blood units issued in month,2023-07-01,267.0,0.007045412565638441
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2023-07-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2023-07-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2023-07-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2023-07-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2023-07-01,940.0,0.0248040742011241
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2023-07-01,815.0,0.021505660078634192
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2023-07-01,11.0,0.0002902604427791118
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2023-07-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2023-07-01,356.0,0.009393883420851255
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2023-07-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2023-07-01,3.0,7.916193893975777e-05
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2023-07-01,42062.0,0.5915393918937923
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2023-07-01,3645.0,0.05126149692009113
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2023-07-01,645.0,0.009070964475571682
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-07-01,452.0,0.006356706888307597
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2023-07-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-07-01,551.0,0.007748994458976739
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2023-07-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-07-01,89.0,0.0012516524625207437
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-07-01,185.0,0.002601749500745366
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-07-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2023-07-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2023-07-01,53.0,0.0007453660731865103
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2023-07-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2023-07-01,3024.0,0.042528056704075605
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2023-07-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2023-07-01,1418.0,0.01994205833544286
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2023-07-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2023-07-01,362.0,0.005090990914972013
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2023-07-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2023-07-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2023-07-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2023-07-01,450.0,0.006328579866677918
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2023-07-01,6.0,0.1935483870967742
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2023-07-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2023-07-01,28.0,0.9032258064516129
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2023-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2023-07-01,28.0,0.9032258064516129
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2023-07-01,13.0,0.009406657018813314
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2023-07-01,13.0,0.009406657018813314
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2023-07-01,47.0,0.03400868306801737
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2023-07-01,45.0,0.03256150506512301
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2023-07-01,73.0,0.052821997105643996
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2023-07-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2023-07-01,0.0,0.0
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2023-07-01,0.0,0.0
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2023-07-01,0.0,0.0
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2023-07-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2023-07-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2023-07-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2023-07-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2023-07-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2023-07-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2023-07-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2023-07-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2023-07-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2023-07-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2023-07-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2023-07-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2023-07-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2023-08-01,356.0,0.22488945041061276
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2023-08-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2023-08-01,15.0,0.009475679090334808
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2023-08-01,16.0,0.01010739102969046
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2023-08-01,29.0,0.01831964624131396
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2023-08-01,28.0,0.017687934301958308
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2023-08-01,28.0,0.017687934301958308
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2023-08-01,44.0,0.027795325331648767
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2023-08-01,29.0,0.01831964624131396
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2023-08-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2023-08-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2023-08-01,138.0,0.08717624763108023
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2023-08-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2023-08-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2023-08-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2023-08-01,138.0,0.08717624763108023
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2023-08-01,138.0,0.08717624763108023
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2023-08-01,106.0,0.06696146557169931
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2023-08-01,13.0,0.0082122552116235
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2023-08-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2023-08-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2023-08-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2023-08-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2023-08-01,56.0,0.035375868603916616
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2023-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2023-08-01,34.0,0.02147820593809223
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2023-08-01,28.0,0.017687934301958308
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2023-08-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2023-08-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2023-08-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2023-08-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2023-08-01,125.0,0.6544502617801047
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2023-08-01,67.0,0.3507853403141361
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2023-08-01,23.0,0.12041884816753927
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2023-08-01,125.0,0.6544502617801047
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2023-08-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2023-08-01,0.0,0.0
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2023-08-01,125.0,0.6544502617801047
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2023-08-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2023-08-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2023-08-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2023-08-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2023-08-01,58.0,0.5463917525773195
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2023-08-01,9.0,0.041237113402061855
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2023-08-01,58.0,0.5463917525773195
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2023-08-01,67.0,0.3507853403141361
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2023-08-01,58.0,0.3036649214659686
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2023-08-01,9.0,0.04712041884816754
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2023-08-01,125.0,0.6544502617801047
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2023-08-01,25.0,0.13089005235602094
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2023-08-01,11.0,0.05759162303664921
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2023-08-01,125.0,0.6544502617801047
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2023-08-01,125.0,0.6544502617801047
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2023-08-01,125.0,0.6544502617801047
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2023-08-01,2.0,0.010471204188481676
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2023-08-01,12.0,0.06282722513089005
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2023-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2023-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2023-08-01,12.0,0.24
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2023-08-01,125.0,0.6009615384615384
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2023-08-01,125.0,0.6009615384615384
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2023-08-01,125.0,0.6009615384615384
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2023-08-01,125.0,0.6009615384615384
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2023-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2023-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2023-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2023-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2023-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2023-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2023-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2023-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2023-08-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2023-08-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2023-08-01,2.0,0.0051813471502590676
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2023-08-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2023-08-01,12.0,0.031088082901554404
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2023-08-01,3.0,0.007772020725388601
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2023-08-01,12.0,0.031088082901554404
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2023-08-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2023-08-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2023-08-01,10.0,0.025906735751295335
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2023-08-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2023-08-01,8.0,0.02072538860103627
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2023-08-01,6.0,0.015544041450777202
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2023-08-01,2.0,0.0051813471502590676
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2023-08-01,0.0,0.0
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2023-08-01,40.0,0.10362694300518134
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2023-08-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2023-08-01,2.0,0.0051813471502590676
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2023-08-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2023-08-01,386.0,1.0
M8,Family Planning,8.17.1,Complications following male sterilization,2023-08-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2023-08-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2023-08-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2023-08-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2023-08-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2023-08-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2023-08-01,13.0,0.03367875647668394
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2023-08-01,125.0,0.6613756613756614
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2023-08-01,125.0,0.6613756613756614
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2023-08-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2023-08-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2023-08-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2023-08-01,125.0,0.6613756613756614
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2023-08-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2023-08-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2023-08-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2023-08-01,125.0,0.6613756613756614
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2023-08-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2023-08-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2023-08-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2023-08-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2023-08-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2023-08-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2023-08-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2023-08-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2023-08-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2023-08-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2023-08-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2023-08-01,9.0,0.047619047619047616
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2023-08-01,10.0,0.05291005291005291
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2023-08-01,1.0,0.005291005291005291
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2023-08-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2023-08-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2023-08-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2023-08-01,6.0,0.031746031746031744
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2023-08-01,3.0,0.015873015873015872
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2023-08-01,4.0,0.021164021164021163
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2023-08-01,1.0,0.005291005291005291
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2023-08-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2023-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2023-08-01,3.0,0.025423728813559324
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2023-08-01,3.0,0.025423728813559324
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2023-08-01,8.0,0.06779661016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2023-08-01,48.0,0.4067796610169492
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2023-08-01,48.0,0.4067796610169492
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2023-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2023-08-01,72.0,0.6101694915254238
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2023-08-01,21.0,0.17796610169491525
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2023-08-01,8.0,0.06779661016949153
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2023-08-01,98.0,0.3684210526315789
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2023-08-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2023-08-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2023-08-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2023-08-01,81.0,0.30451127819548873
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2023-08-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2023-08-01,1.0,0.0037593984962406013
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2023-08-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2023-08-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2023-08-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-08-01,8.0,0.03007518796992481
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-08-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-08-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-08-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2023-08-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2023-08-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2023-08-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2023-08-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2023-08-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2023-08-01,20.0,0.15873015873015872
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2023-08-01,8.0,0.06349206349206349
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2023-08-01,14.0,0.1111111111111111
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2023-08-01,5.0,0.03968253968253968
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2023-08-01,20.0,0.15873015873015872
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2023-08-01,8.0,0.06349206349206349
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2023-08-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2023-08-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2023-08-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2023-08-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2023-08-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2023-08-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2023-08-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2023-08-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2023-08-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2023-08-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2023-08-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2023-08-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2023-08-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2023-08-01,6.0,0.6
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2023-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2023-08-01,929.0,0.024513813758344986
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2023-08-01,775.0,0.02045016755943742
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2023-08-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2023-08-01,276.0,0.007282898382457714
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2023-08-01,1447.0,0.03818244188194316
M14 ,Patient Services,14.1.8,Outpatient - Dental,2023-08-01,993.0,0.02620260178905982
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2023-08-01,1074.0,0.02833997414043328
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2023-08-01,18.0,0.0004749716336385466
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2023-08-01,1150.0,0.03034540992690714
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2023-08-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2023-08-01,680.0,0.017943372826345092
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2023-08-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2023-08-01,21728.0,0.5733435364276855
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2023-08-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2023-08-01,184.0,0.0048552655883051426
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2023-08-01,704.0,0.018576668337863155
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2023-08-01,160.0,0.00422197007678708
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2023-08-01,760.0,0.020054357864738633
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2023-08-01,0.0,0.0
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2023-08-01,163.0,0.004301132015726838
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2023-08-01,685.0,0.01807530939124469
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2023-08-01,129.0,0.003403963374409584
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2023-08-01,768.0,0.02026545636857799
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2023-08-01,0.0,0.0
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2023-08-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2023-08-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2023-08-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2023-08-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2023-08-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2023-08-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2023-08-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2023-08-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2023-08-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2023-08-01,13.0,0.0003430350687389503
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2023-08-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2023-08-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.6,Day Care Admissions,2023-08-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2023-08-01,35.0,0.0009235559542971739
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2023-08-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2023-08-01,0.0,0.0
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2023-08-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2023-08-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2023-08-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2023-08-01,34.0,0.0008971686413172547
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2023-08-01,0.0,0.0
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2023-08-01,68.0,0.0017943372826345093
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2023-08-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2023-08-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2023-08-01,11.0,0.0002902604427791118
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2023-08-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2023-08-01,119.0,0.0031400902446103913
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2023-08-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2023-08-01,1209.0,0.03190226139272238
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2023-08-01,295.0,0.0077842573290761805
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2023-08-01,45.0,0.0011874290840963664
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2023-08-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2023-08-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2023-08-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2023-08-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2023-08-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2023-08-01,11.0,0.0002902604427791118
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2023-08-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2023-08-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2023-08-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2023-08-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2023-08-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2023-08-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2023-08-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2023-08-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2023-08-01,543.0,0.014328310948096156
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2023-08-01,31.0,0.0008180067023774969
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2023-08-01,285.0,0.007520384199276988
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2023-08-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2023-08-01,55.0,0.001451302213895559
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2023-08-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2023-08-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2023-08-01,0.0,0.0
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2023-08-01,9037.0,0.2384621473995303
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2023-08-01,59.0,0.001556851465815236
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2023-08-01,37.0,0.0009763305802570124
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2023-08-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2023-08-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2023-08-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2023-08-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2023-08-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2023-08-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2023-08-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2023-08-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2023-08-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2023-08-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2023-08-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2023-08-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2023-08-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2023-08-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2023-08-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2023-08-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2023-08-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2023-08-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2023-08-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2023-08-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2023-08-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2023-08-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2023-08-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2023-08-01,187.0,0.0049344275272449
M14 ,Patient Services,14.21,Total number of blood units issued in month,2023-08-01,245.0,0.006464891680080217
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2023-08-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2023-08-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2023-08-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2023-08-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2023-08-01,960.0,0.025331820460722486
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2023-08-01,797.0,0.021030688444995647
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2023-08-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2023-08-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2023-08-01,738.0,0.01947383697918041
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2023-08-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2023-08-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2023-08-01,44726.0,0.6290045847045257
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2023-08-01,3648.0,0.05130368745253565
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2023-08-01,29.0,0.0004078418136303547
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-08-01,399.0,0.005611340815121087
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2023-08-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-08-01,479.0,0.006736421680308272
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2023-08-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-08-01,56.0,0.0007875566056310297
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-08-01,226.0,0.0031783534441537985
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-08-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2023-08-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2023-08-01,121.0,0.0017016848085956177
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2023-08-01,11.0,0.000154698618963238
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2023-08-01,2858.0,0.0401935139088122
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2023-08-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2023-08-01,1433.0,0.020153010997665456
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2023-08-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2023-08-01,202.0,0.002840829184597643
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2023-08-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2023-08-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2023-08-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2023-08-01,501.0,0.007045818918234748
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2023-08-01,10.0,0.3225806451612903
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2023-08-01,3.0,0.0967741935483871
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2023-08-01,28.0,0.9032258064516129
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2023-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2023-08-01,28.0,0.9032258064516129
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2023-08-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2023-08-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2023-08-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2023-08-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2023-08-01,83.0,0.060057887120115776
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2023-08-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2023-08-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2023-08-01,3.0,0.002170767004341534
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2023-08-01,3.0,0.002170767004341534
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2023-08-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2023-08-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2023-08-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2023-08-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2023-08-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2023-08-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2023-08-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2023-08-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2023-08-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2023-08-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2023-08-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2023-08-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2023-08-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2023-09-01,1266.0,0.7997473152242578
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2023-09-01,11.0,0.006948831332912192
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2023-09-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2023-09-01,5.0,0.003158559696778269
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2023-09-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2023-09-01,52.0,0.032849020846494
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2023-09-01,52.0,0.032849020846494
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2023-09-01,162.0,0.10233733417561591
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2023-09-01,112.0,0.07075173720783323
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2023-09-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2023-09-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2023-09-01,496.0,0.3133291219204043
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2023-09-01,42.0,0.026531901452937462
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2023-09-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2023-09-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2023-09-01,480.0,0.30322173089071386
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2023-09-01,496.0,0.3133291219204043
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2023-09-01,122.0,0.07706885660138976
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2023-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2023-09-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2023-09-01,7.0,0.004421983575489577
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2023-09-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2023-09-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2023-09-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2023-09-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2023-09-01,106.0,0.5549738219895288
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2023-09-01,54.0,0.28272251308900526
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2023-09-01,15.0,0.07853403141361257
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2023-09-01,106.0,0.5549738219895288
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2023-09-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2023-09-01,4.0,0.020942408376963352
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2023-09-01,102.0,0.5340314136125655
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2023-09-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2023-09-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2023-09-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2023-09-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2023-09-01,52.0,0.4845360824742268
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2023-09-01,8.0,0.030927835051546393
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2023-09-01,52.0,0.4845360824742268
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2023-09-01,53.0,0.2774869109947644
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2023-09-01,53.0,0.2774869109947644
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2023-09-01,12.0,0.06282722513089005
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2023-09-01,106.0,0.5549738219895288
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2023-09-01,7.0,0.03664921465968586
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2023-09-01,5.0,0.02617801047120419
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2023-09-01,106.0,0.5549738219895288
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2023-09-01,106.0,0.5549738219895288
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2023-09-01,106.0,0.5549738219895288
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2023-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2023-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2023-09-01,2.0,0.04
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2023-09-01,94.0,0.4519230769230769
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2023-09-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2023-09-01,0.0,0.0
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2023-09-01,0.0,0.0
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2023-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2023-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2023-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2023-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2023-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2023-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2023-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2023-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2023-09-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2023-09-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2023-09-01,7.0,0.018134715025906734
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2023-09-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2023-09-01,8.0,0.02072538860103627
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2023-09-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2023-09-01,8.0,0.02072538860103627
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2023-09-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2023-09-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2023-09-01,3.0,0.007772020725388601
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2023-09-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2023-09-01,4.0,0.010362694300518135
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2023-09-01,7.0,0.018134715025906734
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2023-09-01,8.0,0.02072538860103627
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2023-09-01,3.0,0.007772020725388601
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2023-09-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2023-09-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2023-09-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2023-09-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2023-09-01,309.0,0.8005181347150259
M8,Family Planning,8.17.1,Complications following male sterilization,2023-09-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2023-09-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2023-09-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2023-09-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2023-09-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2023-09-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2023-09-01,18.0,0.046632124352331605
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2023-09-01,106.0,0.5608465608465608
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2023-09-01,106.0,0.5608465608465608
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2023-09-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2023-09-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2023-09-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2023-09-01,106.0,0.5608465608465608
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2023-09-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2023-09-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2023-09-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2023-09-01,106.0,0.5608465608465608
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2023-09-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2023-09-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2023-09-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2023-09-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2023-09-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2023-09-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2023-09-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2023-09-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2023-09-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2023-09-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2023-09-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2023-09-01,7.0,0.037037037037037035
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2023-09-01,11.0,0.0582010582010582
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2023-09-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2023-09-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2023-09-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2023-09-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2023-09-01,17.0,0.08994708994708994
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2023-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2023-09-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2023-09-01,4.0,0.03389830508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2023-09-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2023-09-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2023-09-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2023-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2023-09-01,45.0,0.3813559322033898
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2023-09-01,27.0,0.2288135593220339
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2023-09-01,3.0,0.025423728813559324
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2023-09-01,101.0,0.37969924812030076
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2023-09-01,1.0,0.0037593984962406013
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2023-09-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2023-09-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2023-09-01,87.0,0.32706766917293234
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2023-09-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2023-09-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2023-09-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2023-09-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2023-09-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-09-01,5.0,0.018796992481203006
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-09-01,5.0,0.018796992481203006
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-09-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-09-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2023-09-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2023-09-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2023-09-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2023-09-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2023-09-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2023-09-01,36.0,0.2857142857142857
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2023-09-01,24.0,0.19047619047619047
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2023-09-01,36.0,0.2857142857142857
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2023-09-01,24.0,0.19047619047619047
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2023-09-01,6.0,0.047619047619047616
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2023-09-01,4.0,0.031746031746031744
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2023-09-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2023-09-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2023-09-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2023-09-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2023-09-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2023-09-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2023-09-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2023-09-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2023-09-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2023-09-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2023-09-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2023-09-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2023-09-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2023-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2023-09-01,875.0,0.023088898857429346
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2023-09-01,790.0,0.02084597725413621
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2023-09-01,229.0,0.006042694672401509
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2023-09-01,252.0,0.006649602870939652
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2023-09-01,1349.0,0.03559648520991107
M14 ,Patient Services,14.1.8,Outpatient - Dental,2023-09-01,887.0,0.023405546613188378
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2023-09-01,1025.0,0.027046995804417235
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2023-09-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2023-09-01,28.0,0.0007388447634377391
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2023-09-01,1110.0,0.029289917407710375
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2023-09-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2023-09-01,608.0,0.016043486291790907
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2023-09-01,20380.0,0.5377734385307544
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2023-09-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2023-09-01,104.0,0.0027442805499116023
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2023-09-01,988.0,0.026070665224160225
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2023-09-01,76.0,0.0020054357864738633
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2023-09-01,793.0,0.02092513919307597
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2023-09-01,0.0,0.0
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2023-09-01,114.0,0.003008153679710795
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2023-09-01,1008.0,0.02659841148375861
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2023-09-01,81.0,0.0021373723513734596
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2023-09-01,832.0,0.02195424439929282
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2023-09-01,0.0,0.0
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2023-09-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2023-09-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2023-09-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2023-09-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2023-09-01,0.0,0.0
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2023-09-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2023-09-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2023-09-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2023-09-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2023-09-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2023-09-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2023-09-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2023-09-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2023-09-01,30.0,0.0007916193893975777
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2023-09-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2023-09-01,237.0,0.006253793176240864
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2023-09-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2023-09-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2023-09-01,40.0,0.00105549251919677
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2023-09-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2023-09-01,50.0,0.0013193656489959627
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2023-09-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2023-09-01,0.0,0.0
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2023-09-01,7.0,0.00018471119085943478
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2023-09-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2023-09-01,67.0,0.0017679499696545901
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2023-09-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2023-09-01,1807.0,0.04768187455471409
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2023-09-01,705.0,0.018603055650843074
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2023-09-01,54.0,0.0014249149009156398
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2023-09-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2023-09-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2023-09-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2023-09-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2023-09-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2023-09-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2023-09-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2023-09-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2023-09-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2023-09-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2023-09-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2023-09-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2023-09-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2023-09-01,0.0,0.0
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2023-09-01,508.0,0.013404754993798982
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2023-09-01,22.0,0.0005805208855582236
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2023-09-01,828.0,0.021848695147373143
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2023-09-01,86.0,0.002269308916273056
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2023-09-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2023-09-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2023-09-01,0.0,0.0
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2023-09-01,8871.0,0.2340818534448637
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2023-09-01,43.0,0.001134654458136528
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2023-09-01,24.0,0.0006332955115180621
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2023-09-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2023-09-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2023-09-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2023-09-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2023-09-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2023-09-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2023-09-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2023-09-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2023-09-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2023-09-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2023-09-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2023-09-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2023-09-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2023-09-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2023-09-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2023-09-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2023-09-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2023-09-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2023-09-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2023-09-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2023-09-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2023-09-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2023-09-01,214.0,0.0056468849777027205
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2023-09-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2023-09-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2023-09-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2023-09-01,944.0,0.024909623453043775
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2023-09-01,829.0,0.021875082460353062
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2023-09-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2023-09-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2023-09-01,480.0,0.012665910230361243
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2023-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2023-09-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2023-09-01,45900.0,0.6455151464011476
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2023-09-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2023-09-01,4371.0,0.06147160577166484
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2023-09-01,28.0,0.00039377830281551486
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-09-01,404.0,0.005681658369195286
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2023-09-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-09-01,656.0,0.00922566309453492
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2023-09-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-09-01,86.0,0.0012094619300762242
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2023-09-01,211.0,0.0029674007819312015
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-09-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2023-09-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2023-09-01,146.0,0.002053272578966613
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2023-09-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2023-09-01,2974.0,0.04182488116333361
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2023-09-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2023-09-01,1408.0,0.019801423227294463
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2023-09-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2023-09-01,41.0,0.0005766039434084325
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2023-09-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2023-09-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2023-09-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2023-09-01,725.0,0.010196045340758866
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2023-09-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2023-09-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-09-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2023-09-01,4.0,0.12903225806451613
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2023-09-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2023-09-01,13.0,0.41935483870967744
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2023-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2023-09-01,13.0,0.41935483870967744
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2023-09-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2023-09-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2023-09-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2023-09-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2023-09-01,88.0,0.06367583212735166
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2023-09-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2023-09-01,3.0,0.002170767004341534
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2023-09-01,1.0,0.000723589001447178
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2023-09-01,1.0,0.000723589001447178
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2023-09-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2023-09-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2023-09-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2023-09-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2023-09-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2023-09-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2023-09-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2023-09-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2023-09-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2023-09-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2023-09-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2023-09-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2023-09-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2023-10-01,1583.0,1.0
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2023-10-01,11.0,0.006948831332912192
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2023-10-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2023-10-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2023-10-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2023-10-01,48.0,0.030322173089071383
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2023-10-01,48.0,0.030322173089071383
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2023-10-01,347.0,0.21920404295641188
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2023-10-01,48.0,0.030322173089071383
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2023-10-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2023-10-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2023-10-01,157.0,0.09917877447883765
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2023-10-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2023-10-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2023-10-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2023-10-01,347.0,0.21920404295641188
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2023-10-01,347.0,0.21920404295641188
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2023-10-01,21.0,0.013265950726468731
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2023-10-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2023-10-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2023-10-01,38.0,0.024005053695514846
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2023-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2023-10-01,18.0,0.011370814908401769
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2023-10-01,20.0,0.012634238787113077
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2023-10-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2023-10-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2023-10-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2023-10-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2023-10-01,138.0,0.7225130890052356
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2023-10-01,74.0,0.387434554973822
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2023-10-01,14.0,0.07329842931937172
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2023-10-01,138.0,0.7225130890052356
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2023-10-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2023-10-01,4.0,0.020942408376963352
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2023-10-01,134.0,0.7015706806282722
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2023-10-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2023-10-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2023-10-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2023-10-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2023-10-01,64.0,0.6082474226804123
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2023-10-01,11.0,0.061855670103092786
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2023-10-01,64.0,0.6082474226804123
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2023-10-01,67.0,0.3507853403141361
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2023-10-01,69.0,0.3612565445026178
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2023-10-01,20.0,0.10471204188481675
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2023-10-01,2.0,0.010471204188481676
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2023-10-01,136.0,0.7120418848167539
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2023-10-01,14.0,0.07329842931937172
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2023-10-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2023-10-01,136.0,0.7120418848167539
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2023-10-01,136.0,0.7120418848167539
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2023-10-01,136.0,0.7120418848167539
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2023-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2023-10-01,2.0,0.04
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2023-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2023-10-01,2.0,0.04
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2023-10-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2023-10-01,187.0,0.8990384615384616
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2023-10-01,187.0,0.8990384615384616
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2023-10-01,187.0,0.8990384615384616
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2023-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2023-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2023-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2023-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2023-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2023-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2023-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2023-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2023-10-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2023-10-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2023-10-01,6.0,0.015544041450777202
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2023-10-01,1.0,0.0025906735751295338
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2023-10-01,4.0,0.010362694300518135
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2023-10-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2023-10-01,12.0,0.031088082901554404
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2023-10-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2023-10-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2023-10-01,8.0,0.02072538860103627
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2023-10-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2023-10-01,12.0,0.031088082901554404
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2023-10-01,8.0,0.02072538860103627
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2023-10-01,4.0,0.010362694300518135
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2023-10-01,10.0,0.025906735751295335
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2023-10-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2023-10-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2023-10-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2023-10-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2023-10-01,72.0,0.18652849740932642
M8,Family Planning,8.17.1,Complications following male sterilization,2023-10-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2023-10-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2023-10-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2023-10-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2023-10-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2023-10-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2023-10-01,94.0,0.24352331606217617
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2023-10-01,136.0,0.7195767195767195
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2023-10-01,136.0,0.7195767195767195
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2023-10-01,41.0,0.21693121693121692
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2023-10-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2023-10-01,36.0,0.19047619047619047
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2023-10-01,136.0,0.7195767195767195
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2023-10-01,41.0,0.21693121693121692
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2023-10-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2023-10-01,36.0,0.19047619047619047
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2023-10-01,136.0,0.7195767195767195
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2023-10-01,41.0,0.21693121693121692
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2023-10-01,36.0,0.19047619047619047
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2023-10-01,41.0,0.21693121693121692
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2023-10-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2023-10-01,36.0,0.19047619047619047
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2023-10-01,41.0,0.21693121693121692
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2023-10-01,36.0,0.19047619047619047
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2023-10-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2023-10-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2023-10-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2023-10-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2023-10-01,12.0,0.06349206349206349
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2023-10-01,10.0,0.05291005291005291
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2023-10-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2023-10-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2023-10-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2023-10-01,1.0,0.005291005291005291
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2023-10-01,1.0,0.005291005291005291
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2023-10-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2023-10-01,10.0,0.05291005291005291
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2023-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2023-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2023-10-01,61.0,0.5169491525423728
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2023-10-01,19.0,0.16101694915254236
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2023-10-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2023-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2023-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2023-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2023-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2023-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2023-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2023-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2023-10-01,51.0,0.4322033898305085
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2023-10-01,51.0,0.4322033898305085
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2023-10-01,51.0,0.4322033898305085
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2023-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2023-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2023-10-01,32.0,0.2711864406779661
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2023-10-01,26.0,0.22033898305084745
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2023-10-01,11.0,0.09322033898305085
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2023-10-01,137.0,0.5150375939849624
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2023-10-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2023-10-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2023-10-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2023-10-01,82.0,0.3082706766917293
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2023-10-01,1.0,0.0037593984962406013
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2023-10-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2023-10-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2023-10-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2023-10-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-10-01,0.0,0.0
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-10-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-10-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-10-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2023-10-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2023-10-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2023-10-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2023-10-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2023-10-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2023-10-01,6.0,0.047619047619047616
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2023-10-01,6.0,0.047619047619047616
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2023-10-01,6.0,0.047619047619047616
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2023-10-01,6.0,0.047619047619047616
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2023-10-01,6.0,0.047619047619047616
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2023-10-01,6.0,0.047619047619047616
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2023-10-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2023-10-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2023-10-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2023-10-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2023-10-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2023-10-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2023-10-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2023-10-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2023-10-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2023-10-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2023-10-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2023-10-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2023-10-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2023-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2023-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2023-10-01,10.0,1.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2023-10-01,10.0,1.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2023-10-01,10.0,1.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2023-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2023-10-01,10.0,1.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2023-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2023-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2023-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2023-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2023-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2023-10-01,860.0,0.022693089162730558
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2023-10-01,780.0,0.02058210412433702
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2023-10-01,254.0,0.006702377496899491
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2023-10-01,243.0,0.006412117054120379
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2023-10-01,1330.0,0.03509512626329261
M14 ,Patient Services,14.1.8,Outpatient - Dental,2023-10-01,867.0,0.022877800353589994
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2023-10-01,975.0,0.025727630155421274
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2023-10-01,44.0,0.0011610417711164472
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2023-10-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2023-10-01,669.0,0.017653112383565983
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2023-10-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2023-10-01,20934.0,0.5523920099216297
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2023-10-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2023-10-01,110.0,0.002902604427791118
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2023-10-01,763.0,0.02013351980367839
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2023-10-01,81.0,0.0021373723513734596
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2023-10-01,685.0,0.01807530939124469
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2023-10-01,420.0,0.011082671451566087
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2023-10-01,105.0,0.002770667862891522
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2023-10-01,754.0,0.01989603398685912
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2023-10-01,81.0,0.0021373723513734596
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2023-10-01,673.0,0.01775866163548566
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2023-10-01,410.0,0.010818798321766894
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2023-10-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2023-10-01,0.0,0.0
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2023-10-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2023-10-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2023-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2023-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2023-10-01,11.0,0.0002902604427791118
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2023-10-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2023-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2023-10-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2023-10-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2023-10-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2023-10-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2023-10-01,27.0,0.0007124574504578199
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2023-10-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2023-10-01,324.0,0.008549489405493839
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2023-10-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2023-10-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2023-10-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2023-10-01,101.0,0.002665118610971845
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2023-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2023-10-01,55.0,0.001451302213895559
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2023-10-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2023-10-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2023-10-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2023-10-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2023-10-01,65.0,0.0017151753436947515
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2023-10-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2023-10-01,1180.0,0.031137029316304722
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2023-10-01,883.0,0.023299997361268702
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2023-10-01,36.0,0.0009499432672770932
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2023-10-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2023-10-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2023-10-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2023-10-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2023-10-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2023-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2023-10-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2023-10-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2023-10-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2023-10-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2023-10-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2023-10-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2023-10-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2023-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2023-10-01,383.0,0.010106340871309075
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2023-10-01,16.0,0.00042219700767870806
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2023-10-01,313.0,0.008259228962714726
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2023-10-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2023-10-01,82.0,0.002163759664353379
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2023-10-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2023-10-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2023-10-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2023-10-01,9258.0,0.24429374356809247
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2023-10-01,52.0,0.0013721402749558012
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2023-10-01,28.0,0.0007388447634377391
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2023-10-01,17.0,0.00044858432065862734
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2023-10-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2023-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2023-10-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2023-10-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2023-10-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2023-10-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2023-10-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2023-10-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2023-10-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2023-10-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2023-10-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2023-10-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2023-10-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2023-10-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2023-10-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2023-10-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2023-10-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2023-10-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2023-10-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2023-10-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2023-10-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2023-10-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2023-10-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2023-10-01,214.0,0.0056468849777027205
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2023-10-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2023-10-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2023-10-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2023-10-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2023-10-01,973.0,0.025674855529461436
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2023-10-01,841.0,0.022191730216112093
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2023-10-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2023-10-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2023-10-01,347.0,0.00915639760403198
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2023-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2023-10-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2023-10-01,46883.0,0.6593395775321351
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2023-10-01,6.0,8.43810648890389e-05
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2023-10-01,4657.0,0.06549376986470902
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2023-10-01,21.0,0.00029533372711163615
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-10-01,377.0,0.005301943577194611
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2023-10-01,64.0,0.0009000646921497482
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-10-01,540.0,0.007594295840013501
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2023-10-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-10-01,347.0,0.004880038252749417
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-10-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-10-01,44.0,0.000618794475852952
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-10-01,223.0,0.0031361629117092793
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-10-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2023-10-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2023-10-01,181.0,0.0025454954574860066
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2023-10-01,16.0,0.00022501617303743706
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2023-10-01,3251.0,0.04572047365904424
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2023-10-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2023-10-01,1297.0,0.018240373526847244
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2023-10-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2023-10-01,353.0,0.004964419317638455
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2023-10-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2023-10-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2023-10-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2023-10-01,809.0,0.011377380249205411
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2023-10-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2023-10-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2023-10-01,13.0,0.41935483870967744
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2023-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2023-10-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2023-10-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2023-10-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2023-10-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2023-10-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2023-10-01,106.0,0.07670043415340087
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2023-10-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2023-10-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2023-10-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2023-10-01,3.0,0.002170767004341534
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2023-10-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2023-10-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2023-10-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2023-10-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2023-10-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2023-10-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2023-10-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2023-10-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2023-10-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2023-10-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2023-10-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2023-10-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2023-10-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2023-11-01,131.0,0.08275426405559065
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2023-11-01,9.0,0.005685407454200884
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2023-11-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2023-11-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2023-11-01,30.0,0.018951358180669616
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2023-11-01,44.0,0.027795325331648767
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2023-11-01,44.0,0.027795325331648767
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2023-11-01,483.0,0.3051168667087808
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2023-11-01,106.0,0.06696146557169931
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2023-11-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2023-11-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2023-11-01,108.0,0.06822488945041061
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2023-11-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2023-11-01,18.0,0.011370814908401769
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2023-11-01,23.0,0.014529374605180037
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2023-11-01,186.0,0.11749842072015161
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2023-11-01,221.0,0.1396083385975995
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2023-11-01,191.0,0.12065698041692988
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2023-11-01,14.0,0.008843967150979154
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2023-11-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2023-11-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2023-11-01,123.0,0.07770056854074542
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2023-11-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2023-11-01,33.0,0.020846493998736577
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2023-11-01,41.0,0.025900189513581806
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2023-11-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2023-11-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2023-11-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2023-11-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2023-11-01,117.0,0.612565445026178
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2023-11-01,56.0,0.2931937172774869
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2023-11-01,23.0,0.12041884816753927
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2023-11-01,117.0,0.612565445026178
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2023-11-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2023-11-01,4.0,0.020942408376963352
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2023-11-01,113.0,0.5916230366492147
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2023-11-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2023-11-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2023-11-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2023-11-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2023-11-01,61.0,0.5773195876288659
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2023-11-01,15.0,0.10309278350515463
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2023-11-01,61.0,0.5773195876288659
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2023-11-01,52.0,0.27225130890052357
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2023-11-01,64.0,0.33507853403141363
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2023-11-01,9.0,0.04712041884816754
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2023-11-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2023-11-01,116.0,0.6073298429319371
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2023-11-01,15.0,0.07853403141361257
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2023-11-01,4.0,0.020942408376963352
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2023-11-01,116.0,0.6073298429319371
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2023-11-01,116.0,0.6073298429319371
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2023-11-01,116.0,0.6073298429319371
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2023-11-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2023-11-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2023-11-01,2.0,0.04
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2023-11-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2023-11-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2023-11-01,117.0,0.5625
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2023-11-01,117.0,0.5625
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2023-11-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2023-11-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2023-11-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2023-11-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2023-11-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2023-11-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2023-11-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2023-11-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2023-11-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2023-11-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2023-11-01,5.0,0.012953367875647668
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2023-11-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2023-11-01,8.0,0.02072538860103627
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2023-11-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2023-11-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2023-11-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2023-11-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2023-11-01,4.0,0.010362694300518135
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2023-11-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2023-11-01,6.0,0.015544041450777202
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2023-11-01,12.0,0.031088082901554404
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2023-11-01,4.0,0.010362694300518135
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2023-11-01,0.0,0.0
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2023-11-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2023-11-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2023-11-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2023-11-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2023-11-01,66.0,0.17098445595854922
M8,Family Planning,8.17.1,Complications following male sterilization,2023-11-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2023-11-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2023-11-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2023-11-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2023-11-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2023-11-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2023-11-01,15.0,0.038860103626943004
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2023-11-01,116.0,0.6137566137566137
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2023-11-01,116.0,0.6137566137566137
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2023-11-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2023-11-01,33.0,0.1746031746031746
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2023-11-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2023-11-01,116.0,0.6137566137566137
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2023-11-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2023-11-01,33.0,0.1746031746031746
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2023-11-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2023-11-01,116.0,0.6137566137566137
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2023-11-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2023-11-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2023-11-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2023-11-01,33.0,0.1746031746031746
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2023-11-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2023-11-01,30.0,0.15873015873015872
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2023-11-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2023-11-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2023-11-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2023-11-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2023-11-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2023-11-01,6.0,0.031746031746031744
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2023-11-01,14.0,0.07407407407407407
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2023-11-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2023-11-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2023-11-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2023-11-01,4.0,0.021164021164021163
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2023-11-01,3.0,0.015873015873015872
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2023-11-01,1.0,0.005291005291005291
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2023-11-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2023-11-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2023-11-01,9.0,0.047619047619047616
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2023-11-01,3.0,0.015873015873015872
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2023-11-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2023-11-01,10.0,0.0847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2023-11-01,6.0,0.05084745762711865
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2023-11-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2023-11-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2023-11-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2023-11-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2023-11-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2023-11-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2023-11-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2023-11-01,6.0,0.05084745762711865
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2023-11-01,6.0,0.05084745762711865
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2023-11-01,6.0,0.05084745762711865
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2023-11-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2023-11-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2023-11-01,21.0,0.17796610169491525
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2023-11-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2023-11-01,6.0,0.05084745762711865
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2023-11-01,104.0,0.39097744360902253
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2023-11-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2023-11-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2023-11-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2023-11-01,51.0,0.19172932330827067
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2023-11-01,2.0,0.007518796992481203
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2023-11-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2023-11-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2023-11-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2023-11-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-11-01,7.0,0.02631578947368421
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-11-01,1.0,0.0037593984962406013
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-11-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-11-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2023-11-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2023-11-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2023-11-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2023-11-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2023-11-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2023-11-01,16.0,0.12698412698412698
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2023-11-01,8.0,0.06349206349206349
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2023-11-01,8.0,0.06349206349206349
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2023-11-01,4.0,0.031746031746031744
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2023-11-01,16.0,0.12698412698412698
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2023-11-01,8.0,0.06349206349206349
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2023-11-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2023-11-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2023-11-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2023-11-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2023-11-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2023-11-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2023-11-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2023-11-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2023-11-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2023-11-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2023-11-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2023-11-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2023-11-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2023-11-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2023-11-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2023-11-01,6.0,0.6
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2023-11-01,6.0,0.6
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2023-11-01,6.0,0.6
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2023-11-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2023-11-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2023-11-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2023-11-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2023-11-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2023-11-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2023-11-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2023-11-01,943.0,0.024883236140063856
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2023-11-01,851.0,0.022455603345911287
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2023-11-01,261.0,0.006887088687758926
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2023-11-01,298.0,0.007863419268015938
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2023-11-01,1602.0,0.042272475393830646
M14 ,Patient Services,14.1.8,Outpatient - Dental,2023-11-01,969.0,0.025569306277541757
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2023-11-01,1182.0,0.03118980394226456
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2023-11-01,511.0,0.013483916932738739
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2023-11-01,201.0,0.00530384990896377
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2023-11-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2023-11-01,606.0,0.01599071166583107
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2023-11-01,22180.0,0.5852706018946091
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2023-11-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2023-11-01,111.0,0.002928991740771037
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2023-11-01,889.0,0.023458321239148216
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2023-11-01,85.0,0.0022429216032931365
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2023-11-01,970.0,0.025595693590521676
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2023-11-01,248.0,0.006544053619019975
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2023-11-01,110.0,0.002902604427791118
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2023-11-01,835.0,0.02203340633823258
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2023-11-01,78.0,0.0020582104124337018
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2023-11-01,901.0,0.023774968994907247
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2023-11-01,237.0,0.006253793176240864
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2023-11-01,0.0,0.0
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2023-11-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2023-11-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2023-11-01,0.0,0.0
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2023-11-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2023-11-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2023-11-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2023-11-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2023-11-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2023-11-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2023-11-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2023-11-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.6,Day Care Admissions,2023-11-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2023-11-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2023-11-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2023-11-01,266.0,0.007019025252658522
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2023-11-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2023-11-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2023-11-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2023-11-01,110.0,0.002902604427791118
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2023-11-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2023-11-01,28.0,0.0007388447634377391
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2023-11-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2023-11-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2023-11-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2023-11-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2023-11-01,0.0,0.0
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2023-11-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2023-11-01,2028.0,0.05351347072327625
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2023-11-01,1380.0,0.03641449191228857
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2023-11-01,39.0,0.0010291052062168509
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2023-11-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2023-11-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2023-11-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2023-11-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2023-11-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2023-11-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2023-11-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2023-11-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2023-11-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2023-11-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2023-11-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2023-11-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2023-11-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2023-11-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2023-11-01,73.0,0.0019262738475341057
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2023-11-01,19.0,0.0005013589466184658
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2023-11-01,0.0,0.0
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2023-11-01,88.0,0.0023220835422328944
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2023-11-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2023-11-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2023-11-01,0.0,0.0
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2023-11-01,10540.0,0.27812227880834894
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2023-11-01,57.0,0.0015040768398553975
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2023-11-01,25.0,0.0006596828244979814
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2023-11-01,24.0,0.0006332955115180621
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2023-11-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2023-11-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2023-11-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2023-11-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2023-11-01,29.0,0.0007652320764176584
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2023-11-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2023-11-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2023-11-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2023-11-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2023-11-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2023-11-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2023-11-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2023-11-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2023-11-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2023-11-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2023-11-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2023-11-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2023-11-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2023-11-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2023-11-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2023-11-01,270.0,0.0071245745045781985
M14 ,Patient Services,14.21,Total number of blood units issued in month,2023-11-01,270.0,0.0071245745045781985
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2023-11-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2023-11-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2023-11-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2023-11-01,736.0,0.01942106235322057
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2023-11-01,661.0,0.017442013879726628
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2023-11-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2023-11-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2023-11-01,483.0,0.012745072169301
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2023-11-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2023-11-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2023-11-01,45663.0,0.6421820943380305
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2023-11-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2023-11-01,3910.0,0.05498832728602368
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2023-11-01,67.0,0.0009422552245942677
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-11-01,318.0,0.004472196439119062
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2023-11-01,8.0,0.00011250808651871853
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-11-01,532.0,0.007481787753494782
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2023-11-01,5.0,7.031755407419908e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-11-01,483.0,0.006792675723567632
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-11-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-11-01,4.0,5.6254043259359264e-05
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-11-01,195.0,0.002742384608893764
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-11-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2023-11-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2023-11-01,13.0,0.00018282564059291762
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2023-11-01,13.0,0.00018282564059291762
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2023-11-01,2881.0,0.04051697465755351
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2023-11-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2023-11-01,1442.0,0.020279582594999016
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2023-11-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2023-11-01,359.0,0.005048800382527494
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2023-11-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2023-11-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2023-11-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2023-11-01,612.0,0.008606868618681967
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2023-11-01,11.0,0.3548387096774194
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2023-11-01,2.0,0.06451612903225806
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2023-11-01,31.0,1.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2023-11-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2023-11-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2023-11-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2023-11-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2023-11-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2023-11-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2023-11-01,164.0,0.11866859623733719
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2023-11-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2023-11-01,6.0,0.004341534008683068
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2023-11-01,6.0,0.004341534008683068
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2023-11-01,3.0,0.002170767004341534
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2023-11-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2023-11-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2023-11-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2023-11-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2023-11-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2023-11-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2023-11-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2023-11-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2023-11-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2023-11-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2023-11-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2023-11-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2023-11-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2023-12-01,121.0,0.0764371446620341
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2023-12-01,7.0,0.004421983575489577
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2023-12-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2023-12-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2023-12-01,41.0,0.025900189513581806
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2023-12-01,102.0,0.06443461781427669
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2023-12-01,182.0,0.114971572962729
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2023-12-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2023-12-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2023-12-01,115.0,0.07264687302590019
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2023-12-01,23.0,0.014529374605180037
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2023-12-01,14.0,0.008843967150979154
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2023-12-01,24.0,0.015161086544535692
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2023-12-01,102.0,0.06443461781427669
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2023-12-01,103.0,0.06506632975363234
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2023-12-01,101.0,0.06380290587492103
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2023-12-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2023-12-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2023-12-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2023-12-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2023-12-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2023-12-01,105.0,0.06632975363234365
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2023-12-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2023-12-01,35.0,0.022109917877447885
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2023-12-01,41.0,0.025900189513581806
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2023-12-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2023-12-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2023-12-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2023-12-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2023-12-01,137.0,0.7172774869109948
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2023-12-01,62.0,0.32460732984293195
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2023-12-01,27.0,0.14136125654450263
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2023-12-01,137.0,0.7172774869109948
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2023-12-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2023-12-01,4.0,0.020942408376963352
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2023-12-01,133.0,0.6963350785340314
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2023-12-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2023-12-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2023-12-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2023-12-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2023-12-01,75.0,0.7216494845360825
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2023-12-01,25.0,0.20618556701030927
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2023-12-01,75.0,0.7216494845360825
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2023-12-01,77.0,0.4031413612565445
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2023-12-01,57.0,0.29842931937172773
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2023-12-01,13.0,0.06806282722513089
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2023-12-01,3.0,0.015706806282722512
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2023-12-01,134.0,0.7015706806282722
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2023-12-01,28.0,0.14659685863874344
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2023-12-01,3.0,0.015706806282722512
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2023-12-01,134.0,0.7015706806282722
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2023-12-01,134.0,0.7015706806282722
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2023-12-01,134.0,0.7015706806282722
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2023-12-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2023-12-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2023-12-01,4.0,0.08
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2023-12-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2023-12-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2023-12-01,208.0,1.0
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2023-12-01,208.0,1.0
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2023-12-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2023-12-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2023-12-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2023-12-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2023-12-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2023-12-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2023-12-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2023-12-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2023-12-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2023-12-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2023-12-01,7.0,0.018134715025906734
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2023-12-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2023-12-01,5.0,0.012953367875647668
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2023-12-01,1.0,0.0025906735751295338
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2023-12-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2023-12-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2023-12-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2023-12-01,4.0,0.010362694300518135
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2023-12-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2023-12-01,8.0,0.02072538860103627
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2023-12-01,12.0,0.031088082901554404
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2023-12-01,2.0,0.0051813471502590676
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2023-12-01,4.0,0.010362694300518135
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2023-12-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2023-12-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2023-12-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2023-12-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2023-12-01,95.0,0.24611398963730569
M8,Family Planning,8.17.1,Complications following male sterilization,2023-12-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2023-12-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2023-12-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2023-12-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2023-12-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2023-12-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2023-12-01,8.0,0.02072538860103627
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2023-12-01,134.0,0.708994708994709
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2023-12-01,134.0,0.708994708994709
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2023-12-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2023-12-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2023-12-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2023-12-01,134.0,0.708994708994709
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2023-12-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2023-12-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2023-12-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2023-12-01,134.0,0.708994708994709
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2023-12-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2023-12-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2023-12-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2023-12-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2023-12-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2023-12-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2023-12-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2023-12-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2023-12-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2023-12-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2023-12-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2023-12-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2023-12-01,7.0,0.037037037037037035
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2023-12-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2023-12-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2023-12-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2023-12-01,12.0,0.06349206349206349
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2023-12-01,12.0,0.06349206349206349
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2023-12-01,12.0,0.06349206349206349
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2023-12-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2023-12-01,8.0,0.042328042328042326
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2023-12-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2023-12-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2023-12-01,14.0,0.11864406779661017
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2023-12-01,3.0,0.025423728813559324
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2023-12-01,1.0,0.00847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2023-12-01,3.0,0.025423728813559324
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2023-12-01,3.0,0.025423728813559324
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2023-12-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2023-12-01,34.0,0.288135593220339
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2023-12-01,16.0,0.13559322033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2023-12-01,3.0,0.025423728813559324
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2023-12-01,117.0,0.4398496240601504
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2023-12-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2023-12-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2023-12-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2023-12-01,37.0,0.13909774436090225
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2023-12-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2023-12-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2023-12-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2023-12-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2023-12-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-12-01,5.0,0.018796992481203006
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-12-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2023-12-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2023-12-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2023-12-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2023-12-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2023-12-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2023-12-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2023-12-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2023-12-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2023-12-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2023-12-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2023-12-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2023-12-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2023-12-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2023-12-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2023-12-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2023-12-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2023-12-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2023-12-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2023-12-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2023-12-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2023-12-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2023-12-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2023-12-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2023-12-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2023-12-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2023-12-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2023-12-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2023-12-01,900.0,0.02374858168192733
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2023-12-01,821.0,0.02166398395651371
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2023-12-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2023-12-01,747.0,0.019711322795999683
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2023-12-01,2152.0,0.056785497532786236
M14 ,Patient Services,14.1.8,Outpatient - Dental,2023-12-01,1282.0,0.03382853524025648
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2023-12-01,1954.0,0.051560809562762225
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2023-12-01,150.0,0.003958096946987889
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2023-12-01,155.0,0.0040900335118874845
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2023-12-01,1250.0,0.032984141224899066
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2023-12-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2023-12-01,713.0,0.01881415415468243
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2023-12-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2023-12-01,33635.0,0.8875372720795841
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2023-12-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2023-12-01,229.0,0.006042694672401509
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2023-12-01,896.0,0.023643032430007652
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2023-12-01,160.0,0.00422197007678708
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2023-12-01,823.0,0.021716758582473548
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2023-12-01,354.0,0.009341108794891416
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2023-12-01,210.0,0.005541335725783044
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2023-12-01,910.0,0.024012454811726522
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2023-12-01,172.0,0.004538617832546112
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2023-12-01,832.0,0.02195424439929282
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2023-12-01,355.0,0.009367496107871336
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2023-12-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2023-12-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2023-12-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2023-12-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2023-12-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2023-12-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2023-12-01,0.0,0.0
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2023-12-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2023-12-01,0.0,0.0
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2023-12-01,0.0,0.0
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2023-12-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2023-12-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.6,Day Care Admissions,2023-12-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2023-12-01,45.0,0.0011874290840963664
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2023-12-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2023-12-01,277.0,0.007309285695437633
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2023-12-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2023-12-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2023-12-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2023-12-01,110.0,0.002902604427791118
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2023-12-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2023-12-01,60.0,0.0015832387787951554
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2023-12-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2023-12-01,15.0,0.00039580969469878884
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2023-12-01,0.0,0.0
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2023-12-01,75.0,0.0019790484734939443
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2023-12-01,0.0,0.0
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2023-12-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2023-12-01,2537.0,0.06694461303005515
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2023-12-01,915.0,0.024144391376626117
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2023-12-01,112.0,0.0029553790537509565
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2023-12-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2023-12-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2023-12-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2023-12-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2023-12-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2023-12-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2023-12-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2023-12-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2023-12-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2023-12-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2023-12-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2023-12-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2023-12-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2023-12-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2023-12-01,462.0,0.012190938596722696
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2023-12-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2023-12-01,323.0,0.00852310209251392
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2023-12-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2023-12-01,148.0,0.0039053223210280498
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2023-12-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2023-12-01,300.0,0.007916193893975777
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2023-12-01,300.0,0.007916193893975777
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2023-12-01,13005.0,0.3431670053038499
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2023-12-01,62.0,0.0016360134047549938
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2023-12-01,40.0,0.00105549251919677
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2023-12-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2023-12-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2023-12-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2023-12-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2023-12-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2023-12-01,13.0,0.0003430350687389503
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2023-12-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2023-12-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2023-12-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2023-12-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2023-12-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2023-12-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2023-12-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2023-12-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2023-12-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2023-12-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2023-12-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2023-12-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2023-12-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2023-12-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2023-12-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2023-12-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2023-12-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2023-12-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2023-12-01,300.0,0.007916193893975777
M14 ,Patient Services,14.21,Total number of blood units issued in month,2023-12-01,300.0,0.007916193893975777
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2023-12-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2023-12-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2023-12-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2023-12-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2023-12-01,967.0,0.02551653165158192
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2023-12-01,866.0,0.022851413040610075
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2023-12-01,13.0,0.0003430350687389503
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2023-12-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2023-12-01,502.0,0.013246431115919466
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2023-12-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2023-12-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2023-12-01,45015.0,0.6330689393300143
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2023-12-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2023-12-01,3938.0,0.0553821055888392
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2023-12-01,64.0,0.0009000646921497482
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-12-01,435.0,0.00611762720445532
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2023-12-01,4.0,5.6254043259359264e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-12-01,502.0,0.007059882429049588
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-12-01,528.0,0.007425533710235423
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2023-12-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2023-12-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-12-01,42.0,0.0005906674542232723
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-12-01,238.0,0.0033471155739318763
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2023-12-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2023-12-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2023-12-01,95.0,0.0013360335274097827
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2023-12-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2023-12-01,3197.0,0.044961044075042894
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2023-12-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2023-12-01,1310.0,0.01842319916744016
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2023-12-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2023-12-01,419.0,0.005892611031417883
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2023-12-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2023-12-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2023-12-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2023-12-01,700.0,0.009844457570387872
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2023-12-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2023-12-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2023-12-01,6.0,0.1935483870967742
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2023-12-01,2.0,0.06451612903225806
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2023-12-01,13.0,0.41935483870967744
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2023-12-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2023-12-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2023-12-01,0.0,0.0
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2023-12-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2023-12-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2023-12-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2023-12-01,240.0,0.1736613603473227
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2023-12-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2023-12-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2023-12-01,2.0,0.001447178002894356
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2023-12-01,3.0,0.002170767004341534
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2023-12-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2023-12-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2023-12-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2023-12-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2023-12-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2023-12-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2023-12-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2023-12-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2023-12-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2023-12-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2023-12-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2023-12-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2023-12-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2024-01-01,155.0,0.09791535060012634
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2024-01-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2024-01-01,7.0,0.004421983575489577
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2024-01-01,3.0,0.0018951358180669614
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2024-01-01,24.0,0.015161086544535692
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2024-01-01,22.0,0.013897662665824383
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2024-01-01,22.0,0.013897662665824383
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2024-01-01,38.0,0.024005053695514846
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2024-01-01,73.0,0.04611497157296273
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2024-01-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2024-01-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2024-01-01,118.0,0.07454200884396715
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2024-01-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2024-01-01,3.0,0.0018951358180669614
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2024-01-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2024-01-01,134.0,0.08464939987365762
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2024-01-01,134.0,0.08464939987365762
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2024-01-01,22.0,0.013897662665824383
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2024-01-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2024-01-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2024-01-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2024-01-01,42.0,0.026531901452937462
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2024-01-01,30.0,0.018951358180669616
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2024-01-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2024-01-01,8.0,0.00505369551484523
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2024-01-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2024-01-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2024-01-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2024-01-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2024-01-01,113.0,0.5916230366492147
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2024-01-01,60.0,0.31413612565445026
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2024-01-01,30.0,0.15706806282722513
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2024-01-01,113.0,0.5916230366492147
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2024-01-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2024-01-01,19.0,0.09947643979057591
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2024-01-01,94.0,0.49214659685863876
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2024-01-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2024-01-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2024-01-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2024-01-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2024-01-01,53.0,0.4948453608247423
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2024-01-01,10.0,0.05154639175257732
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2024-01-01,53.0,0.4948453608247423
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2024-01-01,57.0,0.29842931937172773
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2024-01-01,56.0,0.2931937172774869
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2024-01-01,10.0,0.05235602094240838
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2024-01-01,113.0,0.5916230366492147
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2024-01-01,6.0,0.031413612565445025
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2024-01-01,113.0,0.5916230366492147
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2024-01-01,113.0,0.5916230366492147
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2024-01-01,113.0,0.5916230366492147
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2024-01-01,10.0,0.05235602094240838
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2024-01-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2024-01-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2024-01-01,12.0,0.24
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2024-01-01,2.0,0.009615384615384616
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2024-01-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2024-01-01,0.0,0.0
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2024-01-01,0.0,0.0
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2024-01-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2024-01-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2024-01-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2024-01-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2024-01-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2024-01-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2024-01-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2024-01-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2024-01-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2024-01-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2024-01-01,8.0,0.02072538860103627
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2024-01-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2024-01-01,12.0,0.031088082901554404
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2024-01-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2024-01-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2024-01-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2024-01-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2024-01-01,6.0,0.015544041450777202
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2024-01-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2024-01-01,4.0,0.010362694300518135
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2024-01-01,2.0,0.0051813471502590676
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2024-01-01,1.0,0.0025906735751295338
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2024-01-01,1.0,0.0025906735751295338
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2024-01-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2024-01-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2024-01-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2024-01-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2024-01-01,0.0,0.0
M8,Family Planning,8.17.1,Complications following male sterilization,2024-01-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2024-01-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2024-01-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2024-01-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2024-01-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2024-01-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2024-01-01,16.0,0.04145077720207254
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2024-01-01,113.0,0.5978835978835979
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2024-01-01,113.0,0.5978835978835979
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2024-01-01,45.0,0.23809523809523808
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2024-01-01,21.0,0.1111111111111111
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2024-01-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2024-01-01,113.0,0.5978835978835979
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2024-01-01,45.0,0.23809523809523808
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2024-01-01,21.0,0.1111111111111111
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2024-01-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2024-01-01,113.0,0.5978835978835979
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2024-01-01,45.0,0.23809523809523808
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2024-01-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2024-01-01,45.0,0.23809523809523808
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2024-01-01,21.0,0.1111111111111111
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2024-01-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2024-01-01,45.0,0.23809523809523808
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2024-01-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2024-01-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2024-01-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2024-01-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2024-01-01,6.0,0.031746031746031744
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2024-01-01,6.0,0.031746031746031744
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2024-01-01,12.0,0.06349206349206349
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2024-01-01,12.0,0.06349206349206349
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2024-01-01,12.0,0.06349206349206349
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2024-01-01,3.0,0.015873015873015872
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2024-01-01,3.0,0.015873015873015872
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2024-01-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2024-01-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2024-01-01,5.0,0.0423728813559322
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2024-01-01,5.0,0.0423728813559322
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2024-01-01,3.0,0.025423728813559324
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2024-01-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2024-01-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2024-01-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2024-01-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2024-01-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2024-01-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2024-01-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2024-01-01,10.0,0.0847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2024-01-01,10.0,0.0847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2024-01-01,10.0,0.0847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2024-01-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2024-01-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2024-01-01,15.0,0.1271186440677966
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2024-01-01,17.0,0.1440677966101695
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2024-01-01,8.0,0.06779661016949153
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2024-01-01,96.0,0.3609022556390977
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2024-01-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2024-01-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2024-01-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2024-01-01,33.0,0.12406015037593984
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2024-01-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2024-01-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2024-01-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2024-01-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2024-01-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-01-01,40.0,0.15037593984962405
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-01-01,22.0,0.08270676691729323
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-01-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-01-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2024-01-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2024-01-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2024-01-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2024-01-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2024-01-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2024-01-01,16.0,0.12698412698412698
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2024-01-01,7.0,0.05555555555555555
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2024-01-01,16.0,0.12698412698412698
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2024-01-01,7.0,0.05555555555555555
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2024-01-01,16.0,0.12698412698412698
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2024-01-01,6.0,0.047619047619047616
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2024-01-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2024-01-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2024-01-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2024-01-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2024-01-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2024-01-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2024-01-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2024-01-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2024-01-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2024-01-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2024-01-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2024-01-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2024-01-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2024-01-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2024-01-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2024-01-01,1.0,0.1
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2024-01-01,1.0,0.1
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2024-01-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2024-01-01,1.0,0.1
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2024-01-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2024-01-01,1.0,0.1
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2024-01-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2024-01-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2024-01-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2024-01-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2024-01-01,800.0,0.021109850383935404
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2024-01-01,701.0,0.018497506398923398
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2024-01-01,878.0,0.023168060796369107
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2024-01-01,2516.0,0.06639047945747685
M14 ,Patient Services,14.1.8,Outpatient - Dental,2024-01-01,1367.0,0.03607145684354962
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2024-01-01,2212.0,0.05836873631158139
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2024-01-01,18.0,0.0004749716336385466
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2024-01-01,26.0,0.0006860701374779006
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2024-01-01,350.0,0.00923555954297174
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2024-01-01,1267.0,0.03343272554555769
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2024-01-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2024-01-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2024-01-01,774.0,0.020423780246457503
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2024-01-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2024-01-01,37897.0,1.0
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2024-01-01,160.0,0.00422197007678708
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2024-01-01,857.0,0.0226139272237908
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2024-01-01,173.0,0.004565005145526031
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2024-01-01,911.0,0.02403884212470644
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2024-01-01,374.0,0.0098688550544898
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2024-01-01,173.0,0.004565005145526031
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2024-01-01,851.0,0.022455603345911287
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2024-01-01,158.0,0.004169195450827242
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2024-01-01,891.0,0.023511095865108057
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2024-01-01,374.0,0.0098688550544898
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2024-01-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2024-01-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2024-01-01,52.0,0.0013721402749558012
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2024-01-01,268.0,0.0070717998786183605
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2024-01-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2024-01-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2024-01-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2024-01-01,65.0,0.0017151753436947515
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2024-01-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2024-01-01,50.0,0.0013193656489959627
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2024-01-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2024-01-01,0.0,0.0
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2024-01-01,25.0,0.0006596828244979814
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2024-01-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2024-01-01,101.0,0.002665118610971845
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2024-01-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2024-01-01,1534.0,0.04047813811119614
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2024-01-01,570.0,0.015040768398553976
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2024-01-01,110.0,0.002902604427791118
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2024-01-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2024-01-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2024-01-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2024-01-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2024-01-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2024-01-01,7.0,0.00018471119085943478
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2024-01-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2024-01-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2024-01-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2024-01-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2024-01-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2024-01-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2024-01-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2024-01-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2024-01-01,442.0,0.01166319233712431
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2024-01-01,17.0,0.00044858432065862734
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2024-01-01,293.0,0.007731482703116342
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2024-01-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2024-01-01,134.0,0.0035358999393091802
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2024-01-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2024-01-01,187.0,0.0049344275272449
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2024-01-01,187.0,0.0049344275272449
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2024-01-01,12914.0,0.34076575982267726
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2024-01-01,49.0,0.0012929783360160435
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2024-01-01,26.0,0.0006860701374779006
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2024-01-01,18.0,0.0004749716336385466
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2024-01-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2024-01-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2024-01-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2024-01-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2024-01-01,47.0,0.001240203710056205
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2024-01-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2024-01-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2024-01-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2024-01-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2024-01-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2024-01-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2024-01-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2024-01-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2024-01-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2024-01-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2024-01-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2024-01-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2024-01-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2024-01-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2024-01-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2024-01-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2024-01-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2024-01-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2024-01-01,187.0,0.0049344275272449
M14 ,Patient Services,14.21,Total number of blood units issued in month,2024-01-01,187.0,0.0049344275272449
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2024-01-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2024-01-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2024-01-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2024-01-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2024-01-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2024-01-01,929.0,0.024513813758344986
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2024-01-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2024-01-01,1064.0,0.028076101010634087
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2024-01-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2024-01-01,434.0,0.011452093833284957
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2024-01-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2024-01-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2024-01-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2024-01-01,45403.0,0.6385255815261722
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2024-01-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2024-01-01,3619.0,0.0508958456389053
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2024-01-01,17.0,0.0002390796838522769
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-01-01,460.0,0.006469214974826316
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2024-01-01,7.0,9.844457570387872e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-01-01,591.0,0.008311534891570332
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2024-01-01,5.0,7.031755407419908e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-01-01,434.0,0.00610356369364048
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-01-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-01-01,39.0,0.0005484769217787528
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-01-01,269.0,0.0037830844091919107
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-01-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2024-01-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2024-01-01,124.0,0.0017438753410401373
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2024-01-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2024-01-01,2986.0,0.04199364329311169
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2024-01-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2024-01-01,1361.0,0.01914043821899699
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2024-01-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2024-01-01,368.0,0.005175371979861052
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2024-01-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2024-01-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2024-01-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2024-01-01,800.0,0.011250808651871853
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2024-01-01,10.0,0.3225806451612903
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2024-01-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2024-01-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2024-01-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2024-01-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2024-01-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2024-01-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2024-01-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2024-01-01,2.0,0.001447178002894356
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2024-01-01,1382.0,1.0
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2024-01-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2024-01-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2024-01-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2024-01-01,3.0,0.002170767004341534
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2024-01-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2024-01-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2024-01-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2024-01-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2024-01-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2024-01-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2024-01-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2024-01-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2024-01-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2024-01-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2024-01-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2024-01-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2024-01-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2024-02-01,180.0,0.11370814908401769
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2024-02-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2024-02-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2024-02-01,7.0,0.004421983575489577
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2024-02-01,24.0,0.015161086544535692
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2024-02-01,45.0,0.028427037271004423
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2024-02-01,45.0,0.028427037271004423
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2024-02-01,28.0,0.017687934301958308
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2024-02-01,42.0,0.026531901452937462
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2024-02-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2024-02-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2024-02-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2024-02-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2024-02-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2024-02-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2024-02-01,38.0,0.024005053695514846
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2024-02-01,39.0,0.024636765634870498
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2024-02-01,52.0,0.032849020846494
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2024-02-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2024-02-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2024-02-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2024-02-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2024-02-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2024-02-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2024-02-01,4.0,0.002526847757422615
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2024-02-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2024-02-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2024-02-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2024-02-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2024-02-01,128.0,0.6701570680628273
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2024-02-01,76.0,0.39790575916230364
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2024-02-01,42.0,0.2198952879581152
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2024-02-01,128.0,0.6701570680628273
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2024-02-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2024-02-01,0.0,0.0
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2024-02-01,14.0,0.07329842931937172
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2024-02-01,114.0,0.5968586387434555
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2024-02-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2024-02-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2024-02-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2024-02-01,52.0,0.4845360824742268
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2024-02-01,8.0,0.030927835051546393
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2024-02-01,52.0,0.4845360824742268
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2024-02-01,69.0,0.3612565445026178
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2024-02-01,57.0,0.29842931937172773
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2024-02-01,10.0,0.05235602094240838
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2024-02-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2024-02-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2024-02-01,3.0,0.015706806282722512
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2024-02-01,126.0,0.6596858638743456
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2024-02-01,19.0,0.09947643979057591
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2024-02-01,4.0,0.020942408376963352
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2024-02-01,126.0,0.6596858638743456
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2024-02-01,126.0,0.6596858638743456
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2024-02-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2024-02-01,126.0,0.6596858638743456
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2024-02-01,3.0,0.015706806282722512
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2024-02-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2024-02-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2024-02-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2024-02-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2024-02-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2024-02-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2024-02-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2024-02-01,3.0,0.015706806282722512
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2024-02-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2024-02-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2024-02-01,12.0,0.24
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2024-02-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2024-02-01,201.0,0.9663461538461539
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2024-02-01,201.0,0.9663461538461539
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2024-02-01,201.0,0.9663461538461539
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2024-02-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2024-02-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2024-02-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2024-02-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2024-02-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2024-02-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2024-02-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2024-02-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2024-02-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2024-02-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2024-02-01,5.0,0.012953367875647668
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2024-02-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2024-02-01,6.0,0.015544041450777202
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2024-02-01,1.0,0.0025906735751295338
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2024-02-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2024-02-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2024-02-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2024-02-01,4.0,0.010362694300518135
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2024-02-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2024-02-01,4.0,0.010362694300518135
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2024-02-01,2.0,0.0051813471502590676
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2024-02-01,4.0,0.010362694300518135
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2024-02-01,2.0,0.0051813471502590676
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2024-02-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2024-02-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2024-02-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2024-02-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2024-02-01,66.0,0.17098445595854922
M8,Family Planning,8.17.1,Complications following male sterilization,2024-02-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2024-02-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2024-02-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2024-02-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2024-02-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2024-02-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2024-02-01,12.0,0.031088082901554404
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2024-02-01,126.0,0.6666666666666666
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2024-02-01,126.0,0.6666666666666666
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2024-02-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2024-02-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2024-02-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2024-02-01,126.0,0.6666666666666666
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2024-02-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2024-02-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2024-02-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2024-02-01,126.0,0.6666666666666666
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2024-02-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2024-02-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2024-02-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2024-02-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2024-02-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2024-02-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2024-02-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2024-02-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2024-02-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2024-02-01,35.0,0.18518518518518517
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2024-02-01,10.0,0.05291005291005291
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2024-02-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2024-02-01,4.0,0.021164021164021163
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2024-02-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2024-02-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2024-02-01,9.0,0.047619047619047616
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2024-02-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2024-02-01,19.0,0.16101694915254236
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2024-02-01,4.0,0.03389830508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2024-02-01,5.0,0.0423728813559322
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2024-02-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2024-02-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2024-02-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2024-02-01,1.0,0.00847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2024-02-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2024-02-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2024-02-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2024-02-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2024-02-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2024-02-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2024-02-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2024-02-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2024-02-01,23.0,0.19491525423728814
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2024-02-01,19.0,0.16101694915254236
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2024-02-01,9.0,0.07627118644067797
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2024-02-01,85.0,0.31954887218045114
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2024-02-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2024-02-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2024-02-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2024-02-01,82.0,0.3082706766917293
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2024-02-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2024-02-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2024-02-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2024-02-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2024-02-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-02-01,14.0,0.05263157894736842
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-02-01,2.0,0.007518796992481203
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-02-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-02-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2024-02-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2024-02-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2024-02-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2024-02-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2024-02-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2024-02-01,126.0,1.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2024-02-01,119.0,0.9444444444444444
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2024-02-01,126.0,1.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2024-02-01,119.0,0.9444444444444444
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2024-02-01,126.0,1.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2024-02-01,119.0,0.9444444444444444
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2024-02-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2024-02-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2024-02-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2024-02-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2024-02-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2024-02-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2024-02-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2024-02-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2024-02-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2024-02-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2024-02-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2024-02-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2024-02-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2024-02-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2024-02-01,1.0,0.1
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2024-02-01,2.0,0.2
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2024-02-01,2.0,0.2
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2024-02-01,2.0,0.2
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2024-02-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2024-02-01,2.0,0.2
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2024-02-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2024-02-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2024-02-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2024-02-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2024-02-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2024-02-01,750.0,0.01979048473493944
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2024-02-01,655.0,0.017283690001847114
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2024-02-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2024-02-01,907.0,0.023933292872786765
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2024-02-01,2452.0,0.064701691426762
M14 ,Patient Services,14.1.8,Outpatient - Dental,2024-02-01,1562.0,0.04121698287463388
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2024-02-01,2278.0,0.060110298968256065
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2024-02-01,29.0,0.0007652320764176584
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2024-02-01,22.0,0.0005805208855582236
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2024-02-01,398.0,0.010502150566007864
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2024-02-01,1387.0,0.03659920310314801
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2024-02-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2024-02-01,768.0,0.02026545636857799
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2024-02-01,37385.0,0.9864896957542814
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2024-02-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2024-02-01,196.0,0.005171913344064174
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2024-02-01,799.0,0.021083463070955485
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2024-02-01,143.0,0.0037733857561284534
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2024-02-01,797.0,0.021030688444995647
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2024-02-01,388.0,0.01023827743620867
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2024-02-01,201.0,0.00530384990896377
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2024-02-01,782.0,0.020634878750296858
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2024-02-01,151.0,0.003984484259967808
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2024-02-01,813.0,0.021452885452674354
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2024-02-01,381.0,0.010053566245349236
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2024-02-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2024-02-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2024-02-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2024-02-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2024-02-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2024-02-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2024-02-01,7.0,0.00018471119085943478
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2024-02-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2024-02-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2024-02-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2024-02-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2024-02-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2024-02-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2024-02-01,48.0,0.0012665910230361243
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2024-02-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2024-02-01,252.0,0.006649602870939652
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2024-02-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2024-02-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2024-02-01,68.0,0.0017943372826345093
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2024-02-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2024-02-01,45.0,0.0011874290840963664
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2024-02-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2024-02-01,0.0,0.0
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2024-02-01,30.0,0.0007916193893975777
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2024-02-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2024-02-01,131.0,0.0034567380003694224
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2024-02-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2024-02-01,1390.0,0.03667836504208776
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2024-02-01,420.0,0.011082671451566087
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2024-02-01,92.0,0.0024276327941525713
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2024-02-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2024-02-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2024-02-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2024-02-01,0.0,0.0
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2024-02-01,498.0,0.013140881863999788
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2024-02-01,15.0,0.00039580969469878884
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2024-02-01,318.0,0.008391165527614323
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2024-02-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2024-02-01,130.0,0.003430350687389503
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2024-02-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2024-02-01,169.0,0.004459455893606354
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2024-02-01,169.0,0.004459455893606354
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2024-02-01,12268.0,0.3237195556376494
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2024-02-01,60.0,0.0015832387787951554
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2024-02-01,40.0,0.00105549251919677
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2024-02-01,20.0,0.000527746259598385
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2024-02-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2024-02-01,0.0,0.0
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2024-02-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2024-02-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2024-02-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2024-02-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2024-02-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2024-02-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2024-02-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2024-02-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2024-02-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2024-02-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2024-02-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2024-02-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2024-02-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2024-02-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2024-02-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2024-02-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2024-02-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2024-02-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2024-02-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2024-02-01,169.0,0.004459455893606354
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2024-02-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2024-02-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2024-02-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2024-02-01,382.0,0.010079953558329155
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2024-02-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2024-02-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2024-02-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2024-02-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2024-02-01,1.0,2.6387312979919254e-05
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2024-02-01,57804.0,0.8129271791410008
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2024-02-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2024-02-01,4939.0,0.06945967991449385
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2024-02-01,22.0,0.000309397237926476
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-02-01,534.0,0.007509914775124462
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2024-02-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-02-01,637.0,0.008958456389052964
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2024-02-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-02-01,382.0,0.00537226113126881
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-02-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-02-01,6.0,8.43810648890389e-05
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-02-01,278.0,0.003909656006525469
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-02-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2024-02-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2024-02-01,113.0,0.0015891767220768992
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2024-02-01,13.0,0.00018282564059291762
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2024-02-01,2995.0,0.04212021489044525
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2024-02-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2024-02-01,1299.0,0.01826850054847692
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2024-02-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2024-02-01,444.0,0.006244198801788879
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2024-02-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2024-02-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2024-02-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2024-02-01,1016.0,0.014288526987877253
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2024-02-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2024-02-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2024-02-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2024-02-01,6.0,0.1935483870967742
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2024-02-01,3.0,0.0967741935483871
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2024-02-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2024-02-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2024-02-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2024-02-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2024-02-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2024-02-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2024-02-01,185.0,0.13386396526772792
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2024-02-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2024-02-01,6.0,0.004341534008683068
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2024-02-01,2.0,0.001447178002894356
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2024-02-01,3.0,0.002170767004341534
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2024-02-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2024-02-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2024-02-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2024-02-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2024-02-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2024-02-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2024-02-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2024-02-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2024-02-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2024-02-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2024-02-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2024-02-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2024-02-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2024-03-01,1397.0,0.8825015792798484
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2024-03-01,11.0,0.006948831332912192
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2024-03-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2024-03-01,5.0,0.003158559696778269
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2024-03-01,31.0,0.01958307012002527
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2024-03-01,52.0,0.032849020846494
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2024-03-01,52.0,0.032849020846494
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2024-03-01,451.0,0.28490208464939987
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2024-03-01,132.0,0.08338597599494631
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2024-03-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2024-03-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2024-03-01,147.0,0.09286165508528112
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2024-03-01,18.0,0.011370814908401769
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2024-03-01,451.0,0.28490208464939987
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2024-03-01,200.0,0.12634238787113075
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2024-03-01,200.0,0.12634238787113075
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2024-03-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2024-03-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2024-03-01,132.0,0.08338597599494631
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2024-03-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2024-03-01,41.0,0.025900189513581806
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2024-03-01,0.0,0.0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2024-03-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2024-03-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2024-03-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2024-03-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2024-03-01,140.0,0.7329842931937173
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2024-03-01,75.0,0.39267015706806285
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2024-03-01,33.0,0.17277486910994763
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2024-03-01,140.0,0.7329842931937173
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2024-03-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2024-03-01,6.0,0.031413612565445025
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2024-03-01,134.0,0.7015706806282722
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2024-03-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2024-03-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2024-03-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2024-03-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2024-03-01,65.0,0.6185567010309279
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2024-03-01,16.0,0.1134020618556701
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2024-03-01,65.0,0.6185567010309279
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2024-03-01,72.0,0.3769633507853403
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2024-03-01,66.0,0.34554973821989526
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2024-03-01,18.0,0.09424083769633508
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2024-03-01,2.0,0.010471204188481676
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2024-03-01,138.0,0.7225130890052356
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2024-03-01,22.0,0.11518324607329843
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2024-03-01,3.0,0.015706806282722512
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2024-03-01,138.0,0.7225130890052356
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2024-03-01,138.0,0.7225130890052356
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2024-03-01,138.0,0.7225130890052356
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2024-03-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2024-03-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2024-03-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2024-03-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2024-03-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2024-03-01,0.0,0.0
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2024-03-01,0.0,0.0
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2024-03-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2024-03-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2024-03-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2024-03-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2024-03-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2024-03-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2024-03-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2024-03-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2024-03-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2024-03-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2024-03-01,11.0,0.02849740932642487
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2024-03-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2024-03-01,12.0,0.031088082901554404
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2024-03-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2024-03-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2024-03-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2024-03-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2024-03-01,8.0,0.02072538860103627
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2024-03-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2024-03-01,6.0,0.015544041450777202
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2024-03-01,7.0,0.018134715025906734
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2024-03-01,4.0,0.010362694300518135
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2024-03-01,4.0,0.010362694300518135
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2024-03-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2024-03-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2024-03-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2024-03-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2024-03-01,78.0,0.20207253886010362
M8,Family Planning,8.17.1,Complications following male sterilization,2024-03-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2024-03-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2024-03-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2024-03-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2024-03-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2024-03-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2024-03-01,0.0,0.0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2024-03-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2024-03-01,138.0,0.7301587301587301
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2024-03-01,138.0,0.7301587301587301
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2024-03-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2024-03-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2024-03-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2024-03-01,138.0,0.7301587301587301
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2024-03-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2024-03-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2024-03-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2024-03-01,138.0,0.7301587301587301
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2024-03-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2024-03-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2024-03-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2024-03-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2024-03-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2024-03-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2024-03-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2024-03-01,16.0,0.08465608465608465
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2024-03-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2024-03-01,16.0,0.08465608465608465
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2024-03-01,16.0,0.08465608465608465
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2024-03-01,20.0,0.10582010582010581
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2024-03-01,11.0,0.0582010582010582
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2024-03-01,5.0,0.026455026455026454
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2024-03-01,5.0,0.026455026455026454
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2024-03-01,5.0,0.026455026455026454
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2024-03-01,3.0,0.015873015873015872
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2024-03-01,3.0,0.015873015873015872
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2024-03-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2024-03-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2024-03-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2024-03-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2024-03-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2024-03-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2024-03-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2024-03-01,7.0,0.037037037037037035
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2024-03-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2024-03-01,10.0,0.05291005291005291
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2024-03-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2024-03-01,11.0,0.0582010582010582
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2024-03-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2024-03-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2024-03-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2024-03-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2024-03-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2024-03-01,16.0,0.08465608465608465
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2024-03-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2024-03-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2024-03-01,12.0,0.1016949152542373
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2024-03-01,4.0,0.03389830508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2024-03-01,2.0,0.01694915254237288
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2024-03-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2024-03-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2024-03-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2024-03-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2024-03-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2024-03-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2024-03-01,1.0,0.00847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2024-03-01,21.0,0.17796610169491525
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2024-03-01,21.0,0.17796610169491525
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2024-03-01,21.0,0.17796610169491525
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2024-03-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2024-03-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2024-03-01,22.0,0.1864406779661017
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2024-03-01,12.0,0.1016949152542373
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2024-03-01,21.0,0.17796610169491525
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2024-03-01,110.0,0.41353383458646614
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2024-03-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2024-03-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2024-03-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2024-03-01,22.0,0.08270676691729323
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2024-03-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2024-03-01,1.0,0.0037593984962406013
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2024-03-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2024-03-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2024-03-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-03-01,3.0,0.011278195488721804
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-03-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-03-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-03-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2024-03-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2024-03-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2024-03-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2024-03-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2024-03-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2024-03-01,20.0,0.15873015873015872
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2024-03-01,11.0,0.0873015873015873
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2024-03-01,16.0,0.12698412698412698
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2024-03-01,8.0,0.06349206349206349
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2024-03-01,20.0,0.15873015873015872
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2024-03-01,11.0,0.0873015873015873
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2024-03-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2024-03-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2024-03-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2024-03-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2024-03-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2024-03-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2024-03-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2024-03-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2024-03-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2024-03-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2024-03-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2024-03-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2024-03-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2024-03-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2024-03-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2024-03-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2024-03-01,3.0,0.3
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2024-03-01,3.0,0.3
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2024-03-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2024-03-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2024-03-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2024-03-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2024-03-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2024-03-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2024-03-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2024-03-01,630.0,0.01662400717734913
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2024-03-01,560.0,0.014776895268754782
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2024-03-01,737.0,0.01944744966620049
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2024-03-01,2162.0,0.057049370662585426
M14 ,Patient Services,14.1.8,Outpatient - Dental,2024-03-01,1480.0,0.0390532232102805
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2024-03-01,1944.0,0.051296936432963035
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2024-03-01,20.0,0.000527746259598385
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2024-03-01,328.0,0.008655038657413516
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2024-03-01,1240.0,0.032720268095099876
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2024-03-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2024-03-01,707.0,0.018655830276802912
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2024-03-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2024-03-01,33539.0,0.8850040900335119
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2024-03-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2024-03-01,167.0,0.004406681267646515
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2024-03-01,701.0,0.018497506398923398
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2024-03-01,121.0,0.0031928648705702297
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2024-03-01,743.0,0.019605773544080007
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2024-03-01,353.0,0.009314721481911497
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2024-03-01,170.0,0.004485843206586273
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2024-03-01,761.0,0.020080745177718552
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2024-03-01,130.0,0.003430350687389503
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2024-03-01,791.0,0.02087236456711613
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2024-03-01,368.0,0.009710531176610285
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2024-03-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2024-03-01,0.0,0.0
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2024-03-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2024-03-01,0.0,0.0
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2024-03-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2024-03-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2024-03-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2024-03-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2024-03-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2024-03-01,7.0,0.00018471119085943478
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2024-03-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2024-03-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2024-03-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2024-03-01,0.0,0.0
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2024-03-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2024-03-01,285.0,0.007520384199276988
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2024-03-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2024-03-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2024-03-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2024-03-01,25.0,0.0006596828244979814
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2024-03-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2024-03-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2024-03-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2024-03-01,19.0,0.0005013589466184658
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2024-03-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2024-03-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2024-03-01,0.0,0.0
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2024-03-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2024-03-01,2645.0,0.06979444283188643
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2024-03-01,740.0,0.01952661160514025
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2024-03-01,83.0,0.002190146977333298
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2024-03-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2024-03-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2024-03-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2024-03-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2024-03-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2024-03-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2024-03-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2024-03-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2024-03-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2024-03-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2024-03-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2024-03-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2024-03-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2024-03-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2024-03-01,491.0,0.012956170673140354
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2024-03-01,19.0,0.0005013589466184658
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2024-03-01,281.0,0.007414834947357311
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2024-03-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2024-03-01,148.0,0.0039053223210280498
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2024-03-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2024-03-01,240.0,0.0063329551151806215
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2024-03-01,240.0,0.0063329551151806215
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2024-03-01,11486.0,0.3030846768873526
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2024-03-01,70.0,0.0018471119085943478
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2024-03-01,43.0,0.001134654458136528
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2024-03-01,20.0,0.000527746259598385
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2024-03-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2024-03-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2024-03-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2024-03-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2024-03-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2024-03-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2024-03-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2024-03-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2024-03-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2024-03-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2024-03-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2024-03-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2024-03-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2024-03-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2024-03-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2024-03-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2024-03-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2024-03-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2024-03-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2024-03-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2024-03-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2024-03-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2024-03-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2024-03-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2024-03-01,240.0,0.0063329551151806215
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2024-03-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2024-03-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2024-03-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2024-03-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2024-03-01,1011.0,0.026677573422698365
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2024-03-01,877.0,0.023141673483389188
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2024-03-01,16.0,0.00042219700767870806
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2024-03-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2024-03-01,451.0,0.011900678153943583
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2024-03-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2024-03-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2024-03-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2024-03-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2024-03-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2024-03-01,55790.0,0.7846032683599133
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2024-03-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2024-03-01,3982.0,0.05600090006469215
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2024-03-01,10.0,0.00014063510814839815
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-03-01,415.0,0.005836356988158524
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2024-03-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-03-01,601.0,0.00845216999971873
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2024-03-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-03-01,451.0,0.006342643377492757
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2024-03-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-03-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2024-03-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2024-03-01,52.0,0.0007313025623716705
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-03-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-03-01,8.0,0.00011250808651871853
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-03-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-03-01,255.0,0.0035861952577841533
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-03-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2024-03-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2024-03-01,70.0,0.0009844457570387872
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2024-03-01,6.0,8.43810648890389e-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2024-03-01,2863.0,0.040263831462886396
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2024-03-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2024-03-01,1324.0,0.018620088318847917
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2024-03-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2024-03-01,476.0,0.006694231147863753
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2024-03-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2024-03-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2024-03-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2024-03-01,963.0,0.013543160914690744
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2024-03-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2024-03-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2024-03-01,3.0,0.0967741935483871
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2024-03-01,3.0,0.0967741935483871
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2024-03-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2024-03-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2024-03-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2024-03-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2024-03-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2024-03-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2024-03-01,198.0,0.14327062228654125
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2024-03-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2024-03-01,7.0,0.005065123010130246
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2024-03-01,7.0,0.005065123010130246
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2024-03-01,3.0,0.002170767004341534
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2024-03-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2024-03-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2024-03-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2024-03-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2024-03-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2024-03-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2024-03-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2024-03-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2024-03-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2024-03-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2024-03-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2024-03-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2024-03-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2024-04-01,881.0,0.556538218572331
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2024-04-01,7.0,0.004421983575489577
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2024-04-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2024-04-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2024-04-01,34.0,0.02147820593809223
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2024-04-01,22.0,0.013897662665824383
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2024-04-01,36.0,0.022741629816803537
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2024-04-01,36.0,0.022741629816803537
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2024-04-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2024-04-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2024-04-01,40.0,0.025268477574226154
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2024-04-01,187.0,0.11813013265950727
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2024-04-01,22.0,0.013897662665824383
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2024-04-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2024-04-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2024-04-01,48.0,0.030322173089071383
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2024-04-01,48.0,0.030322173089071383
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2024-04-01,82.0,0.05180037902716361
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2024-04-01,23.0,0.014529374605180037
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2024-04-01,22.0,0.013897662665824383
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2024-04-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2024-04-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2024-04-01,40.0,0.025268477574226154
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2024-04-01,8.0,0.00505369551484523
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2024-04-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2024-04-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2024-04-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2024-04-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2024-04-01,161.0,0.8429319371727748
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2024-04-01,86.0,0.450261780104712
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2024-04-01,31.0,0.16230366492146597
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2024-04-01,161.0,0.8429319371727748
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2024-04-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2024-04-01,5.0,0.02617801047120419
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2024-04-01,156.0,0.8167539267015707
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2024-04-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2024-04-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2024-04-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2024-04-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2024-04-01,75.0,0.7216494845360825
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2024-04-01,32.0,0.27835051546391754
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2024-04-01,75.0,0.7216494845360825
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2024-04-01,94.0,0.49214659685863876
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2024-04-01,71.0,0.3717277486910995
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2024-04-01,11.0,0.05759162303664921
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2024-04-01,12.0,0.06282722513089005
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2024-04-01,165.0,0.8638743455497382
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2024-04-01,4.0,0.020942408376963352
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2024-04-01,2.0,0.010471204188481676
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2024-04-01,165.0,0.8638743455497382
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2024-04-01,165.0,0.8638743455497382
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2024-04-01,165.0,0.8638743455497382
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2024-04-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2024-04-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2024-04-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2024-04-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2024-04-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2024-04-01,161.0,0.7740384615384616
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2024-04-01,161.0,0.7740384615384616
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2024-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2024-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2024-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2024-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2024-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2024-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2024-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2024-04-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2024-04-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2024-04-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2024-04-01,10.0,0.025906735751295335
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2024-04-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2024-04-01,13.0,0.03367875647668394
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2024-04-01,1.0,0.0025906735751295338
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2024-04-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2024-04-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2024-04-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2024-04-01,4.0,0.010362694300518135
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2024-04-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2024-04-01,6.0,0.015544041450777202
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2024-04-01,2.0,0.0051813471502590676
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2024-04-01,4.0,0.010362694300518135
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2024-04-01,4.0,0.010362694300518135
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2024-04-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2024-04-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2024-04-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2024-04-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2024-04-01,108.0,0.27979274611398963
M8,Family Planning,8.17.1,Complications following male sterilization,2024-04-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2024-04-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2024-04-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2024-04-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2024-04-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2024-04-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2024-04-01,0.0,0.0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2024-04-01,165.0,0.873015873015873
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2024-04-01,165.0,0.873015873015873
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2024-04-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2024-04-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2024-04-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2024-04-01,165.0,0.873015873015873
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2024-04-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2024-04-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2024-04-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2024-04-01,165.0,0.873015873015873
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2024-04-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2024-04-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2024-04-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2024-04-01,23.0,0.12169312169312169
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2024-04-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2024-04-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2024-04-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2024-04-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2024-04-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2024-04-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2024-04-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2024-04-01,11.0,0.0582010582010582
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2024-04-01,8.0,0.042328042328042326
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2024-04-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2024-04-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2024-04-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2024-04-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2024-04-01,6.0,0.031746031746031744
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2024-04-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2024-04-01,4.0,0.021164021164021163
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2024-04-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2024-04-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2024-04-01,12.0,0.06349206349206349
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2024-04-01,11.0,0.09322033898305085
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2024-04-01,7.0,0.059322033898305086
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2024-04-01,4.0,0.03389830508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2024-04-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2024-04-01,8.0,0.06779661016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2024-04-01,2.0,0.01694915254237288
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2024-04-01,11.0,0.09322033898305085
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2024-04-01,86.0,0.3233082706766917
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2024-04-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2024-04-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2024-04-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2024-04-01,10.0,0.03759398496240601
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2024-04-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2024-04-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2024-04-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2024-04-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2024-04-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-04-01,12.0,0.045112781954887216
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-04-01,8.0,0.03007518796992481
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-04-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-04-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2024-04-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2024-04-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2024-04-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2024-04-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2024-04-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2024-04-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2024-04-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2024-04-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2024-04-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2024-04-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2024-04-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2024-04-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2024-04-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2024-04-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2024-04-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2024-04-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2024-04-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2024-04-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2024-04-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2024-04-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2024-04-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2024-04-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2024-04-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2024-04-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2024-04-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2024-04-01,550.0,0.01451302213895559
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2024-04-01,480.0,0.012665910230361243
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2024-04-01,285.0,0.007520384199276988
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2024-04-01,1320.0,0.03483125313349342
M14 ,Patient Services,14.1.8,Outpatient - Dental,2024-04-01,834.0,0.022007019025252657
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2024-04-01,996.0,0.026281763727999577
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2024-04-01,15.0,0.00039580969469878884
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2024-04-01,363.0,0.00957859461171069
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2024-04-01,950.0,0.025067947330923292
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2024-04-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2024-04-01,575.0,0.01517270496345357
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2024-04-01,18975.0,0.5006992637939679
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2024-04-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2024-04-01,184.0,0.0048552655883051426
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2024-04-01,670.0,0.017679499696545902
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2024-04-01,134.0,0.0035358999393091802
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2024-04-01,677.0,0.017864210887405335
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2024-04-01,336.0,0.00886613716125287
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2024-04-01,183.0,0.0048288782753252235
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2024-04-01,659.0,0.01738923925376679
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2024-04-01,125.0,0.003298414122489907
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2024-04-01,689.0,0.018180858643164367
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2024-04-01,340.0,0.008971686413172546
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2024-04-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2024-04-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2024-04-01,0.0,0.0
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2024-04-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2024-04-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2024-04-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2024-04-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2024-04-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2024-04-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2024-04-01,7.0,0.00018471119085943478
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2024-04-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2024-04-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2024-04-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2024-04-01,0.0,0.0
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2024-04-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2024-04-01,308.0,0.008127292397815131
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2024-04-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2024-04-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2024-04-01,19.0,0.0005013589466184658
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2024-04-01,0.0,0.0
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2024-04-01,0.0,0.0
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2024-04-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2024-04-01,0.0,0.0
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2024-04-01,0.0,0.0
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2024-04-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2024-04-01,0.0,0.0
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2024-04-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2024-04-01,1801.0,0.04752355067683458
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2024-04-01,860.0,0.022693089162730558
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2024-04-01,78.0,0.0020582104124337018
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2024-04-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2024-04-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2024-04-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2024-04-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2024-04-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2024-04-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2024-04-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2024-04-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2024-04-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2024-04-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2024-04-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2024-04-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2024-04-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2024-04-01,0.0,0.0
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2024-04-01,417.0,0.011003509512626328
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2024-04-01,11.0,0.0002902604427791118
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2024-04-01,294.0,0.007757870016096261
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2024-04-01,138.0,0.003641449191228857
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2024-04-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2024-04-01,202.0,0.00533023722194369
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2024-04-01,0.0,0.0
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2024-04-01,9057.0,0.23898989365912868
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2024-04-01,75.0,0.0019790484734939443
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2024-04-01,44.0,0.0011610417711164472
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2024-04-01,28.0,0.0007388447634377391
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2024-04-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2024-04-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2024-04-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2024-04-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2024-04-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2024-04-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2024-04-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2024-04-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2024-04-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2024-04-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2024-04-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2024-04-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2024-04-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2024-04-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2024-04-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2024-04-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2024-04-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2024-04-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2024-04-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2024-04-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2024-04-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2024-04-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2024-04-01,202.0,0.00533023722194369
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2024-04-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2024-04-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2024-04-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2024-04-01,242.0,0.0063857297411404595
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2024-04-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2024-04-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2024-04-01,52033.0,0.7317666582285601
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2024-04-01,3595.0,0.05055832137934914
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2024-04-01,23.0,0.00032346074874131577
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-04-01,393.0,0.005526959750232048
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2024-04-01,4.0,5.6254043259359264e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-04-01,610.0,0.008578741597052289
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-04-01,10.0,0.00014063510814839815
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-04-01,236.0,0.0033189885523021967
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-04-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2024-04-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2024-04-01,78.0,0.0010969538435575057
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2024-04-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2024-04-01,2775.0,0.03902624251118049
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2024-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2024-04-01,1202.0,0.01690433999943746
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2024-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2024-04-01,489.0,0.00687705678845667
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2024-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2024-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2024-04-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2024-04-01,1090.0,0.0153292267881754
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2024-04-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2024-04-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2024-04-01,5.0,0.16129032258064516
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2024-04-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2024-04-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2024-04-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2024-04-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2024-04-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2024-04-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2024-04-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2024-04-01,208.0,0.15050651230101303
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2024-04-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2024-04-01,7.0,0.005065123010130246
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2024-04-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2024-04-01,5.0,0.00361794500723589
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2024-04-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2024-04-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2024-04-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2024-04-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2024-04-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2024-04-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2024-04-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2024-04-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2024-04-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2024-04-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2024-04-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2024-04-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2024-04-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2024-05-01,890.0,0.5622236260265319
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2024-05-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2024-05-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2024-05-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2024-05-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2024-05-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2024-05-01,40.0,0.025268477574226154
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2024-05-01,40.0,0.025268477574226154
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2024-05-01,210.0,0.1326595072646873
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2024-05-01,40.0,0.025268477574226154
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2024-05-01,13.0,0.0082122552116235
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2024-05-01,13.0,0.0082122552116235
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2024-05-01,185.0,0.11686670878079596
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2024-05-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2024-05-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2024-05-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2024-05-01,480.0,0.30322173089071386
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2024-05-01,482.0,0.3044851547694251
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2024-05-01,80.0,0.05053695514845231
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2024-05-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2024-05-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2024-05-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2024-05-01,30.0,0.018951358180669616
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2024-05-01,6.0,0.003790271636133923
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2024-05-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2024-05-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2024-05-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2024-05-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2024-05-01,181.0,0.9476439790575916
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2024-05-01,96.0,0.5026178010471204
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2024-05-01,60.0,0.31413612565445026
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2024-05-01,181.0,0.9476439790575916
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2024-05-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2024-05-01,0.0,0.0
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2024-05-01,181.0,0.9476439790575916
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2024-05-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2024-05-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2024-05-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2024-05-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2024-05-01,85.0,0.8247422680412371
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2024-05-01,25.0,0.20618556701030927
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2024-05-01,85.0,0.8247422680412371
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2024-05-01,87.0,0.45549738219895286
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2024-05-01,94.0,0.49214659685863876
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2024-05-01,12.0,0.06282722513089005
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2024-05-01,10.0,0.05235602094240838
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2024-05-01,181.0,0.9476439790575916
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2024-05-01,35.0,0.18324607329842932
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2024-05-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2024-05-01,181.0,0.9476439790575916
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2024-05-01,181.0,0.9476439790575916
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2024-05-01,181.0,0.9476439790575916
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2024-05-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2024-05-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2024-05-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2024-05-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2024-05-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2024-05-01,181.0,0.8701923076923077
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2024-05-01,181.0,0.8701923076923077
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2024-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2024-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2024-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2024-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2024-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2024-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2024-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2024-05-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2024-05-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2024-05-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2024-05-01,13.0,0.03367875647668394
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2024-05-01,5.0,0.012953367875647668
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2024-05-01,14.0,0.03626943005181347
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2024-05-01,1.0,0.0025906735751295338
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2024-05-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2024-05-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2024-05-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2024-05-01,6.0,0.015544041450777202
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2024-05-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2024-05-01,8.0,0.02072538860103627
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2024-05-01,4.0,0.010362694300518135
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2024-05-01,4.0,0.010362694300518135
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2024-05-01,5.0,0.012953367875647668
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2024-05-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2024-05-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2024-05-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2024-05-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2024-05-01,100.0,0.25906735751295334
M8,Family Planning,8.17.1,Complications following male sterilization,2024-05-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2024-05-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2024-05-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2024-05-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2024-05-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2024-05-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2024-05-01,0.0,0.0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2024-05-01,181.0,0.9576719576719577
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2024-05-01,181.0,0.9576719576719577
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2024-05-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2024-05-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2024-05-01,21.0,0.1111111111111111
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2024-05-01,181.0,0.9576719576719577
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2024-05-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2024-05-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2024-05-01,21.0,0.1111111111111111
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2024-05-01,181.0,0.9576719576719577
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2024-05-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2024-05-01,21.0,0.1111111111111111
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2024-05-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2024-05-01,22.0,0.1164021164021164
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2024-05-01,21.0,0.1111111111111111
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2024-05-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2024-05-01,21.0,0.1111111111111111
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2024-05-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2024-05-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2024-05-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2024-05-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2024-05-01,11.0,0.0582010582010582
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2024-05-01,14.0,0.07407407407407407
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2024-05-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2024-05-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2024-05-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2024-05-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2024-05-01,4.0,0.021164021164021163
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2024-05-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2024-05-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2024-05-01,25.0,0.13227513227513227
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2024-05-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2024-05-01,118.0,1.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2024-05-01,118.0,1.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2024-05-01,118.0,1.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2024-05-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2024-05-01,18.0,0.15254237288135594
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2024-05-01,1.0,0.00847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2024-05-01,38.0,0.3220338983050847
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2024-05-01,91.0,0.34210526315789475
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2024-05-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2024-05-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2024-05-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2024-05-01,9.0,0.03383458646616541
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2024-05-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2024-05-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2024-05-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2024-05-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2024-05-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-05-01,2.0,0.007518796992481203
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-05-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-05-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-05-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2024-05-01,1.0,0.0037593984962406013
M11,NVBDCP,11.4.2,No. of JE positive cases,2024-05-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2024-05-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2024-05-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2024-05-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2024-05-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2024-05-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2024-05-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2024-05-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2024-05-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2024-05-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2024-05-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2024-05-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2024-05-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2024-05-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2024-05-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2024-05-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2024-05-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2024-05-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2024-05-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2024-05-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2024-05-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2024-05-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2024-05-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2024-05-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2024-05-01,570.0,0.015040768398553976
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2024-05-01,466.0,0.012296487848642373
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2024-05-01,614.0,0.016201810169670424
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2024-05-01,2406.0,0.06348787502968573
M14 ,Patient Services,14.1.8,Outpatient - Dental,2024-05-01,1409.0,0.03717972398870623
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2024-05-01,1843.0,0.048631817821991184
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2024-05-01,17.0,0.00044858432065862734
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2024-05-01,334.0,0.00881336253529303
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2024-05-01,1850.0,0.04881652901285062
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2024-05-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2024-05-01,707.0,0.018655830276802912
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2024-05-01,31547.0,0.8324405625775128
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2024-05-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2024-05-01,192.0,0.005066364092144497
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2024-05-01,874.0,0.023062511544449427
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2024-05-01,184.0,0.0048552655883051426
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2024-05-01,895.0,0.023616645117027733
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2024-05-01,461.0,0.012164551283742777
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2024-05-01,187.0,0.0049344275272449
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2024-05-01,814.0,0.021479272765654273
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2024-05-01,163.0,0.004301132015726838
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2024-05-01,838.0,0.022112568277172336
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2024-05-01,429.0,0.01132015726838536
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2024-05-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2024-05-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2024-05-01,0.0,0.0
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2024-05-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2024-05-01,0.0,0.0
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2024-05-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2024-05-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2024-05-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2024-05-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2024-05-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2024-05-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2024-05-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.3.6,Day Care Admissions,2024-05-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2024-05-01,0.0,0.0
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2024-05-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2024-05-01,357.0,0.009420270733831174
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2024-05-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2024-05-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2024-05-01,25.0,0.0006596828244979814
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2024-05-01,0.0,0.0
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2024-05-01,0.0,0.0
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2024-05-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2024-05-01,0.0,0.0
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2024-05-01,0.0,0.0
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2024-05-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2024-05-01,0.0,0.0
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2024-05-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2024-05-01,2134.0,0.05631052589914769
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2024-05-01,935.0,0.024672137636224504
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2024-05-01,92.0,0.0024276327941525713
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2024-05-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2024-05-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2024-05-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2024-05-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2024-05-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2024-05-01,15.0,0.00039580969469878884
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2024-05-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2024-05-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2024-05-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2024-05-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2024-05-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2024-05-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2024-05-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2024-05-01,0.0,0.0
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2024-05-01,604.0,0.01593793703987123
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2024-05-01,19.0,0.0005013589466184658
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2024-05-01,362.0,0.009552207298730771
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2024-05-01,140.0,0.0036942238171886956
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2024-05-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2024-05-01,200.0,0.005277462595983851
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2024-05-01,200.0,0.005277462595983851
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2024-05-01,12413.0,0.3275457160197377
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2024-05-01,0.0,0.0
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2024-05-01,37.0,0.0009763305802570124
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2024-05-01,28.0,0.0007388447634377391
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2024-05-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2024-05-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2024-05-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2024-05-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2024-05-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2024-05-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2024-05-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2024-05-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2024-05-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2024-05-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2024-05-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2024-05-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2024-05-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2024-05-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2024-05-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2024-05-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2024-05-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2024-05-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2024-05-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2024-05-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2024-05-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2024-05-01,200.0,0.005277462595983851
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2024-05-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2024-05-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2024-05-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2024-05-01,1161.0,0.030635670369686254
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2024-05-01,956.0,0.025226271208802806
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2024-05-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2024-05-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2024-05-01,240.0,0.0063329551151806215
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2024-05-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2024-05-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2024-05-01,61943.0,0.8711360504036227
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2024-05-01,4512.0,0.06345456079655726
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2024-05-01,25.0,0.0003515877703709954
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-05-01,469.0,0.006595786572159874
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2024-05-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-05-01,682.0,0.009591314375720755
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2024-05-01,4.0,5.6254043259359264e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-05-01,15.0,0.00021095266222259724
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-05-01,262.0,0.003684639833488032
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2024-05-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2024-05-01,60.0,0.000843810648890389
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2024-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2024-05-01,3062.0,0.04306247011503952
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2024-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2024-05-01,1437.0,0.020209265040924816
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2024-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2024-05-01,541.0,0.007608359350828341
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2024-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2024-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2024-05-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2024-05-01,989.0,0.013908812195876578
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2024-05-01,5.0,0.16129032258064516
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2024-05-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2024-05-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2024-05-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2024-05-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2024-05-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2024-05-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2024-05-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2024-05-01,249.0,0.18017366136034732
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2024-05-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2024-05-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2024-05-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2024-05-01,3.0,0.002170767004341534
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2024-05-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2024-05-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2024-05-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2024-05-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2024-05-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2024-05-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2024-05-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2024-05-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2024-05-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2024-05-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2024-05-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2024-05-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2024-05-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2024-06-01,1098.0,0.693619709412508
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2024-06-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2024-06-01,9.0,0.005685407454200884
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2024-06-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2024-06-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2024-06-01,15.0,0.009475679090334808
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2024-06-01,40.0,0.025268477574226154
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2024-06-01,40.0,0.025268477574226154
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2024-06-01,50.0,0.03158559696778269
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2024-06-01,40.0,0.025268477574226154
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2024-06-01,9.0,0.005685407454200884
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2024-06-01,9.0,0.005685407454200884
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2024-06-01,42.0,0.026531901452937462
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2024-06-01,25.0,0.015792798483891344
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2024-06-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2024-06-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2024-06-01,50.0,0.03158559696778269
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2024-06-01,488.0,0.30827542640555905
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2024-06-01,80.0,0.05053695514845231
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2024-06-01,16.0,0.01010739102969046
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2024-06-01,15.0,0.009475679090334808
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2024-06-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2024-06-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2024-06-01,25.0,0.015792798483891344
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2024-06-01,0.0,0.0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2024-06-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2024-06-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2024-06-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2024-06-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2024-06-01,144.0,0.7539267015706806
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2024-06-01,71.0,0.3717277486910995
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2024-06-01,29.0,0.1518324607329843
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2024-06-01,144.0,0.7539267015706806
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2024-06-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2024-06-01,2.0,0.010471204188481676
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2024-06-01,142.0,0.743455497382199
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2024-06-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2024-06-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2024-06-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2024-06-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2024-06-01,73.0,0.7010309278350515
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2024-06-01,21.0,0.16494845360824742
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2024-06-01,73.0,0.7010309278350515
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2024-06-01,74.0,0.387434554973822
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2024-06-01,66.0,0.34554973821989526
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2024-06-01,22.0,0.11518324607329843
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2024-06-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2024-06-01,3.0,0.015706806282722512
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2024-06-01,7.0,0.03664921465968586
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2024-06-01,140.0,0.7329842931937173
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2024-06-01,20.0,0.10471204188481675
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2024-06-01,5.0,0.02617801047120419
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2024-06-01,140.0,0.7329842931937173
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2024-06-01,140.0,0.7329842931937173
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2024-06-01,140.0,0.7329842931937173
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2024-06-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2024-06-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2024-06-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2024-06-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2024-06-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2024-06-01,140.0,0.6730769230769231
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2024-06-01,140.0,0.6730769230769231
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2024-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2024-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2024-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2024-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2024-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2024-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2024-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2024-06-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2024-06-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2024-06-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2024-06-01,6.0,0.015544041450777202
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2024-06-01,1.0,0.0025906735751295338
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2024-06-01,9.0,0.023316062176165803
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2024-06-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2024-06-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2024-06-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2024-06-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2024-06-01,6.0,0.015544041450777202
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2024-06-01,8.0,0.02072538860103627
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2024-06-01,4.0,0.010362694300518135
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2024-06-01,4.0,0.010362694300518135
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2024-06-01,5.0,0.012953367875647668
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2024-06-01,0.0,0.0
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2024-06-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2024-06-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2024-06-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2024-06-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2024-06-01,67.0,0.17357512953367876
M8,Family Planning,8.17.1,Complications following male sterilization,2024-06-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2024-06-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2024-06-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2024-06-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2024-06-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2024-06-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2024-06-01,0.0,0.0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2024-06-01,140.0,0.7407407407407407
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2024-06-01,140.0,0.7407407407407407
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2024-06-01,44.0,0.2328042328042328
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2024-06-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2024-06-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2024-06-01,140.0,0.7407407407407407
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2024-06-01,44.0,0.2328042328042328
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2024-06-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2024-06-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2024-06-01,140.0,0.7407407407407407
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2024-06-01,44.0,0.2328042328042328
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2024-06-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2024-06-01,44.0,0.2328042328042328
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2024-06-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2024-06-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2024-06-01,44.0,0.2328042328042328
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2024-06-01,18.0,0.09523809523809523
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2024-06-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2024-06-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2024-06-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2024-06-01,28.0,0.14814814814814814
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2024-06-01,14.0,0.07407407407407407
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2024-06-01,14.0,0.07407407407407407
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2024-06-01,14.0,0.07407407407407407
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2024-06-01,14.0,0.07407407407407407
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2024-06-01,5.0,0.026455026455026454
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2024-06-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2024-06-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2024-06-01,24.0,0.2033898305084746
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2024-06-01,24.0,0.2033898305084746
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2024-06-01,24.0,0.2033898305084746
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2024-06-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2024-06-01,6.0,0.05084745762711865
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2024-06-01,2.0,0.01694915254237288
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2024-06-01,24.0,0.2033898305084746
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2024-06-01,115.0,0.4323308270676692
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2024-06-01,1.0,0.0037593984962406013
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2024-06-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2024-06-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2024-06-01,28.0,0.10526315789473684
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2024-06-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2024-06-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2024-06-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2024-06-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2024-06-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-06-01,2.0,0.007518796992481203
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-06-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-06-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-06-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2024-06-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2024-06-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2024-06-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2024-06-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2024-06-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2024-06-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2024-06-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2024-06-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2024-06-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2024-06-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2024-06-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2024-06-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2024-06-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2024-06-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2024-06-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2024-06-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2024-06-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2024-06-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2024-06-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2024-06-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2024-06-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2024-06-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2024-06-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2024-06-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2024-06-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2024-06-01,525.0,0.013853339314457608
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2024-06-01,450.0,0.011874290840963664
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2024-06-01,909.0,0.023986067498746603
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2024-06-01,2142.0,0.056521624402987046
M14 ,Patient Services,14.1.8,Outpatient - Dental,2024-06-01,1156.0,0.03050373380478666
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2024-06-01,1780.0,0.04696941710425628
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2024-06-01,15.0,0.00039580969469878884
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2024-06-01,341.0,0.008998073726152465
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2024-06-01,1624.0,0.04285299627938887
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2024-06-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2024-06-01,577.0,0.01522547958941341
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2024-06-01,33292.0,0.8784864237274719
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2024-06-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2024-06-01,182.0,0.0048024909623453045
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2024-06-01,857.0,0.0226139272237908
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2024-06-01,143.0,0.0037733857561284534
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2024-06-01,827.0,0.021822307834393224
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2024-06-01,465.0,0.012270100535662453
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2024-06-01,178.0,0.004696941710425628
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2024-06-01,866.0,0.022851413040610075
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2024-06-01,153.0,0.004037258885927646
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2024-06-01,835.0,0.02203340633823258
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2024-06-01,489.0,0.012903396047180516
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2024-06-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2024-06-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2024-06-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2024-06-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2024-06-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2024-06-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2024-06-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2024-06-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2024-06-01,7.0,0.00018471119085943478
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2024-06-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2024-06-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2024-06-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.6,Day Care Admissions,2024-06-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2024-06-01,0.0,0.0
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2024-06-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2024-06-01,398.0,0.010502150566007864
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2024-06-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2024-06-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2024-06-01,82.0,0.002163759664353379
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2024-06-01,0.0,0.0
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2024-06-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2024-06-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2024-06-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2024-06-01,24.0,0.0006332955115180621
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2024-06-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2024-06-01,0.0,0.0
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2024-06-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2024-06-01,2012.0,0.05309127371559754
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2024-06-01,830.0,0.02190146977333298
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2024-06-01,91.0,0.0024012454811726523
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2024-06-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2024-06-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2024-06-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2024-06-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2024-06-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2024-06-01,16.0,0.00042219700767870806
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2024-06-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2024-06-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2024-06-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2024-06-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2024-06-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2024-06-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2024-06-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2024-06-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2024-06-01,558.0,0.014724120642794944
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2024-06-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2024-06-01,325.0,0.008575876718473758
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2024-06-01,130.0,0.003430350687389503
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2024-06-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2024-06-01,286.0,0.007546771512256907
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2024-06-01,286.0,0.007546771512256907
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2024-06-01,14371.0,0.3792120748344196
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2024-06-01,0.0,0.0
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2024-06-01,0.0,0.0
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2024-06-01,0.0,0.0
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2024-06-01,0.0,0.0
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2024-06-01,0.0,0.0
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2024-06-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2024-06-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2024-06-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2024-06-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2024-06-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2024-06-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2024-06-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2024-06-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2024-06-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2024-06-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2024-06-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2024-06-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2024-06-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2024-06-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2024-06-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2024-06-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2024-06-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2024-06-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2024-06-01,286.0,0.007546771512256907
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2024-06-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2024-06-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2024-06-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2024-06-01,1203.0,0.03174393751484286
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2024-06-01,1068.0,0.028181650262553763
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2024-06-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2024-06-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2024-06-01,240.0,0.0063329551151806215
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2024-06-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2024-06-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2024-06-01,66280.0,0.9321294968075831
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2024-06-01,200.0,0.002812702162967963
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2024-06-01,6402.0,0.09003459623660451
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2024-06-01,23.0,0.00032346074874131577
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-06-01,535.0,0.0075239782859393015
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2024-06-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-06-01,585.0,0.008227153826681292
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2024-06-01,3.0,4.219053244451945e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-06-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-06-01,8.0,0.00011250808651871853
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-06-01,308.0,0.0043315613309706635
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-06-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2024-06-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2024-06-01,108.0,0.0015188591680027003
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2024-06-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2024-06-01,2938.0,0.04131859477399938
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2024-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2024-06-01,1365.0,0.01919669226225635
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2024-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2024-06-01,500.0,0.007031755407419908
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2024-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2024-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2024-06-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2024-06-01,688.0,0.009675695440609793
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2024-06-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2024-06-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2024-06-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2024-06-01,7.0,0.22580645161290322
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2024-06-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2024-06-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2024-06-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2024-06-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2024-06-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2024-06-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2024-06-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2024-06-01,255.0,0.18451519536903038
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2024-06-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2024-06-01,7.0,0.005065123010130246
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2024-06-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2024-06-01,5.0,0.00361794500723589
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2024-06-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2024-06-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2024-06-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2024-06-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2024-06-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2024-06-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2024-06-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2024-06-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2024-06-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2024-06-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2024-06-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2024-06-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2024-06-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2024-07-01,1379.0,0.8711307643714467
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2024-07-01,9.0,0.005685407454200884
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2024-07-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2024-07-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2024-07-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2024-07-01,40.0,0.025268477574226154
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2024-07-01,40.0,0.025268477574226154
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2024-07-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2024-07-01,15.0,0.009475679090334808
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2024-07-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2024-07-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2024-07-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2024-07-01,20.0,0.012634238787113077
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2024-07-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2024-07-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2024-07-01,49.0,0.03095388502842704
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2024-07-01,15.0,0.009475679090334808
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2024-07-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2024-07-01,15.0,0.009475679090334808
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2024-07-01,15.0,0.009475679090334808
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2024-07-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2024-07-01,30.0,0.018951358180669616
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2024-07-01,8.0,0.00505369551484523
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2024-07-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2024-07-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2024-07-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2024-07-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2024-07-01,122.0,0.6387434554973822
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2024-07-01,64.0,0.33507853403141363
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2024-07-01,23.0,0.12041884816753927
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2024-07-01,122.0,0.6387434554973822
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2024-07-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2024-07-01,2.0,0.010471204188481676
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2024-07-01,120.0,0.6282722513089005
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2024-07-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2024-07-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2024-07-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2024-07-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2024-07-01,58.0,0.5463917525773195
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2024-07-01,21.0,0.16494845360824742
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2024-07-01,58.0,0.5463917525773195
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2024-07-01,56.0,0.2931937172774869
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2024-07-01,66.0,0.34554973821989526
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2024-07-01,16.0,0.08376963350785341
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2024-07-01,1.0,0.005235602094240838
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2024-07-01,9.0,0.04712041884816754
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2024-07-01,122.0,0.6387434554973822
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2024-07-01,21.0,0.1099476439790576
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2024-07-01,9.0,0.04712041884816754
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2024-07-01,122.0,0.6387434554973822
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2024-07-01,122.0,0.6387434554973822
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2024-07-01,122.0,0.6387434554973822
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2024-07-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2024-07-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2024-07-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2024-07-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2024-07-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2024-07-01,122.0,0.5865384615384616
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2024-07-01,122.0,0.5865384615384616
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2024-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2024-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2024-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2024-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2024-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2024-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2024-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2024-07-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2024-07-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2024-07-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2024-07-01,3.0,0.007772020725388601
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2024-07-01,1.0,0.0025906735751295338
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2024-07-01,8.0,0.02072538860103627
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2024-07-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2024-07-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2024-07-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2024-07-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2024-07-01,4.0,0.010362694300518135
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2024-07-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2024-07-01,8.0,0.02072538860103627
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2024-07-01,4.0,0.010362694300518135
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2024-07-01,4.0,0.010362694300518135
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2024-07-01,5.0,0.012953367875647668
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2024-07-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2024-07-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2024-07-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2024-07-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2024-07-01,90.0,0.23316062176165803
M8,Family Planning,8.17.1,Complications following male sterilization,2024-07-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2024-07-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2024-07-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2024-07-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2024-07-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2024-07-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2024-07-01,0.0,0.0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2024-07-01,122.0,0.6455026455026455
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2024-07-01,122.0,0.6455026455026455
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2024-07-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2024-07-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2024-07-01,34.0,0.17989417989417988
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2024-07-01,122.0,0.6455026455026455
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2024-07-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2024-07-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2024-07-01,34.0,0.17989417989417988
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2024-07-01,122.0,0.6455026455026455
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2024-07-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2024-07-01,34.0,0.17989417989417988
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2024-07-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2024-07-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2024-07-01,34.0,0.17989417989417988
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2024-07-01,37.0,0.19576719576719576
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2024-07-01,34.0,0.17989417989417988
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2024-07-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2024-07-01,17.0,0.08994708994708994
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2024-07-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2024-07-01,19.0,0.10052910052910052
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2024-07-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2024-07-01,14.0,0.07407407407407407
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2024-07-01,17.0,0.08994708994708994
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2024-07-01,17.0,0.08994708994708994
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2024-07-01,17.0,0.08994708994708994
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2024-07-01,17.0,0.08994708994708994
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2024-07-01,5.0,0.026455026455026454
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2024-07-01,5.0,0.026455026455026454
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2024-07-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2024-07-01,28.0,0.23728813559322035
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2024-07-01,28.0,0.23728813559322035
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2024-07-01,28.0,0.23728813559322035
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2024-07-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2024-07-01,15.0,0.1271186440677966
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2024-07-01,4.0,0.03389830508474576
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2024-07-01,14.0,0.11864406779661017
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2024-07-01,176.0,0.6616541353383458
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2024-07-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2024-07-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2024-07-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2024-07-01,46.0,0.17293233082706766
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2024-07-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2024-07-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2024-07-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2024-07-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2024-07-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-07-01,2.0,0.007518796992481203
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-07-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-07-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-07-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2024-07-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2024-07-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2024-07-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2024-07-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2024-07-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2024-07-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2024-07-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2024-07-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2024-07-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2024-07-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2024-07-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2024-07-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2024-07-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2024-07-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2024-07-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2024-07-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2024-07-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2024-07-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2024-07-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2024-07-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2024-07-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2024-07-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2024-07-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2024-07-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2024-07-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2024-07-01,575.0,0.01517270496345357
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2024-07-01,480.0,0.012665910230361243
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2024-07-01,1072.0,0.028287199514473442
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2024-07-01,2270.0,0.059899200464416706
M14 ,Patient Services,14.1.8,Outpatient - Dental,2024-07-01,1469.0,0.03876296276750139
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2024-07-01,2072.0,0.054674512494392695
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2024-07-01,16.0,0.00042219700767870806
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2024-07-01,355.0,0.009367496107871336
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2024-07-01,1731.0,0.04567643876824023
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2024-07-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2024-07-01,911.0,0.02403884212470644
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2024-07-01,36697.0,0.9683352244240969
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2024-07-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2024-07-01,187.0,0.0049344275272449
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2024-07-01,933.0,0.024619363010264666
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2024-07-01,164.0,0.004327519328706758
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2024-07-01,857.0,0.0226139272237908
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2024-07-01,456.0,0.01203261471884318
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2024-07-01,184.0,0.0048552655883051426
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2024-07-01,954.0,0.02517349658284297
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2024-07-01,161.0,0.004248357389767
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2024-07-01,858.0,0.02264031453677072
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2024-07-01,444.0,0.011715966963084148
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2024-07-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2024-07-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2024-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2024-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2024-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2024-07-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2024-07-01,11.0,0.0002902604427791118
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2024-07-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2024-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2024-07-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2024-07-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2024-07-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2024-07-01,30.0,0.0007916193893975777
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2024-07-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2024-07-01,261.0,0.006887088687758926
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2024-07-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2024-07-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2024-07-01,112.0,0.0029553790537509565
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2024-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2024-07-01,29.0,0.0007652320764176584
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2024-07-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2024-07-01,0.0,0.0
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2024-07-01,17.0,0.00044858432065862734
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2024-07-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2024-07-01,130.0,0.003430350687389503
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2024-07-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2024-07-01,1766.0,0.046599994722537404
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2024-07-01,650.0,0.017151753436947515
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2024-07-01,75.0,0.0019790484734939443
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2024-07-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2024-07-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2024-07-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2024-07-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2024-07-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2024-07-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2024-07-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2024-07-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2024-07-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2024-07-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2024-07-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2024-07-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2024-07-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2024-07-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2024-07-01,532.0,0.014038050505317043
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2024-07-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2024-07-01,344.0,0.009077235665092224
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2024-07-01,120.0,0.0031664775575903107
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2024-07-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2024-07-01,370.0,0.009763305802570125
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2024-07-01,370.0,0.009763305802570125
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2024-07-01,13952.0,0.36815579069583343
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2024-07-01,56.0,0.0014776895268754783
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2024-07-01,28.0,0.0007388447634377391
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2024-07-01,23.0,0.0006069081985381428
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2024-07-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2024-07-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2024-07-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2024-07-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2024-07-01,42.0,0.0011082671451566088
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2024-07-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2024-07-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2024-07-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2024-07-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2024-07-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2024-07-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2024-07-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2024-07-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2024-07-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2024-07-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2024-07-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2024-07-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2024-07-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2024-07-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2024-07-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2024-07-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2024-07-01,370.0,0.009763305802570125
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2024-07-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2024-07-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2024-07-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2024-07-01,1139.0,0.030055149484128033
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2024-07-01,985.0,0.025991503285220464
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2024-07-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2024-07-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2024-07-01,250.0,0.006596828244979814
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2024-07-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2024-07-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2024-07-01,71106.0,1.0
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2024-07-01,5539.0,0.07789778640339774
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2024-07-01,23.0,0.00032346074874131577
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-07-01,430.0,0.006047309650381121
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2024-07-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-07-01,583.0,0.008199026805051614
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2024-07-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-07-01,15.0,0.00021095266222259724
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-07-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-07-01,218.0,0.00306584535763508
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-07-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-07-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2024-07-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2024-07-01,126.0,0.0017720023626698169
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2024-07-01,13.0,0.00018282564059291762
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2024-07-01,3165.0,0.04451101172896802
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2024-07-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2024-07-01,1589.0,0.02234691868478047
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2024-07-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2024-07-01,498.0,0.007003628385790228
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2024-07-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2024-07-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2024-07-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2024-07-01,1527.0,0.0214749810142604
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2024-07-01,11.0,0.3548387096774194
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2024-07-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2024-07-01,2.0,0.06451612903225806
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2024-07-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2024-07-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2024-07-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2024-07-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2024-07-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2024-07-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2024-07-01,250.0,0.1808972503617945
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2024-07-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2024-07-01,6.0,0.004341534008683068
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2024-07-01,6.0,0.004341534008683068
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2024-07-01,2.0,0.001447178002894356
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2024-07-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2024-07-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2024-07-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2024-07-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2024-07-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2024-07-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2024-07-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2024-07-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2024-07-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2024-07-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2024-07-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2024-07-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2024-07-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2024-08-01,959.0,0.605811749842072
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2024-08-01,5.0,0.003158559696778269
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2024-08-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2024-08-01,46.0,0.029058749210360075
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2024-08-01,22.0,0.013897662665824383
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2024-08-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2024-08-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2024-08-01,19.0,0.012002526847757423
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2024-08-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2024-08-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2024-08-01,12.0,0.007580543272267846
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2024-08-01,13.0,0.0082122552116235
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2024-08-01,9.0,0.005685407454200884
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2024-08-01,3.0,0.0018951358180669614
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2024-08-01,6.0,0.003790271636133923
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2024-08-01,16.0,0.01010739102969046
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2024-08-01,21.0,0.013265950726468731
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2024-08-01,32.0,0.02021478205938092
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2024-08-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2024-08-01,0.0,0.0
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2024-08-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2024-08-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2024-08-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2024-08-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2024-08-01,174.0,0.9109947643979057
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2024-08-01,105.0,0.5497382198952879
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2024-08-01,46.0,0.24083769633507854
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2024-08-01,174.0,0.9109947643979057
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2024-08-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2024-08-01,4.0,0.020942408376963352
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2024-08-01,170.0,0.8900523560209425
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2024-08-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2024-08-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2024-08-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2024-08-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2024-08-01,69.0,0.6597938144329897
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2024-08-01,24.0,0.1958762886597938
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2024-08-01,69.0,0.6597938144329897
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2024-08-01,82.0,0.4293193717277487
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2024-08-01,90.0,0.4712041884816754
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2024-08-01,22.0,0.11518324607329843
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2024-08-01,2.0,0.010471204188481676
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2024-08-01,172.0,0.900523560209424
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2024-08-01,32.0,0.16753926701570682
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2024-08-01,5.0,0.02617801047120419
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2024-08-01,172.0,0.900523560209424
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2024-08-01,172.0,0.900523560209424
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2024-08-01,172.0,0.900523560209424
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2024-08-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2024-08-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2024-08-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2024-08-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2024-08-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2024-08-01,172.0,0.8269230769230769
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2024-08-01,172.0,0.8269230769230769
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2024-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2024-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2024-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2024-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2024-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2024-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2024-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2024-08-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2024-08-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2024-08-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2024-08-01,4.0,0.010362694300518135
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2024-08-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2024-08-01,7.0,0.018134715025906734
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2024-08-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2024-08-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2024-08-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2024-08-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2024-08-01,2.0,0.0051813471502590676
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2024-08-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2024-08-01,2.0,0.0051813471502590676
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2024-08-01,1.0,0.0025906735751295338
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2024-08-01,3.0,0.007772020725388601
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2024-08-01,0.0,0.0
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2024-08-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2024-08-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2024-08-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2024-08-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2024-08-01,66.0,0.17098445595854922
M8,Family Planning,8.17.1,Complications following male sterilization,2024-08-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2024-08-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2024-08-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2024-08-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2024-08-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2024-08-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2024-08-01,12.0,0.031088082901554404
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2024-08-01,172.0,0.91005291005291
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2024-08-01,172.0,0.91005291005291
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2024-08-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2024-08-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2024-08-01,38.0,0.20105820105820105
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2024-08-01,172.0,0.91005291005291
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2024-08-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2024-08-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2024-08-01,38.0,0.20105820105820105
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2024-08-01,172.0,0.91005291005291
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2024-08-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2024-08-01,38.0,0.20105820105820105
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2024-08-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2024-08-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2024-08-01,38.0,0.20105820105820105
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2024-08-01,29.0,0.15343915343915343
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2024-08-01,38.0,0.20105820105820105
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2024-08-01,17.0,0.08994708994708994
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2024-08-01,17.0,0.08994708994708994
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2024-08-01,17.0,0.08994708994708994
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2024-08-01,17.0,0.08994708994708994
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2024-08-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2024-08-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2024-08-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2024-08-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2024-08-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2024-08-01,8.0,0.06779661016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2024-08-01,8.0,0.06779661016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2024-08-01,8.0,0.06779661016949153
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2024-08-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2024-08-01,18.0,0.15254237288135594
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2024-08-01,3.0,0.025423728813559324
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2024-08-01,8.0,0.06779661016949153
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2024-08-01,251.0,0.943609022556391
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2024-08-01,1.0,0.0037593984962406013
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2024-08-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2024-08-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2024-08-01,41.0,0.15413533834586465
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2024-08-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2024-08-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2024-08-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2024-08-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2024-08-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-08-01,3.0,0.011278195488721804
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-08-01,0.0,0.0
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-08-01,3.0,0.011278195488721804
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-08-01,1.0,0.0037593984962406013
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2024-08-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2024-08-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2024-08-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2024-08-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2024-08-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2024-08-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2024-08-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2024-08-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2024-08-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2024-08-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2024-08-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2024-08-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2024-08-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2024-08-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2024-08-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2024-08-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2024-08-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2024-08-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2024-08-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2024-08-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2024-08-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2024-08-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2024-08-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2024-08-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2024-08-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2024-08-01,675.0,0.017811436261445497
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2024-08-01,520.0,0.013721402749558012
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2024-08-01,809.0,0.021347336200754678
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2024-08-01,2197.0,0.0579729266168826
M14 ,Patient Services,14.1.8,Outpatient - Dental,2024-08-01,1399.0,0.036915850858907036
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2024-08-01,1857.0,0.04900124020371006
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2024-08-01,18.0,0.0004749716336385466
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2024-08-01,421.0,0.011109058764546006
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2024-08-01,1550.0,0.04090033511887484
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2024-08-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2024-08-01,657.0,0.01733646462780695
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2024-08-01,33595.0,0.8864817795603873
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2024-08-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2024-08-01,239.0,0.006306567802200702
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2024-08-01,934.0,0.024645750323244585
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2024-08-01,202.0,0.00533023722194369
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2024-08-01,957.0,0.025252658521782725
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2024-08-01,428.0,0.011293769955405441
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2024-08-01,234.0,0.006174631237301106
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2024-08-01,952.0,0.02512072195688313
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2024-08-01,212.0,0.0055941103517428824
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2024-08-01,976.0,0.025754017468401193
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2024-08-01,433.0,0.011425706520305038
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2024-08-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2024-08-01,0.0,0.0
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2024-08-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2024-08-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2024-08-01,0.0,0.0
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2024-08-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2024-08-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2024-08-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2024-08-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2024-08-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2024-08-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2024-08-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.6,Day Care Admissions,2024-08-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2024-08-01,35.0,0.0009235559542971739
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2024-08-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2024-08-01,264.0,0.006966250626698684
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2024-08-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2024-08-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2024-08-01,170.0,0.004485843206586273
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2024-08-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2024-08-01,33.0,0.0008707813283373355
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2024-08-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2024-08-01,50.0,0.0013193656489959627
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2024-08-01,25.0,0.0006596828244979814
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2024-08-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2024-08-01,90.0,0.002374858168192733
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2024-08-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2024-08-01,1277.0,0.03369659867535689
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2024-08-01,550.0,0.01451302213895559
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2024-08-01,80.0,0.00211098503839354
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2024-08-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2024-08-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2024-08-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2024-08-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2024-08-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2024-08-01,19.0,0.0005013589466184658
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2024-08-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2024-08-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2024-08-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2024-08-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2024-08-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2024-08-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2024-08-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2024-08-01,0.0,0.0
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2024-08-01,492.0,0.012982557986120273
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2024-08-01,13.0,0.0003430350687389503
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2024-08-01,298.0,0.007863419268015938
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2024-08-01,142.0,0.003746998443148534
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2024-08-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2024-08-01,376.0,0.00992162968044964
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2024-08-01,376.0,0.00992162968044964
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2024-08-01,13383.0,0.35314140961025936
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2024-08-01,0.0,0.0
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2024-08-01,44.0,0.0011610417711164472
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2024-08-01,29.0,0.0007652320764176584
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2024-08-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2024-08-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2024-08-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2024-08-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2024-08-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2024-08-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2024-08-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2024-08-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2024-08-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2024-08-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2024-08-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2024-08-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2024-08-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2024-08-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2024-08-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2024-08-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2024-08-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2024-08-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2024-08-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2024-08-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2024-08-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2024-08-01,376.0,0.00992162968044964
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2024-08-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2024-08-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2024-08-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2024-08-01,1118.0,0.029501015911549727
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2024-08-01,994.0,0.02622898910203974
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2024-08-01,11.0,0.0002902604427791118
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2024-08-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2024-08-01,168.0,0.004433068580626435
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2024-08-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2024-08-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2024-08-01,68323.0,0.9608612494023008
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2024-08-01,4.0,5.6254043259359264e-05
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2024-08-01,5713.0,0.08034483728517987
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2024-08-01,16.0,0.00022501617303743706
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-08-01,469.0,0.006595786572159874
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2024-08-01,7.0,9.844457570387872e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-08-01,546.0,0.00767867690490254
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2024-08-01,8.0,0.00011250808651871853
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-08-01,168.0,0.002362669816893089
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2024-08-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-08-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-08-01,20.0,0.0002812702162967963
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-08-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-08-01,276.0,0.0038815289848957895
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-08-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-08-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2024-08-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2024-08-01,174.0,0.002447050881782128
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2024-08-01,13.0,0.00018282564059291762
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2024-08-01,3036.0,0.042696818833853685
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2024-08-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2024-08-01,1477.0,0.02077180547351841
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2024-08-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2024-08-01,473.0,0.0066520406154192335
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2024-08-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2024-08-01,189.0,0.0026580035440047253
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2024-08-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2024-08-01,967.0,0.013599414957950102
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2024-08-01,6.0,0.1935483870967742
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2024-08-01,5.0,0.16129032258064516
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2024-08-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2024-08-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2024-08-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2024-08-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2024-08-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2024-08-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2024-08-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2024-08-01,232.0,0.1678726483357453
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2024-08-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2024-08-01,6.0,0.004341534008683068
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2024-08-01,3.0,0.002170767004341534
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2024-08-01,2.0,0.001447178002894356
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2024-08-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2024-08-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2024-08-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2024-08-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2024-08-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2024-08-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2024-08-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2024-08-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2024-08-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2024-08-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2024-08-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2024-08-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2024-08-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2024-09-01,450.0,0.28427037271004424
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2024-09-01,8.0,0.00505369551484523
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2024-09-01,10.0,0.006317119393556538
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2024-09-01,9.0,0.005685407454200884
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2024-09-01,18.0,0.011370814908401769
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2024-09-01,11.0,0.006948831332912192
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2024-09-01,11.0,0.006948831332912192
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2024-09-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2024-09-01,19.0,0.012002526847757423
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2024-09-01,19.0,0.012002526847757423
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2024-09-01,19.0,0.012002526847757423
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2024-09-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2024-09-01,41.0,0.025900189513581806
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2024-09-01,31.0,0.01958307012002527
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2024-09-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2024-09-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2024-09-01,70.0,0.04421983575489577
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2024-09-01,14.0,0.008843967150979154
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2024-09-01,58.0,0.03663929248262792
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2024-09-01,9.0,0.005685407454200884
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2024-09-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2024-09-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2024-09-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2024-09-01,53.0,0.033480732785849655
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2024-09-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2024-09-01,44.0,0.027795325331648767
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2024-09-01,13.0,0.0082122552116235
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2024-09-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2024-09-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2024-09-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2024-09-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2024-09-01,160.0,0.837696335078534
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2024-09-01,79.0,0.41361256544502617
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2024-09-01,41.0,0.21465968586387435
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2024-09-01,160.0,0.837696335078534
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2024-09-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2024-09-01,16.0,0.08376963350785341
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2024-09-01,144.0,0.7539267015706806
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2024-09-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2024-09-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2024-09-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2024-09-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2024-09-01,81.0,0.7835051546391752
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2024-09-01,30.0,0.25773195876288657
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2024-09-01,81.0,0.7835051546391752
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2024-09-01,84.0,0.4397905759162304
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2024-09-01,74.0,0.387434554973822
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2024-09-01,17.0,0.08900523560209424
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2024-09-01,2.0,0.010471204188481676
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2024-09-01,158.0,0.8272251308900523
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2024-09-01,38.0,0.19895287958115182
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2024-09-01,4.0,0.020942408376963352
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2024-09-01,158.0,0.8272251308900523
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2024-09-01,158.0,0.8272251308900523
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2024-09-01,158.0,0.8272251308900523
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2024-09-01,2.0,0.010471204188481676
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2024-09-01,5.0,0.02617801047120419
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2024-09-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2024-09-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2024-09-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2024-09-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2024-09-01,158.0,0.7596153846153846
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2024-09-01,158.0,0.7596153846153846
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2024-09-01,158.0,0.7596153846153846
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2024-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2024-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2024-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2024-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2024-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2024-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2024-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2024-09-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2024-09-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2024-09-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2024-09-01,7.0,0.018134715025906734
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2024-09-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2024-09-01,8.0,0.02072538860103627
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2024-09-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2024-09-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2024-09-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2024-09-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2024-09-01,0.0,0.0
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2024-09-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2024-09-01,0.0,0.0
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2024-09-01,0.0,0.0
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2024-09-01,0.0,0.0
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2024-09-01,0.0,0.0
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2024-09-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2024-09-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2024-09-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2024-09-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2024-09-01,0.0,0.0
M8,Family Planning,8.17.1,Complications following male sterilization,2024-09-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2024-09-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2024-09-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2024-09-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2024-09-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2024-09-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2024-09-01,0.0,0.0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2024-09-01,158.0,0.8359788359788359
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2024-09-01,158.0,0.8359788359788359
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2024-09-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2024-09-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2024-09-01,31.0,0.164021164021164
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2024-09-01,158.0,0.8359788359788359
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2024-09-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2024-09-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2024-09-01,31.0,0.164021164021164
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2024-09-01,158.0,0.8359788359788359
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2024-09-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2024-09-01,31.0,0.164021164021164
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2024-09-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2024-09-01,24.0,0.12698412698412698
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2024-09-01,31.0,0.164021164021164
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2024-09-01,40.0,0.21164021164021163
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2024-09-01,31.0,0.164021164021164
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2024-09-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2024-09-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2024-09-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2024-09-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2024-09-01,62.0,0.328042328042328
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2024-09-01,60.0,0.31746031746031744
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2024-09-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2024-09-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2024-09-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2024-09-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2024-09-01,6.0,0.031746031746031744
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2024-09-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2024-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2024-09-01,14.0,0.11864406779661017
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2024-09-01,16.0,0.13559322033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2024-09-01,1.0,0.00847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2024-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2024-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2024-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2024-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2024-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2024-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2024-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2024-09-01,22.0,0.1864406779661017
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2024-09-01,22.0,0.1864406779661017
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2024-09-01,22.0,0.1864406779661017
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2024-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2024-09-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2024-09-01,44.0,0.3728813559322034
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2024-09-01,14.0,0.11864406779661017
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2024-09-01,6.0,0.05084745762711865
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2024-09-01,266.0,1.0
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2024-09-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2024-09-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2024-09-01,1.0,0.0037593984962406013
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2024-09-01,46.0,0.17293233082706766
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2024-09-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2024-09-01,1.0,0.0037593984962406013
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2024-09-01,1.0,0.0037593984962406013
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2024-09-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2024-09-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-09-01,66.0,0.24812030075187969
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-09-01,10.0,0.03759398496240601
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-09-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-09-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2024-09-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2024-09-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2024-09-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2024-09-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2024-09-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2024-09-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2024-09-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2024-09-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2024-09-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2024-09-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2024-09-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2024-09-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2024-09-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2024-09-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2024-09-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2024-09-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2024-09-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2024-09-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2024-09-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2024-09-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2024-09-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2024-09-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2024-09-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2024-09-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2024-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2024-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2024-09-01,4.0,0.4
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2024-09-01,4.0,0.4
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2024-09-01,4.0,0.4
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2024-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2024-09-01,4.0,0.4
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2024-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2024-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2024-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2024-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2024-09-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2024-09-01,655.0,0.017283690001847114
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2024-09-01,535.0,0.014117212444256802
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2024-09-01,775.0,0.02045016755943742
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2024-09-01,1966.0,0.05187745731852125
M14 ,Patient Services,14.1.8,Outpatient - Dental,2024-09-01,1303.0,0.03438266881283479
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2024-09-01,1786.0,0.04712774098213579
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2024-09-01,19.0,0.0005013589466184658
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2024-09-01,467.0,0.012322875161622292
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2024-09-01,175.0,0.00461777977148587
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2024-09-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2024-09-01,657.0,0.01733646462780695
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2024-09-01,31966.0,0.8434968467160989
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2024-09-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2024-09-01,236.0,0.006227405863260944
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2024-09-01,1000.0,0.026387312979919256
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2024-09-01,209.0,0.005514948412803125
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2024-09-01,935.0,0.024672137636224504
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2024-09-01,245.0,0.006464891680080217
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2024-09-01,243.0,0.006412117054120379
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2024-09-01,885.0,0.02335277198722854
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2024-09-01,203.0,0.005356624534923609
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2024-09-01,1000.0,0.026387312979919256
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2024-09-01,261.0,0.006887088687758926
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2024-09-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2024-09-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2024-09-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2024-09-01,0.0,0.0
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2024-09-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2024-09-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2024-09-01,13.0,0.0003430350687389503
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2024-09-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2024-09-01,0.0,0.0
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2024-09-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2024-09-01,6.0,0.00015832387787951554
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2024-09-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2024-09-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2024-09-01,30.0,0.0007916193893975777
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2024-09-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2024-09-01,314.0,0.008285616275694647
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2024-09-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2024-09-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2024-09-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2024-09-01,165.0,0.004353906641686677
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2024-09-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2024-09-01,44.0,0.0011610417711164472
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2024-09-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2024-09-01,35.0,0.0009235559542971739
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2024-09-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2024-09-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2024-09-01,87.0,0.002295696229252975
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2024-09-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2024-09-01,1262.0,0.0333007889806581
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2024-09-01,350.0,0.00923555954297174
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2024-09-01,75.0,0.0019790484734939443
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2024-09-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2024-09-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2024-09-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2024-09-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2024-09-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2024-09-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2024-09-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2024-09-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2024-09-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2024-09-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2024-09-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2024-09-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2024-09-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2024-09-01,0.0,0.0
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2024-09-01,379.0,0.010000791619389398
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2024-09-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2024-09-01,256.0,0.006755152122859329
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2024-09-01,144.0,0.003799773069108373
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2024-09-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2024-09-01,366.0,0.009657756550650447
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2024-09-01,366.0,0.009657756550650447
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2024-09-01,12767.0,0.3368868248146291
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2024-09-01,71.0,0.001873499221574267
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2024-09-01,41.0,0.0010818798321766895
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2024-09-01,19.0,0.0005013589466184658
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2024-09-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2024-09-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2024-09-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2024-09-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2024-09-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2024-09-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2024-09-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2024-09-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2024-09-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2024-09-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2024-09-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2024-09-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2024-09-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2024-09-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2024-09-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2024-09-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2024-09-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2024-09-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2024-09-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2024-09-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2024-09-01,0.0,0.0
M14 ,Patient Services,14.21,Total number of blood units issued in month,2024-09-01,366.0,0.009657756550650447
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2024-09-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2024-09-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2024-09-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2024-09-01,1032.0,0.02723170699527667
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2024-09-01,926.0,0.02443465181940523
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2024-09-01,8.0,0.00021109850383935403
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2024-09-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2024-09-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2024-09-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2024-09-01,66838.0,0.9399769358422637
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2024-09-01,13.0,0.00018282564059291762
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2024-09-01,5773.0,0.08118864793407025
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2024-09-01,14.0,0.00019688915140775743
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-09-01,453.0,0.006370770399122437
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2024-09-01,5.0,7.031755407419908e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-09-01,613.0,0.008620932129496807
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2024-09-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-09-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-09-01,32.0,0.0004500323460748741
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-09-01,266.0,0.003740893876747391
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-09-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-09-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2024-09-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2024-09-01,165.0,0.0023204792844485696
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2024-09-01,1.0,1.4063510814839816e-05
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2024-09-01,3223.0,0.04532669535622873
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2024-09-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2024-09-01,1408.0,0.019801423227294463
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2024-09-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2024-09-01,475.0,0.006680167637048913
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2024-09-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2024-09-01,160.0,0.0022501617303743704
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2024-09-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2024-09-01,789.0,0.011096110032908616
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2024-09-01,2.0,0.06451612903225806
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2024-09-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2024-09-01,1.0,0.03225806451612903
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2024-09-01,7.0,0.22580645161290322
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2024-09-01,3.0,0.0967741935483871
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2024-09-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2024-09-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2024-09-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2024-09-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2024-09-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2024-09-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2024-09-01,264.0,0.191027496382055
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2024-09-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2024-09-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2024-09-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2024-09-01,3.0,0.002170767004341534
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2024-09-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2024-09-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2024-09-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2024-09-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2024-09-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2024-09-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2024-09-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2024-09-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2024-09-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2024-09-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2024-09-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2024-09-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2024-09-01,0.0,
M1,Ante Natal Care (ANC),1.1,Total number of NEW Pregnant Women registered for ANC ,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.a,Out of total number of NEW Pregnant Women registered with age <15 years,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.b,Out of total number of NEW Pregnant Women registered with age 15-19 years,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.c,Out of total number of NEW Pregnant Women registered with age >19 to 49 years,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.d,Out of total number of NEW Pregnant Women registered with age >49 years,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.1,"Out of the total NEW ANC registered, number registered within 1st trimester (within 12 weeks)",2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.1.2,Total ANC footfall/cases (Old cases + New Registration) attended ,2024-10-01,1138.0,0.7188881869867341
M1,Ante Natal Care (ANC),1.2.1,Number of PW given Td1 (Tetanus Diptheria dose 1),2024-10-01,3.0,0.0018951358180669614
M1,Ante Natal Care (ANC),1.2.2,Number of PW given Td2 (Tetanus Diptheria dose 2),2024-10-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.2.3,Number of PW given Td Booster (Tetanus Diptheria dose booster),2024-10-01,7.0,0.004421983575489577
M1,Ante Natal Care (ANC),1.2.4,Number of PW provided full course 180 Iron Folic Acid (IFA) tablets ,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.5,Number of PW provided full course 360 Calcium tablets ,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.6,Number of PW given one Albendazole tablet after 1st trimester,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.7,Number of PW received 4 or more ANC check ups,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.2.8,Number of PW given ANC Corticosteroids in Pre-Term Labour,2024-10-01,18.0,0.011370814908401769
M1,Ante Natal Care (ANC),1.3.1,New cases of PW with hypertension detected ,2024-10-01,9.0,0.005685407454200884
M1,Ante Natal Care (ANC),1.3.1.a,Number of PW with hypertension managed at institution ,2024-10-01,14.0,0.008843967150979154
M1,Ante Natal Care (ANC),1.3.2,Number of Eclampsia cases managed during delivery,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.4.1,Number of PW tested for Haemoglobin (Hb ) 4 or more than 4 times for respective ANCs,2024-10-01,30.0,0.018951358180669616
M1,Ante Natal Care (ANC),1.4.2,Number of PW having Hb level<11(7.1 to 10.9 g/dl) (Out of total tested cases),2024-10-01,14.0,0.008843967150979154
M1,Ante Natal Care (ANC),1.4.3,Number of PW having Hb level<=7 g/dl (Out of total tested cases),2024-10-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.4.4,Number of PW treated for severe anaemia (Hb<=7g/dl) (Out of total tested cases),2024-10-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.5.1,Number of PW tested for Blood Sugar using OGTT(Oral Glucose Tolerance Test),2024-10-01,14.0,0.008843967150979154
M1,Ante Natal Care (ANC),1.5.2,Number of PW tested positive for GDM out of total OGTT(Oral Glucose Tolerance Test) conducted,2024-10-01,7.0,0.004421983575489577
M1,Ante Natal Care (ANC),1.5.3,Number of PW given Insulin out of total tested positive for GDM,2024-10-01,1.0,0.0006317119393556538
M1,Ante Natal Care (ANC),1.5.4,Number of PW given Metformin out of total tested positive for GDM,2024-10-01,2.0,0.0012634238787113076
M1,Ante Natal Care (ANC),1.6.1.a,Number of pregnant/Direct-In-Labor (DIL) women screened/tested (with VDRL/RPR/TPHA/RDT/PoC) for Syphilis,2024-10-01,30.0,0.018951358180669616
M1,Ante Natal Care (ANC),1.6.1.b,Number of pregnant/DIL women found Seropositive for Syphilis by VDRL/RPR/TPHA/RDT/PoC test,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.c,Number of pregnant/DIL women found Syphilis-Seropositive and given treatment with injection Benzathine Penicillin (IM),2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.d,Number of live births among Syphilis Seropositive Pregnant Women,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.e,Number of babies born to Syphilis-Seropositive Pregnant Women tested positive/ clinically diagnosed for congenital Syphilis ,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.6.1.f,"Out of above, babies with congenital Syphilis received curative treatment ",2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.7.1,Number of Pregnant Women tested positive for Thyroid disorder,2024-10-01,34.0,0.02147820593809223
M1,Ante Natal Care (ANC),1.7.2,Number of Pregnant Women treated for thyroid disorder,2024-10-01,78.0,0.049273531269740996
M1,Ante Natal Care (ANC),1.8.1,Number of Pregnant Women screened for TB ,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.2,Number of Pregnant Women identified with Presumptive TB symptoms,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.8.3,Number of Pregnant Women referred out of those identified with Presumptive TB symptoms ,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1,Total High Risk Pregnancy (HRP) Intrapartum including following:,2024-10-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.9.1.a,Number of Pregnant Women with Post-Partum Haemorrhage(Immediately after delivery) in the facility.,2024-10-01,4.0,0.002526847757422615
M1,Ante Natal Care (ANC),1.9.1.b,Number of Pregnant Women with Sepsis in the facility.,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.c,Number of Pregnant Women identified with Eclampsia in the facility,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.1.d,Number of Pregnant Women identified with obstructed labour in the facility.,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.2,Total High Risk Pregnancy (HRP) Antepartum (Only New Cases are to be reported),2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.3,Total no. of ANC or PNC cases referred to Higher/ any other facility,2024-10-01,0.0,0.0
M1,Ante Natal Care (ANC),1.9.4,Total no. of ANC or PNC cases referred in to the facility,2024-10-01,64.0,0.04042956411876184
M1,Ante Natal Care (ANC),1.9.5,Number of Complicated pregnancies treated with Blood Transfusion,2024-10-01,9.0,0.005685407454200884
M2,Deliveries,2.1.1.a,Number of Home Deliveries attended by Skill Birth Attendant(SBA) (Doctor/Nurse/ANM) ,2024-10-01,0.0,0.0
M2,Deliveries,2.1.1.b,Number of Home Deliveries attended by Non SBA (Trained Birth Attendant(TBA) /Relatives/etc.),2024-10-01,0.0,0.0
M2,Deliveries,2.1.2,Number of PW given Tablet Misoprostol during home delivery,2024-10-01,0.0,0.0
M2,Deliveries,2.1.3,Number of newborns received 7 Home Based Newborn Care (HBNC) visits in case of Home delivery,2024-10-01,0.0,0.0
M2,Deliveries,2.2,Number of Institutional Deliveries conducted (Including C-Sections),2024-10-01,191.0,1.0
M2,Deliveries,2.2.1,"Out of total institutional deliveries(excluding C-section), number of women stayed for 48 hours or more after delivery",2024-10-01,86.0,0.450261780104712
M2,Deliveries,2.2.2,"Out of total Institutional deliveries, number of Institutional Deliveries (Excluding C-Sections) conducted at night (8 PM- 8 AM)",2024-10-01,43.0,0.225130890052356
M2,Deliveries,2.3,Age wise total number of delivery (Home +Institutional) reported (2.3.1+2.3.2+2.3.3+2.3.4),2024-10-01,191.0,1.0
M2,Deliveries,2.3.1,"Out of total number of delivery, PW with age <15 years",2024-10-01,0.0,0.0
M2,Deliveries,2.3.2,"Out of total number of delivery, PW with age 15-19 years",2024-10-01,19.0,0.09947643979057591
M2,Deliveries,2.3.3,"Out of total number of delivery, PW with age >19-49 years",2024-10-01,172.0,0.900523560209424
M2,Deliveries,2.3.4,"Out of total number of delivery, PW with age > 49 years",2024-10-01,0.0,0.0
M2,Deliveries,2.4,Number of newborns received 6 HBNC visits after Institutional Delivery,2024-10-01,0.0,0.0
M2,Deliveries,2.5,No. of identified Sick new-borns referred by ASHA to facility under HBNC Programme,2024-10-01,0.0,0.0
M2,Deliveries,2.6,Total number of Children received all scheduled 5 Home visits under HBYC ,2024-10-01,0.0,0.0
M3,Number of Caesarean (C-Section) deliveries,3.1,Total number of C -Section deliveries performed,2024-10-01,102.0,1.0
M3,Number of Caesarean (C-Section) deliveries,3.1.1,"Out of total C-sections, number performed at night (8 PM- 8 AM)",2024-10-01,36.0,0.31958762886597936
M3,Number of Caesarean (C-Section) deliveries,3.1.2,"Out of total C-section, number of women stayed for 72 hours or more after delivery",2024-10-01,99.0,0.9690721649484536
M4,Pregnancy outcome & details of new-born,4.1.1.a,Live Birth - Male,2024-10-01,108.0,0.5654450261780105
M4,Pregnancy outcome & details of new-born,4.1.1.b,Live Birth - Female,2024-10-01,83.0,0.43455497382198954
M4,Pregnancy outcome & details of new-born,4.1.2,Number of Pre-term newborns ( < 37 weeks of pregnancy),2024-10-01,19.0,0.09947643979057591
M4,Pregnancy outcome & details of new-born,4.1.3.a,Intrapartum (Fresh) Still Birth,2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.1.3.b,Antepartum (Macerated) Still Birth,2024-10-01,2.0,0.010471204188481676
M4,Pregnancy outcome & details of new-born,4.2,Abortion (spontaneous),2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.4.1,Number of Newborns weighed at birth,2024-10-01,191.0,1.0
M4,Pregnancy outcome & details of new-born,4.4.2,Number of Newborns having weight less than 2500 gms,2024-10-01,46.0,0.24083769633507854
M4,Pregnancy outcome & details of new-born,4.4.2.a,"Out of the above, number of Newborns having weight less than 1800 gms",2024-10-01,2.0,0.010471204188481676
M4,Pregnancy outcome & details of new-born,4.4.3,Number of Newborns breast fed within 1 hour of birth,2024-10-01,126.0,0.6596858638743456
M4,Pregnancy outcome & details of new-born,4.4.4,No. of Newborns discharged from the facility were exclusively breastfed till discharge,2024-10-01,191.0,1.0
M4,Pregnancy outcome & details of new-born,4.4.5,Number of Newborns received Donor Human Milk (DHM) in the facility,2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.1,"Number of Newborns screened for defects at birth (as per Comprehensive Newborn Screening, RBSK)",2024-10-01,191.0,1.0
M4,Pregnancy outcome & details of new-born,4.5.1.a,"Number of Newborns identified with visible birth defects (including Neural tube defect, Down's Syndrome, Cleft Lip & Palate, Club foot and Developmental dysplasia of the hip)",2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2,Number of children (6 Weeks to 6 years) screened by RBSK mobile health teams at Anganwadi center ,2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.2.a,Number of children (6 years to 18 years) screened by RBSK mobile health teams at Govt and Govt aided schools ,2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.3,Number of SNCU discharged babies screened in DEIC,2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.a.1,Number of children identified with Disease by RBSK Mobile Health teams,2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.b.1,Number of children identified with Deficiency by RBSK Mobile Health teams,2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.c.1,Number of children identified with Developmental delay by RBSK Mobile Health teams,2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.4.d.1,Number of children (0 - 18 years) identified with selected birth defect by RBSK Mobile Health teams,2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.5,"Number of children till age 18 years (affected with selected health conditions) managed for 4 Ds (Disease, Deficiency, Developmental Delay & Defect)",2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.6,Number of children till age 18 years (affected with selected health conditions) managed by Intervention - Surgical,2024-10-01,0.0,0.0
M4,Pregnancy outcome & details of new-born,4.5.7,Number of children till age 18 years managed at DEIC (District Early Intervention Centre),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.1,"Number of women of reproductive age (WRA) 20-49 years (non-pregnant, non-lactating), provided 4 Red Iron and folic acid (IFA) tablets in a month",2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.2,Number of children (6-59 months old) provided 8-10 doses (1ml) of IFA syrup (Bi weekly),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.a,Number of out of school children (5 -9 years) given 4-5 IFA Pink tablets at Anganwadi Centres ,2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.1.3.b,Number of in-school children (5 - 9 years) provided 4-5 IFA Pink tablets in schools,2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.a,Number of in-school Children (5-9 years) having anaemia (Hb 8.1-11.4 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.b,Number of in-school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.c,Number of out of school adolescent girls (10-19 years) having anaemia (Hb 8.1-11.9 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.i,Number of boys 10-11 years having anaemia (Hb 8.1-11.4 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.ii,Number of boys 12-14 years having anaemia (Hb 8.1-11.9 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.d.iii,Number of boys 15-19 years having anaemia (Hb 8.1-12.9 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.e,Number of lactating mothers (of 0-6 months old child) having anaemia (Hb 8.1-11.9 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.1.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having anaemia (Hb 8.1-11.9 g/dl)",2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.a,Number of in-school Children (5-9 years) having severe anaemia (Hb <8 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.b,Number of in-school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.c,Number of out of school adolescent girls (10-19 years) having severe anaemia (Hb <8 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.d,Number of in-school adolescent boys (10-19 years) having severe anaemia (Hb <8 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.e,Number of lactating mothers (of 0-6 months old child) having severe anaemia ((Hb <8 g/dl),2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.2.f,"Number of women of reproductive age (non-pregnant, non-lactating) (20-49 years) having severe anaemia (Hb <8 g/dl)",2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.a,Number of anaemic in-school Children (5-9 years) put on treatment,2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.b,Number of anaemic in-school adolescent girls (10-19 years) put on treatment,2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.c,Number of anaemic out of school adolescent girls (10-19 years) put on treatment,2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.d,Number of anaemic in-school adolescent boys (10-19 years) put on treatment,2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.e,Number of anaemic lactating mothers (of 0-6 months old child) put on treatment,2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.3.f,"Number of anaemic women of reproductive age (non-pregnant, non-lactating) (20-49 years) put on treatment",2024-10-01,0.0,0.0
M5,Anaemia Mukt Bharat,5.2.4.a,Number of lactating mothers (of 0-6 months old child) diagnosed with severe anaemia and put on treatment,2024-10-01,0.0,0.0
M6,Post Natal Care (PNC),6.1,"In case of home delivery, number of women receiving 1st Postpartum checkups within 48 hours",2024-10-01,0.0,0.0
M6,Post Natal Care (PNC),6.2,Number of women receiving Postpartum checkup between 48 hours and 14 days after Institutional delivery,2024-10-01,0.0,0.0
M6,Post Natal Care (PNC),6.3,Number of mothers provided full course of 180 IFA tablets after delivery,2024-10-01,191.0,0.9182692307692307
M6,Post Natal Care (PNC),6.4,Number of mothers provided full course 360 Calcium tablets after delivery,2024-10-01,191.0,0.9182692307692307
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1,Number of males assessed for STI/RTI,2024-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.a,"Out of the above, number of males diagnosed with STI/RTI",2024-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.1.b,"Out of the above, number of males treated for STI/RTI",2024-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2,Number of females (all females) assessed for STI/RTI,2024-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.a,"Out of the above, number of females (all females) diagnosed with STI/RTI",2024-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.2.b,"Out of the above, number of females (all females) treated for STI/RTI",2024-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3,Number of H/TG assessed for STI/RTI,2024-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.a,"Out of the above, number of H/TG people diagnosed with STI/RTI",2024-10-01,0.0,
M7,Reproductive Tract Infections/Sexually transmitted infections (RTI/STI) Cases,7.1.3.b,"Out of the above, number of H/TG people treated for STI/RTI",2024-10-01,0.0,
M8,Family Planning,8.1.1,Number of Non Scalpel Vasectomy (NSV) / Conventional Vasectomy conducted,2024-10-01,0.0,0.0
M8,Family Planning,8.2.1,Number of Laparoscopic sterilizations (excluding post-abortion) conducted,2024-10-01,10.0,0.025906735751295335
M8,Family Planning,8.2.2,Number of Interval sterilizations (Mini-lap/Conventional) (other than post-partum and post abortion) conducted,2024-10-01,0.0,0.0
M8,Family Planning,8.2.3,Number of Postpartum sterilizations (within 7 days of delivery by minilap or concurrent with caesarean section) conducted,2024-10-01,13.0,0.03367875647668394
M8,Family Planning,8.2.4,Number of Post-abortion sterilizations (within 7 days of spontaneous or surgical abortion) conducted,2024-10-01,0.0,0.0
M8,Family Planning,8.3,Number of Interval IUCD Insertions (excluding PPIUCD and PAIUCD),2024-10-01,0.0,0.0
M8,Family Planning,8.4,Number of Postpartum (within 48 hours of delivery) IUCD insertions,2024-10-01,0.0,0.0
M8,Family Planning,8.5,Number of Post-abortion (within 12 days of spontaneous or surgical abortion) IUCD insertions,2024-10-01,0.0,0.0
M8,Family Planning,8.6,Number of IUCD Removals ,2024-10-01,0.0,0.0
M8,Family Planning,8.7,Number of complications following IUCD Insertion,2024-10-01,0.0,0.0
M8,Family Planning,8.8,Injectable Contraceptive MPA- First Dose,2024-10-01,2.0,0.0051813471502590676
M8,Family Planning,8.9,Injectable Contraceptive MPA- Second Dose,2024-10-01,4.0,0.010362694300518135
M8,Family Planning,8.1,Injectable Contraceptive MPA- Third Dose,2024-10-01,6.0,0.015544041450777202
M8,Family Planning,8.11,Injectable Contraceptive MPA- Fourth and above Dose,2024-10-01,2.0,0.0051813471502590676
M8,Family Planning,8.12,Number of Combined Oral Pill cycles distributed to the beneficiary,2024-10-01,0.0,0.0
M8,Family Planning,8.13,Number of Condom pieces distributed to the beneficiary,2024-10-01,0.0,0.0
M8,Family Planning,8.14,Number of Centchroman (weekly) pill strips distributed to the beneficiary,2024-10-01,0.0,0.0
M8,Family Planning,8.15,Number of Emergency Contraceptive Pills (ECP) given to the beneficiary,2024-10-01,0.0,0.0
M8,Family Planning,8.16,Number of Pregnancy Test Kits (PTK) utilized,2024-10-01,65.0,0.16839378238341968
M8,Family Planning,8.17.1,Complications following male sterilization,2024-10-01,0.0,0.0
M8,Family Planning,8.17.2,Complications following female sterilization ,2024-10-01,0.0,0.0
M8,Family Planning,8.17.3,Failures following male sterilization,2024-10-01,0.0,0.0
M8,Family Planning,8.17.4,Failures following female sterilization,2024-10-01,0.0,0.0
M8,Family Planning,8.17.5,Deaths following male sterilization,2024-10-01,0.0,0.0
M8,Family Planning,8.17.6,Deaths following female sterilization,2024-10-01,0.0,0.0
M8,Family Planning,8.18.1,Number of cases of Female Sterilization followed up (after 1 month or on the resumption of her menstrual cycle whichever is earlier),2024-10-01,0.0,0.0
M8,Family Planning,8.18.2,Number of cases of Male Sterilization followed up (after 3 months),2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.1.1,Child immunisation - Vitamin K (Birth Dose),2024-10-01,189.0,1.0
M9,CHILD IMMUNISATION,9.1.2,Child immunisation - BCG,2024-10-01,184.0,0.9735449735449735
M9,CHILD IMMUNISATION,9.1.3,Child immunisation - Pentavalent 1,2024-10-01,43.0,0.2275132275132275
M9,CHILD IMMUNISATION,9.1.4,Child immunisation - Pentavalent 2,2024-10-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.5,Child immunisation - Pentavalent 3,2024-10-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.6,Child immunisation - OPV 0 (Birth Dose),2024-10-01,184.0,0.9735449735449735
M9,CHILD IMMUNISATION,9.1.7,Child immunisation - OPV1,2024-10-01,43.0,0.2275132275132275
M9,CHILD IMMUNISATION,9.1.8,Child immunisation - OPV2,2024-10-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.9,Child immunisation - OPV3,2024-10-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.10,Child immunisation - Hepatitis-B0 (Birth Dose),2024-10-01,184.0,0.9735449735449735
M9,CHILD IMMUNISATION,9.1.11,Child immunisation - Inactivated Injectable Polio Vaccine 1 (IPV 1),2024-10-01,43.0,0.2275132275132275
M9,CHILD IMMUNISATION,9.1.12,Child immunisation - Inactivated Injectable Polio Vaccine 2 (IPV 2) ,2024-10-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.13,Child immunisation - Rotavirus 1,2024-10-01,43.0,0.2275132275132275
M9,CHILD IMMUNISATION,9.1.14,Child immunisation - Rotavirus 2,2024-10-01,27.0,0.14285714285714285
M9,CHILD IMMUNISATION,9.1.15,Child immunisation - Rotavirus 3,2024-10-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.1.16,Child immunisation - PCV1,2024-10-01,43.0,0.2275132275132275
M9,CHILD IMMUNISATION,9.1.17,Child immunisation - PCV2,2024-10-01,26.0,0.13756613756613756
M9,CHILD IMMUNISATION,9.2.1,Child immunisation(9 - 11 months) - Inactivated Injectable Polio Vaccine 3 (IPV 3),2024-10-01,21.0,0.1111111111111111
M9,CHILD IMMUNISATION,9.2.2,Child immunisation (9-11months) - Measles & Rubella (MR)/Measles containing vaccine(MCV) - 1st Dose,2024-10-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.2.3,Child immunisation (9-11months) - JE 1st dose,2024-10-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.2.4,Child immunisation - PCV Booster,2024-10-01,21.0,0.1111111111111111
M9,CHILD IMMUNISATION,9.2.5.a,FULLY IMMUNIZED children aged between 9 and <12 months- Male,2024-10-01,13.0,0.06878306878306878
M9,CHILD IMMUNISATION,9.2.5.b,FULLY IMMUNIZED children aged between 9 and <12 months- Female,2024-10-01,8.0,0.042328042328042326
M9,CHILD IMMUNISATION,9.3.1,Child immunisation(after 12 months-delayed vaccination) - Measles & Rubella (MR)/Measles containing vaccine(MCV)- 1st Dose,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.2,Child immunisation (after 12 months-delayed vaccination) - JE 1st dose,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.3,Child immunisation - DPT 1 after 12 months of age (delayed vaccination) ,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.4,Child immunisation - DPT 2 after 12 months of age (delayed vaccination) ,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.5,Child immunisation - DPT 3 after 12 months of age (delayed vaccination) ,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.6,Child immunisation - DPT Booster after 24 months of age (delayed vaccination) ,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.7,Child immunisation - OPV Booster after 24 months of age (delayed vaccination) ,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.3.8,Child immunisation - JE Booster after 24 months of age (delayed vaccination) ,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.4.1,Child immunisation - Measles & Rubella (MR)/ Measles containing vaccine(MCV)- 2nd Dose (16-24 months),2024-10-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.4.2,Child immunisation - DPT 1st Booster ,2024-10-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.4.3,Child immunisation - OPV Booster,2024-10-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.4.4,Number of children more than 16 months of age who received Japanese Encephalitis (JE) vaccine- 2nd dose (16-24 months),2024-10-01,15.0,0.07936507936507936
M9,CHILD IMMUNISATION,9.5.1,Child Immunization- Typhoid,2024-10-01,10.0,0.05291005291005291
M9,CHILD IMMUNISATION,9.5.2,Children more than 5 years received DPT5 (2nd Booster),2024-10-01,2.0,0.010582010582010581
M9,CHILD IMMUNISATION,9.5.3,Children more than 10 years received Td10 (Tetanus Diptheria10),2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.5.4,Children more than 16 years received Td16 (Tetanus Diptheria16),2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.1,"Number of cases of AEFI -Minor (eg.- fever, rash, pain etc)",2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.2,"Number of cases of AEFI - Severe (eg.- anaphylaxis, fever>102 degrees, not requiring hospitalization etc.)",2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3,"Number of cases of AEFI - Serious (eg.- hospitalization, death, disability , cluster etc.)",2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.6.3.a,"Out of Number of cases of AEFI - Serious , total number of AEFI deaths",2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.1,Immunisation sessions planned ,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.7.2,Immunisation sessions held ,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.1,Child immunisation - Vitamin A Dose - 1,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.2,Child immunisation - Vitamin A Dose - 5,2024-10-01,0.0,0.0
M9,CHILD IMMUNISATION,9.8.3,Child immunisation - Vitamin A Dose - 9,2024-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.1,Childhood Diseases - Pneumonia,2024-10-01,20.0,0.1694915254237288
M10,Number of cases of Childhood Diseases (0-5 years),10.1.2,Childhood Diseases - Asthma,2024-10-01,10.0,0.0847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.1.3,Childhood Diseases - Sepsis ,2024-10-01,3.0,0.025423728813559324
M10,Number of cases of Childhood Diseases (0-5 years),10.1.4,Childhood Diseases - Diphtheria ,2024-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.5,Childhood Diseases - Pertussis ,2024-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.6,Childhood Diseases - Tetanus Neonatorum,2024-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.7,Childhood Diseases - Tuberculosis (TB),2024-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.8,Childhood Diseases - Acute Flaccid Paralysis(AFP),2024-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.9,Childhood Diseases - Measles,2024-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.10,Childhood Diseases - Malaria,2024-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.11,Childhood Diseases - Diarrhoea ,2024-10-01,20.0,0.1694915254237288
M10,Number of cases of Childhood Diseases (0-5 years),10.1.12,Childhood Diseases - Diarrhoea treated with ORS,2024-10-01,20.0,0.1694915254237288
M10,Number of cases of Childhood Diseases (0-5 years),10.1.13,Childhood Diseases - Diarrhoea treated with Zinc for 14 days,2024-10-01,20.0,0.1694915254237288
M10,Number of cases of Childhood Diseases (0-5 years),10.1.14,Childhood Diseases -Leprosy Cases,2024-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.1.15,Childhood Diseases- Leprosy with Grade II disability ,2024-10-01,0.0,0.0
M10,Number of cases of Childhood Diseases (0-5 years),10.2.1,Children admitted with Respiratory Infections,2024-10-01,16.0,0.13559322033898305
M10,Number of cases of Childhood Diseases (0-5 years),10.2.2,Children admitted with Pneumonia,2024-10-01,10.0,0.0847457627118644
M10,Number of cases of Childhood Diseases (0-5 years),10.2.3,Children admitted with Diarrhoea ,2024-10-01,12.0,0.1016949152542373
M11,NVBDCP,11.1.1.a,Total Blood Smears Examined for Malaria ,2024-10-01,152.0,0.5714285714285714
M11,NVBDCP,11.1.1.b,Malaria (Microscopy Tests ) - Plasmodium Vivax test positive,2024-10-01,0.0,0.0
M11,NVBDCP,11.1.1.c,Malaria (Microscopy Tests ) - Plasmodium Falciparum test positive,2024-10-01,0.0,0.0
M11,NVBDCP,11.1.1.d,Malaria (Microscopy Tests ) - Mixed test positive,2024-10-01,0.0,0.0
M11,NVBDCP,11.1.2.a,RDT conducted for Malaria,2024-10-01,28.0,0.10526315789473684
M11,NVBDCP,11.1.2.b,Malaria (RDT) - Plasmodium Vivax test positive,2024-10-01,0.0,0.0
M11,NVBDCP,11.1.2.c,Malaria (RDT) - Plasmodium Falciparum test positive,2024-10-01,0.0,0.0
M11,NVBDCP,11.1.2.d,Malaria (RDT) - Mixed test positive,2024-10-01,0.0,0.0
M11,NVBDCP,11.2.1,Kala Azar (RDT) - Tests Conducted,2024-10-01,0.0,0.0
M11,NVBDCP,11.2.2,Kala Azar Positive Cases,2024-10-01,0.0,0.0
M11,NVBDCP,11.3.1,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-10-01,45.0,0.16917293233082706
M11,NVBDCP,11.3.2,Dengue - Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-10-01,20.0,0.07518796992481203
M11,NVBDCP,11.3.3,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test conducted,2024-10-01,0.0,0.0
M11,NVBDCP,11.3.4,Chikungunya Enzyme- Linked Immuno Sorbent Assay (ELISA) test found positive,2024-10-01,0.0,0.0
M11,NVBDCP,11.4.1,No. of AES cases tested for JE(IgM ELISA),2024-10-01,0.0,0.0
M11,NVBDCP,11.4.2,No. of JE positive cases,2024-10-01,0.0,0.0
M11,NVBDCP,11.5.1,Number of persons that consumed MDA(Mass Drug Administration) drugs during the MDA round ,2024-10-01,0.0,0.0
M11,NVBDCP,11.5.2,Number of Lymphatic Filarisis lymphoedema patients received MMDP(Morbidity Management And Disability Prevention) kits ,2024-10-01,0.0,0.0
M11,NVBDCP,11.5.3,Number of Hydrocele surgeries conducted in Lymphatic Filariasis (MMDP),2024-10-01,0.0,0.0
M12,Adolescent Health,12.1.1.a,Girls registered in AFHC,2024-10-01,0.0,0.0
M12,Adolescent Health,12.1.1.b,Boys registered in AFHC,2024-10-01,0.0,0.0
M12,Adolescent Health,12.1.2.a,"Out of Girls registered, Girls received clinical services",2024-10-01,0.0,0.0
M12,Adolescent Health,12.1.2.b,"Out of Boys registered, Boys received clinical services",2024-10-01,0.0,0.0
M12,Adolescent Health,12.1.3.a,"Out of Girls registered, Girls received counselling",2024-10-01,0.0,0.0
M12,Adolescent Health,12.1.3.b,"Out of Boys registered, Boys received counselling",2024-10-01,0.0,0.0
M12,Adolescent Health,12.2.1.a,Number of Girls (6th -12th class) provided 4/5 IFA tablets in schools,2024-10-01,0.0,0.0
M12,Adolescent Health,12.2.1.b,Number of Boys (6th -12th class) provided 4/5 IFA tablets in schools,2024-10-01,0.0,0.0
M12,Adolescent Health,12.2.2.a,Number of Girls (6th -12th class) provided albendazole in schools,2024-10-01,0.0,0.0
M12,Adolescent Health,12.2.2.b,Number of Boys (6th -12th class) provided albendazole in schools,2024-10-01,0.0,0.0
M12,Adolescent Health,12.2.3,Number of out of school adolescent girls (10-19 years) provided 4/5 IFA tablets at Anganwadi Centres,2024-10-01,0.0,0.0
M12,Adolescent Health,12.2.4,Number of out of school adolescent girls (10-19 years) provided albendazole tablet at Anganwadi Centres,2024-10-01,0.0,0.0
M12,Adolescent Health,12.3.1,Number of adolescent girls provided sanitary napkin packs by ASHA,2024-10-01,0.0,0.0
M12,Adolescent Health,12.3.2,Number of sanitary napkin packs distributed free to ASHA (for her personal use),2024-10-01,0.0,0.0
M12,Adolescent Health,12.3.3,Number of adolescent girls attended monthly meeting,2024-10-01,0.0,0.0
M12,Adolescent Health,12.3.4,Number of adolescent girls provided sanitary napkin packs by State/UT supported Menstrual Hygiene Scheme (MHS),2024-10-01,0.0,0.0
M12,Adolescent Health,12.4.1,Number of Peer Educators selected,2024-10-01,0.0,0.0
M12,Adolescent Health,12.4.2,"Out of the selected Peer Educators, numbers trained",2024-10-01,0.0,0.0
M12,Adolescent Health,12.4.3,Number of Adolescent Health & Wellness Days organized,2024-10-01,0.0,0.0
M12,Adolescent Health,12.4.4,Number of Adolescent Friendly Club Meetings organized,2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,Number of notified TB patients who are on Anti Tuberculosis Therapy,2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.2,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified ,2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing,2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.a,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing within the facility,2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.3.b,Number of Presumptive TB (ie with 4 Symptom complex of TB) identified and sent for any TB testing outside the facility,2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.4,"Of the number sent for testing, number who were tested (by any test) for TB within the facility",2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.5,"Of the number sent for testing, number who were tested (by any test) for TB outside the facility",2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.6,"Of the number tested, number of persons diagnosed as TB patients.",2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.7,Number of TB patients availing treatment through a Treatment supporter for the reporting month,2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.8,Number of beneficiarys who are registered at the ICTC centre.,2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.9,"Of the number registered at the ICTC centre, the number of presumptive TB cases identified and referred for TB testing and diagnosis.",2024-10-01,0.0,0.0
M13,National TB Elimination Programme (NTEP),13.1,"Number of Directly Observed Treatment, Short-course (DOTS) cases completed successfully ",2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.1,Outpatient - Diabetes,2024-10-01,630.0,0.01662400717734913
M14 ,Patient Services,14.1.2,Outpatient - Hypertension,2024-10-01,520.0,0.013721402749558012
M14 ,Patient Services,14.1.3,Outpatient - Stroke (Paralysis),2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.4,Outpatient - Cardiovascular Disease,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.5,Outpatient - Mental illness,2024-10-01,696.0,0.0183655698340238
M14 ,Patient Services,14.1.6,Outpatient - Epilepsy,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.7,Outpatient - Ophthalmic Related,2024-10-01,1885.0,0.049740084967147796
M14 ,Patient Services,14.1.8,Outpatient - Dental,2024-10-01,1369.0,0.03612423146950946
M14 ,Patient Services,14.1.9,Outpatient - ENT ,2024-10-01,1932.0,0.050980288677204
M14 ,Patient Services,14.1.10,Outpatients- Asthma,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.11,Outpatient - Oral Cancer,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.12,Outpatient - Breast Cancer,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.13,Outpatient - Cervical Cancer,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.14,Outpatient - Other Cancer,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.15,Outpatient - COPD,2024-10-01,20.0,0.000527746259598385
M14 ,Patient Services,14.1.16,Outpatient - CKD (Chronic Kidney Disease),2024-10-01,392.0,0.010343826688128348
M14 ,Patient Services,14.1.17,Outpatient- Patients undergoing refraction,2024-10-01,1100.0,0.02902604427791118
M14 ,Patient Services,14.1.18,Outpatient - Tuberculosis,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.19,Outpatient - Leprosy Cases,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.20,Outpatient - Leprosy with Grade II disability ,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.21,Outpatient - Geriatric (age>=60 yrs),2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.22,Outpatient - Chronic Liver Disease,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.23,Outpatient - Palliative Care,2024-10-01,0.0,0.0
M14 ,Patient Services,14.1.24.a,Number of patients provided physiotherapy services,2024-10-01,690.0,0.018207245956144286
M14 ,Patient Services,14.1.24.b,Number of Palliative Patients visited at home ,2024-10-01,0.0,0.0
M14 ,Patient Services,14.2.1,Allopathic- Outpatient attendance,2024-10-01,31010.0,0.8182705755072961
M14 ,Patient Services,14.2.2,Ayush - Outpatient attendance,2024-10-01,0.0,0.0
M14 ,Patient Services,14.3.1.a,IPD Admission Male- Children<18yrs,2024-10-01,253.0,0.006675990183919571
M14 ,Patient Services,14.3.1.b,IPD Admission Male- Adults <60yrs,2024-10-01,1025.0,0.027046995804417235
M14 ,Patient Services,14.3.1.c,IPD Admission Female- Children<18yrs,2024-10-01,205.0,0.005409399160883447
M14 ,Patient Services,14.3.1.d,IPD Admission Female- Adults<60yrs,2024-10-01,1070.0,0.028234424888513604
M14 ,Patient Services,14.3.1.e,IPD Admission Geriatric->=60yrs,2024-10-01,384.0,0.010132728184288994
M14 ,Patient Services,14.3.2.a,IPD Discharge Male- Children<18yrs,2024-10-01,253.0,0.006675990183919571
M14 ,Patient Services,14.3.2.b,IPD Discharge Male- Adults<60yrs,2024-10-01,972.0,0.025648468216481517
M14 ,Patient Services,14.3.2.c,IPD Discharge Female- Children<18yrs,2024-10-01,202.0,0.00533023722194369
M14 ,Patient Services,14.3.2.d,IPD Discharge Female- Adults<60yrs,2024-10-01,1015.0,0.026783122674618045
M14 ,Patient Services,14.3.2.e,IPD Discharge Geriatric->=60yrs,2024-10-01,399.0,0.010528537878987783
M14 ,Patient Services,14.3.3.a,IPD Referred Male- Children<18yrs,2024-10-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.3.b,IPD Referred Male- Adults<60yrs,2024-10-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.3.3.c,IPD Referred Female- Children<18yrs,2024-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.d,IPD Referred Female- Adults<60yrs,2024-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.3.e,IPD Referred Geriatric->=60yrs,2024-10-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.3.4.a,IPD Deaths Male- Children<18yrs,2024-10-01,0.0,0.0
M14 ,Patient Services,14.3.4.b,IPD Deaths Male- Adults<60yrs,2024-10-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.3.4.c,IPD Deaths Female- Children<18yrs,2024-10-01,0.0,0.0
M14 ,Patient Services,14.3.4.d,IPD Deaths Female- Adults<60yrs,2024-10-01,5.0,0.00013193656489959626
M14 ,Patient Services,14.3.4.e,IPD Deaths Geriatric->=60yrs,2024-10-01,14.0,0.00036942238171886957
M14 ,Patient Services,14.3.5.a,Total cases Referred out (OPD+IPD+Emergency)-During Day ,2024-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.3.5.b,Total cases Referred out (OPD+IPD+Emergency)-At Night (8 PM- 8 AM),2024-10-01,3.0,7.916193893975777e-05
M14 ,Patient Services,14.3.6,Day Care Admissions,2024-10-01,0.0,0.0
M14 ,Patient Services,14.3.7.a,Number of Total Left Against Medical Advice (LAMA) cases reported at the facility,2024-10-01,25.0,0.0006596828244979814
M14 ,Patient Services,14.3.7.b,Number of delivery LAMA cases reported at the facility,2024-10-01,0.0,0.0
M14 ,Patient Services,14.3.8,Total number of Medico Legal Cases reported at the facility,2024-10-01,341.0,0.008998073726152465
M14 ,Patient Services,14.3.9,Total number of postmortem conducted at the facility,2024-10-01,0.0,0.0
M14 ,Patient Services,14.3.10,Total number of telemedicine consultation provided,2024-10-01,0.0,0.0
M14 ,Patient Services,14.4.1,Inpatient - Malaria ,2024-10-01,0.0,0.0
M14 ,Patient Services,14.4.2,Inpatient - Dengue,2024-10-01,60.0,0.0015832387787951554
M14 ,Patient Services,14.4.3,Inpatient - Typhoid,2024-10-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.4.4,"Inpatient - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory infections",2024-10-01,41.0,0.0010818798321766895
M14 ,Patient Services,14.4.5,Inpatient - Tuberculosis,2024-10-01,0.0,0.0
M14 ,Patient Services,14.4.6,Inpatient - Pyrexia of unknown origin (PUO),2024-10-01,28.0,0.0007388447634377391
M14 ,Patient Services,14.4.7,Inpatient - Diarrhoea with dehydration,2024-10-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.4.8,Inpatient - Leprosy (Reconstructive Surgery),2024-10-01,0.0,0.0
M14 ,Patient Services,14.4.9,Inpatient - Operated for Cataract,2024-10-01,94.0,0.00248040742011241
M14 ,Patient Services,14.4.10,Inpatient - Pallative Care,2024-10-01,0.0,0.0
M14 ,Patient Services,14.5.1,Patients registered at Emergency Department,2024-10-01,1327.0,0.035015964324352854
M14 ,Patient Services,14.5.2,No. of Emergencies managed at night (8 PM- 8 AM),2024-10-01,510.0,0.01345752961975882
M14 ,Patient Services,14.6.1.a,"Emergency - Trauma ( accident, injury, poisoning etc) -Admission",2024-10-01,110.0,0.002902604427791118
M14 ,Patient Services,14.6.1.b,"Emergency - Trauma ( accident, injury, poisoning etc) -Deaths",2024-10-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.6.2.a,Emergency - Burn -Admission,2024-10-01,0.0,0.0
M14 ,Patient Services,14.6.2.b,Emergency - Burn -Deaths,2024-10-01,0.0,0.0
M14 ,Patient Services,14.6.3.a,Emergency - Obstetrics complications -Admission,2024-10-01,0.0,0.0
M14 ,Patient Services,14.6.3.b,Emergency - Obstetrics complications -Deaths,2024-10-01,0.0,0.0
M14 ,Patient Services,14.6.4.a,Emergency - Snake Bite -Admission,2024-10-01,12.0,0.0003166477557590311
M14 ,Patient Services,14.6.4.b,Emergency - Snake Bite -Deaths,2024-10-01,0.0,0.0
M14 ,Patient Services,14.6.5.a,Emergency - Acute Cardiac Emergencies - Admission,2024-10-01,0.0,0.0
M14 ,Patient Services,14.6.5.b,Emergency - Acute Cardiac Emergencies - Deaths,2024-10-01,0.0,0.0
M14 ,Patient Services,14.6.6.a,Emergency - CVA (Cerebrovascular Disease)/Stroke -Admission,2024-10-01,0.0,0.0
M14 ,Patient Services,14.6.6.b,Emergency - CVA (Cerebrovascular Disease)/Stroke -Deaths,2024-10-01,0.0,0.0
M14 ,Patient Services,14.6.7.a,Emergency - Dog Bite - Admission,2024-10-01,0.0,0.0
M14 ,Patient Services,14.6.7.b,Emergency - Dog Bite - Deaths,2024-10-01,0.0,0.0
M14 ,Patient Services,14.7,Total number of deaths occurring at Emergency Department,2024-10-01,0.0,0.0
M14 ,Patient Services,14.8.1.a,Total number of Major Operations conducted excluding C-Section (General and spinal anaesthesia),2024-10-01,435.0,0.011478481146264876
M14 ,Patient Services,14.8.1.b,"Out of Major Operation, Gynecology- Hysterectomy surgeries",2024-10-01,10.0,0.0002638731297991925
M14 ,Patient Services,14.8.1.c,"Major Surgeries excluding Obstetrics, Gynaecology and Opthalmology.",2024-10-01,296.0,0.0078106446420560995
M14 ,Patient Services,14.8.1.d,No. of Major Surgeries done at night (8PM to 8 AM) (Excluding C section) ,2024-10-01,0.0,0.0
M14 ,Patient Services,14.8.2,Minor Operations (No or local anaesthesia),2024-10-01,143.0,0.0037733857561284534
M14 ,Patient Services,14.8.3,Number of post operative Surgical Site infection,2024-10-01,4.0,0.00010554925191967702
M14 ,Patient Services,14.9.1,Number of blood units issued for Operations (excluding C-section),2024-10-01,15.0,0.00039580969469878884
M14 ,Patient Services,14.9.2,Number of blood transfusions done during Operations (excluding C-section),2024-10-01,15.0,0.00039580969469878884
M14 ,Patient Services,14.10.,In-Patient Head Count at midnight,2024-10-01,15032.0,0.39665408871414626
M14 ,Patient Services,14.11.1,Number of Admission in NBSU ( New Born Stabilisation Unit),2024-10-01,74.0,0.0019526611605140249
M14 ,Patient Services,14.11.2,Special Newborn Care Unit (SNCU Admissions) - Inborn Male,2024-10-01,51.0,0.001345752961975882
M14 ,Patient Services,14.11.3,Special Newborn Care Unit (SNCU Admissions) - Inborn Female,2024-10-01,23.0,0.0006069081985381428
M14 ,Patient Services,14.11.4,Special Newborn Care Unit (SNCU Admissions) - Outborn Male,2024-10-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.11.5,Special Newborn Care Unit (SNCU Admissions) - Outborn Female,2024-10-01,1.0,2.6387312979919254e-05
M14 ,Patient Services,14.11.6,Special Newborn Care Unit (SNCU Admissions) - referred by ASHA,2024-10-01,0.0,0.0
M14 ,Patient Services,14.12.1,Number of deaths occurred at SNCU,2024-10-01,0.0,0.0
M14 ,Patient Services,14.12.2,Number of Newborns successfully discharged from SNCU,2024-10-01,9.0,0.0002374858168192733
M14 ,Patient Services,14.13.1.a,Total number of PW and PNC - JSSK Beneficiaries,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.b,Number of PW and PNC benificiaries provided - Free Medicines under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.c,Number of PW and PNC benificiaries provided - Free Diet under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.d,Number of PW and PNC benificiaries provided - Free Diagnostics under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.e,Number of PW and PNC benificiaries provided - Free Home to facility transport under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.f,Number of PW and PNC benificiaries provided - Interfacility transfers when needed under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.g,Number of PW and PNC benificiaries provided - Free Drop Back home under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.1.h,Number of PW and PNC benificiaries provided - Free Blood transfusion under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.a,Number of infants admitted at facility due to any sickness- JSSK Beneficiaries,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.b,Number of sick infants provided - Free Medicines under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.c,Number of sick infants provided - Free Diagnostics under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.d,Number of sick infants provided - Free Home to facility transport under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.e,Number of sick infants provided - Interfacility transfers when needed under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.f,Number of sick infants provided - Free Drop Back home under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.13.2.g,Number of sick infants provided - Free Blood transfusion under JSSK,2024-10-01,0.0,0.0
M14 ,Patient Services,14.14.1,Number of sick SAM children admitted in standalone/ integrated NRC ,2024-10-01,0.0,0.0
M14 ,Patient Services,14.14.2,Number of sick SAM children referred to standalone/ integrated NRC by Frontline Workers (AWW/ ASHA/ ANM),2024-10-01,0.0,0.0
M14 ,Patient Services,14.14.3,Number of sick SAM children referred to standalone/ integrated NRC from IPD/OPD of other Health Facility (PHC/CHC/SDH/DH/other NRC),2024-10-01,0.0,0.0
M14 ,Patient Services,14.14.4,Number of children Referred to standalone/ integrated NRC by RBSK Team,2024-10-01,0.0,0.0
M14 ,Patient Services,14.14.5,Number of SAM children discharged from standalone/ integrated NRC who met the discharge criteria,2024-10-01,0.0,0.0
M14 ,Patient Services,14.14.6,Number of admitted children left against medical advice (LAMA) / defaulter,2024-10-01,0.0,0.0
M14 ,Patient Services,14.14.7,Number of children died while admitted in standalone/ intergrated NRC,2024-10-01,0.0,0.0
M14 ,Patient Services,14.14.8,Number of children who completed all four post discharge follow-ups ,2024-10-01,0.0,0.0
M14 ,Patient Services,14.14.9,Number of sick SAM children treated and admitted in the pediatric facility (other than standalone/ integrated NRC),2024-10-01,0.0,0.0
M14 ,Patient Services,14.14.10,In-Patient Head Count at midnight for standalone/ integrated NRC,2024-10-01,0.0,0.0
M14 ,Patient Services,14.15.1,Number of Rogi Kalyan Samiti (RKS) meetings held,2024-10-01,0.0,0.0
M14 ,Patient Services,14.15.2,Number of Jan Arogya Samiti (JAS) meetings held,2024-10-01,0.0,0.0
M14 ,Patient Services,14.16,Number of Anganwadi centres reported to have conducted atleast one Village Health & Nutrition Day (VHNDs)/UHND/ Outreach / Special Outreach sessions,2024-10-01,0.0,0.0
M14 ,Patient Services,14.17,Total number of UHND/VHND sessions conducted in the reporting month,2024-10-01,0.0,0.0
M14 ,Patient Services,14.18,Total number of Outreach/Special Outreach camps conducted in the reporting month,2024-10-01,0.0,0.0
M14 ,Patient Services,14.19.a,Stock out rate of essential Drugs,2024-10-01,0.0,0.0
M14 ,Patient Services,14.19.b,Total no. of essential drugs for which stock-outs reported ,2024-10-01,0.0,0.0
M14 ,Patient Services,14.2,Blood Units Issued on replacement -{Any donor (apart from voluntary blood donor) to be considered as replacement donations},2024-10-01,150.0,0.003958096946987889
M14 ,Patient Services,14.21,Total number of blood units issued in month,2024-10-01,316.0,0.008338390901654485
M14 ,Patient Services,14.22,Patient Satisfaction Score of the facility in percentage (from Mera Aspatal),2024-10-01,0.0,0.0
M14 ,Patient Services,14.23.1.a,Number of patients registered for hemodialysis services in the centre during the reporting month ,2024-10-01,0.0,0.0
M14 ,Patient Services,14.23.1.b,Number of patients on waiting list for hemodialysis services at the end of reporting month,2024-10-01,0.0,0.0
M14 ,Patient Services,14.23.1.c,Number of hemodialysis sessions held during the reporting month,2024-10-01,0.0,0.0
M14 ,Patient Services,14.23.2.a,Number of patients started Peritoneal dialysis under PMNDP during the reporting month ,2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.1.a,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis A (IgM Anti- HAV),2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.1.b,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis B i.e. HBsAg (excluding pregnant women),2024-10-01,1074.0,0.02833997414043328
M14 ,Patient Services,14.24.1.c,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis C(Anti- HCV),2024-10-01,946.0,0.024962398079003616
M14 ,Patient Services,14.24.1.d,Total number of blood samples screened by ELISA/Rapid tests for viral hepatitis E(i.e. IgM Anti-HEV),2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.a,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis A (out of those tested for IgM Anti- HAV),2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.b,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis B (out of those tested for HBsAg excluding pregnant women),2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.b.i,Total number of positive blood samples for hepatitis B by ELISA/ Rapid tests tested for HBV DNA(out of those tested positive for HBsAg excluding pregnant women) ,2024-10-01,7.0,0.00018471119085943478
M14 ,Patient Services,14.24.2.b.ii,Total number of patients found positive for HBsAg eligible for treatment for hepatitis B (excluding pregnant women) ,2024-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.24.2.b.iii,Total number of patients eligible for treatment for Hepatitis B put on treatment(out of those eligible for treatment excluding pregnant women),2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.c,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis C (out of those tested for Anti-HCV),2024-10-01,2.0,5.277462595983851e-05
M14 ,Patient Services,14.24.2.c.i,Total number of positive blood samples for Hepatitis C screened by test (ELISA/ Rapid tests) confirmed by HCV RNA testing (out of those positive for anti-HCV),2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.ii,Total number of patients put on treatment for Hepatitis C (out of those confirmed by HCV RNA i.e. HCV RNA detected),2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iii,Total number of positive Hepatitis C patients who have completed treatment,2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.c.iv,Total number of patients cleared for HCV RNA on sustained virological response at 12 weeks (SVR12),2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.2.d,Total number of blood samples tested positive by ELISA/ Rapid tests for Hepatitis E(out of those tested for IgM Anti-HEV) ,2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.a,Number of Pregnant Women tested for HBsAg,2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.b,Number of Pregnant Women who are HBsAg positive(out of those tested for Hepatitis B i.e. HBsAg),2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.c,Number of Pregnant Women found positive for HBsAg referred out to higher centre for institutional delivery,2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.d,Number of Pregnant Women found positive for HBsAg delivered in an institution,2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.e,Number of newborn who received birth dose of Hepatitis B vaccine born to HBsAg positive pregnant women,2024-10-01,0.0,0.0
M14 ,Patient Services,14.24.3.f,Number of New Borns to Pregnant Women (found positive for HBsAg) received Hepatitis B Immunoglobulin (HBIG) (within 24 hours of birth),2024-10-01,0.0,0.0
M15,Laboratory Testing,15.1.1,Total Number of Lab Tests done- Inhouse,2024-10-01,63969.0,0.8996287233144882
M15,Laboratory Testing,15.1.2,Total Number of Lab Tests done- Outsourced,2024-10-01,30.0,0.0004219053244451945
M15,Laboratory Testing,15.2.1,Number of Hb tests conducted including kit tests,2024-10-01,4936.0,0.06941748938204934
M15,Laboratory Testing,15.2.2,"Out of the total number of Hb tests done, Number having Hb < 7 mg ",2024-10-01,22.0,0.000309397237926476
M15,Laboratory Testing,15.3.1.a,Number of males screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-10-01,415.0,0.005836356988158524
M15,Laboratory Testing,15.3.1.b,"Out of the above, No. of males found reactive for HIV",2024-10-01,2.0,2.8127021629679632e-05
M15,Laboratory Testing,15.3.1.c,Number of HIV reactive males subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.1.d,"Out of the above, No. of males confirmed as HIV Positive ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.2.a,Number of females (non-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-10-01,531.0,0.007467724242679942
M15,Laboratory Testing,15.3.2.b,"Out of the above, No. of females (non-ANC) found reactive for HIV",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.2.c,Number of HIV reactive females (non-ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.2.d,"Out of the above, No. of females (non-ANC) confirmed as HIV Positive ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.a,Number of Pregnant Women (PW-ANC) screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.b,"Out of the above, No. of PW(ANC) found reactive for HIV",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.c,Number of HIV reactive PW(ANC) subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.d,"Out of the above, No. of PW(ANC) confirmed as HIV Positive ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.e,Number of DIL women screened for HIV by Whole Blood Finger Prick/RDT test/POC test ,2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.f,"Out of the above, No. of DIL women found reactive for HIV",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.g,Number of HIV reactive DIL women subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.h,"Out of the above, No. of DIL women confirmed as HIV Positive ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.3.i,Number of Pregnant Women (ANC&DIL) screened for HIV more than once(Repeated testing) ,2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.4.a,Number of H/TG people screened for HIV by Whole Blood Finger Prick/RDT test/POC test,2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.4.b,"Out of the above, No. of H/TG people found reactive for HIV",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.4.c,Number of HIV reactive H/TG people subjected to HIV test at Confirmatory Centre (Stand Alone-ICTC) ,2024-10-01,0.0,0.0
M15,Laboratory Testing,15.3.4.d,"Out of the above, No. of H/TG people confirmed as HIV Positive ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.4.1.a,Total number of males tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-10-01,10.0,0.00014063510814839815
M15,Laboratory Testing,15.4.1.b,"Out of the above, number of males tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.4.1.c,"Out of the above, number of males treated for Syphilis ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.4.2.a,Total number of female (non-ANC) tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-10-01,317.0,0.004458132928304222
M15,Laboratory Testing,15.4.2.b,"Out of the above, number of females (non-ANC) tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.4.2.c,"Out of the above, number of females (non-ANC) treated for Syphilis ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.4.3.a,Total number of H/TG people tested for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ,2024-10-01,0.0,0.0
M15,Laboratory Testing,15.4.3.b,"Out of the above, number of H/TG people tested reactive for Syphilis (RPR/VDRL/PoC/ RDT/TPHA) ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.4.3.c,"Out of the above, number of H/TG people treated for Syphilis ",2024-10-01,0.0,0.0
M15,Laboratory Testing,15.5.1,Widal tests- Number Tested,2024-10-01,97.0,0.0013641605490394622
M15,Laboratory Testing,15.5.2,Widal tests- Number Positive,2024-10-01,15.0,0.00021095266222259724
M15,Laboratory Testing,15.6.1.a.i,X-ray(Inhouse),2024-10-01,3116.0,0.04382189969904087
M15,Laboratory Testing,15.6.1.a.ii,X-ray(Outsource),2024-10-01,0.0,0.0
M15,Laboratory Testing,15.6.1.b.i,Ultrasonography (USG) (Inhouse),2024-10-01,1480.0,0.02081399600596293
M15,Laboratory Testing,15.6.1.b.ii,Ultrasonography (USG)(Outsource),2024-10-01,0.0,0.0
M15,Laboratory Testing,15.6.1.c.i,CT scan (Inhouse),2024-10-01,543.0,0.007636486372458021
M15,Laboratory Testing,15.6.1.c.ii,CT scan (Outsource),2024-10-01,0.0,0.0
M15,Laboratory Testing,15.6.1.d.i,MRI (Inhouse),2024-10-01,243.0,0.0034174331280060755
M15,Laboratory Testing,15.6.1.d.ii,MRI (Outsource),2024-10-01,0.0,0.0
M15,Laboratory Testing,15.6.1.e.i,ECG (Inhouse),2024-10-01,811.0,0.011405507270835091
M15,Laboratory Testing,15.6.1.e.ii,ECG (Outsource),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1a,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth at Facility/Facility to facility in transit,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.1.b,New born deaths within 24 hrs(1 to 23 Hrs 59 minutes) of birth in Community (at home or home to facility transit),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.a,New born deaths within 1 week (1 to 7 days) at Facility/Facility to facility in transit,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.2.b,New born deaths within 1 week (1 to 7 days) At Community (at home or home to facility transit),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.a,New born deaths within 8 to 28 days at Facility/Facility to facility in transit,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.3.b,New born deaths within 8 to 28 days At Community (at home or home to facility transit),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.a,Infant Deaths (>28 days to 12 months) at Facility/Facility to facility in transit,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.1.4.b,Infant Deaths (>28 days to 12 months) At Community (at home or home to facility transit),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.1,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Sepsis,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.2,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Asphyxia,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.3,Neonatal Deaths up to 4 weeks (0 to 28 days) due to complications of Prematurity,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.2.4,Neonatal Deaths up to 4 weeks (0 to 28 days) due to Other causes,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.1,Number of Infant Deaths (>28 days - 12 months) due to Pneumonia,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.2,Number of Infant Deaths (>28 days - 12 months) due to Diarrhoea,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.3,Number of Infant Deaths (>28 days - 12 months) due to Fever related,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.4,Number of Infant Deaths (>28 days - 12 months) due to Measles,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.3.5,Number of Infant Deaths (>28 days - 12 months) due to Others,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.1,Number of Child Deaths (1 -5 years) due to Pneumonia,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.2,Number of Child Deaths (1 -5 years) due to Diarrhoea,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.3,Number of Child Deaths (1 -5 years) due to Fever related,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.4,Number of Child Deaths (1 -5 years) due to Measles,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.4.5,Number of Child Deaths (1 -5 years) due to Others,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.1,Number of Maternal Deaths due to APH (Antepartum Haemmorhage),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.2,Number of Maternal Deaths due to PPH (Post-Partum Haemmorhage),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.3,"Number of Maternal Deaths due to Pregnancy related infection and sepsis, Fever",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.4,Number of Maternal Deaths due to Abortive complication,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.5,Number of Maternal Deaths due to Obstructed/prolonged labour,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.6,"Number of Maternal Deaths due to Severe hypertension/fits & Hypertensive disorder in pregnancy, birth and puerperium",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.7,Number of Maternal Deaths due to Other/Unknown Causes,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8,"Age wise total Maternal Deaths, occurred at Facility",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.8.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.9,"Total Maternal Deaths, occurred at Home to be reported at Block level",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.10,Maternal Death in transit to be reported at Block level,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.a,"Out of total number of maternal deaths, deaths with age<15 years",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.b,"Out of total number of maternal deaths, deaths with age 15-19 years",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.c,"Out of total number maternal deaths, deaths with age more than >19-49 years",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.5.11.d,"Out of total number maternal deaths, deaths with age more than >49 years",2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.6,Total Facility Based Maternal Death Reviews (FBMDR) done,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.1,Number of deaths due to Diarrhoeal diseases,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.2,Number of deaths due to Tuberculosis,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.3,Number of deaths due to Respiratory diseases including infections (other than TB),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.4,Number of deaths due to Other Fever Related,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.5,Number of deaths due to Heart disease/Hypertension related,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.6,Number of deaths due to Cancer,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.7,Number of deaths due to Neurological disease including strokes,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.8,Number of deaths due to Accidents/Burn cases ,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.9,Number of deaths due to Self Harm,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.10,Number of deaths due to Animal bites and stings,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.7.11,Number of deaths due to Known Acute Disease,2024-10-01,9.0,0.2903225806451613
M16,Details of deaths reported with probable causes,16.7.12,Number of deaths due to Known Chronic Disease,2024-10-01,4.0,0.12903225806451613
M16,Details of deaths reported with probable causes,16.7.13,Number of deaths due to Other Causes ,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.1,Number of Deaths due to Malaria- Plasmodium Vivax,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.2,Number of Deaths due to Malaria- Plasmodium Falciparum,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.3,Number of Deaths due to Kala Azar,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.4,Number of Deaths due to Dengue,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.5,Number of Deaths due to Acute Encephelitis Syndrome (AES),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.8.6,Number of Deaths due to Japanese Encephalitis (JE),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9,Total Deaths (above 5 years of age),2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.1,Above 5 years to below 10 years,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.2,Above 10 years to below 19 years,2024-10-01,0.0,0.0
M16,Details of deaths reported with probable causes,16.9.3,Adult above >19 years,2024-10-01,0.0,0.0
M17,QA & BEMMP,17.1.1,Total number of Haematology tests registered under External Quality Assurance Scheme (EQAS) ,2024-10-01,16.0,0.011577424023154847
M17,QA & BEMMP,17.1.2,No. of registered Haematology tests reported EQAS Compliant,2024-10-01,0.0,0.0
M17,QA & BEMMP,17.1.3,Total number of Biochemistry tests registered under External Quality Assurance Scheme (EQAS) ,2024-10-01,69.0,0.049927641099855286
M17,QA & BEMMP,17.1.4,No. of registered Bio chemistry tests report EQAS Compliant,2024-10-01,0.0,0.0
M17,QA & BEMMP,17.1.5,"Total Quantity of Bio medical waste generated in Kg for the month (All Yellow, Red, white & Blue)",2024-10-01,399.0,0.28871201157742404
M17,QA & BEMMP,17.1.6,Total Quantity of General waste generated in Kg for the month,2024-10-01,0.0,0.0
M17,QA & BEMMP,17.2.1,Total number of breakdown calls reported for the month,2024-10-01,7.0,0.005065123010130246
M17,QA & BEMMP,17.2.2,Total number of breakdown attended for the month,2024-10-01,5.0,0.00361794500723589
M17,QA & BEMMP,17.2.3,Number of visit made by the service engineer/ BME for the month,2024-10-01,7.0,0.005065123010130246
M20,Death Reviews (MDR) Done,20.1,Total Maternal Deaths Reviewed (MDR) by CMO,2024-10-01,0.0,
M20,Death Reviews (MDR) Done,20.2,Total Maternal Deaths Reviewed (MDR) by DM,2024-10-01,0.0,
M20,Death Reviews (MDR) Done,20.3,Number of Maternal Deaths reviewed through Community based Maternal Death Review (CBMDR),2024-10-01,0.0,
M20,Death Reviews (MDR) Done,20.4,Total number of Child Deaths Reviewed by CMHO Level,2024-10-01,0.0,
M20,Death Reviews (MDR) Done,20.5,Total number of Child Deaths Reviewed by DM Level,2024-10-01,0.0,
M20,Death Reviews (MDR) Done,20.6,Number of Child Deaths reviewed through Community based Child Death Review (CBCDR),2024-10-01,0.0,
M21,National Ambulance Services,21.1,Average response time (call to scene) for all BLS Ambulances in the district during the month,2024-10-01,0.0,
M21,National Ambulance Services,21.2,Average response time (call to scene) for all ALS Ambulances in the district during the month,2024-10-01,0.0,
M21,National Ambulance Services,21.3,Average number of trips per day by all ALS Ambulances in the district during the month ,2024-10-01,0.0,
M21,National Ambulance Services,21.4,Average number of trips per day by all BLS Ambulances in the district during the month,2024-10-01,0.0,
M21,National Ambulance Services,21.5,Average kilometres travelled by all ALS Ambulances in the district during the month,2024-10-01,0.0,
M21,National Ambulance Services,21.6,Average kilometres travelled by all BLS Ambulances in the district during the month,2024-10-01,0.0,
M22,NLEP,22.1,No. of new leprosy cases found during monthly survey,2024-10-01,0.0,
